CAPILA ISHAN (US)
WO1994004678A1 | 1994-03-03 | |||
WO1992018619A1 | 1992-10-29 | |||
WO1991017271A1 | 1991-11-14 | |||
WO1992020791A1 | 1992-11-26 | |||
WO1992015679A1 | 1992-09-17 | |||
WO1993001288A1 | 1993-01-21 | |||
WO1992001047A1 | 1992-01-23 | |||
WO1992009690A2 | 1992-06-11 | |||
WO1990002809A1 | 1990-03-22 | |||
WO1991000906A1 | 1991-01-24 | |||
WO1991010741A1 | 1991-07-25 | |||
WO1992003918A1 | 1992-03-19 | |||
WO1992003917A1 | 1992-03-19 | |||
WO1987002671A1 | 1987-05-07 | |||
WO1986001533A1 | 1986-03-13 | |||
WO2009089004A1 | 2009-07-16 | |||
WO2006106905A1 | 2006-10-12 | |||
WO2010129304A2 | 2010-11-11 | |||
WO2007110205A2 | 2007-10-04 | |||
WO2008119353A1 | 2008-10-09 | |||
WO2011131746A2 | 2011-10-27 | |||
WO2013060867A2 | 2013-05-02 | |||
WO2000006605A2 | 2000-02-10 | |||
WO2002072635A2 | 2002-09-19 | |||
WO2004081051A1 | 2004-09-23 | |||
WO2006020258A2 | 2006-02-23 | |||
WO2007044887A2 | 2007-04-19 | |||
WO2007095338A2 | 2007-08-23 | |||
WO2007137760A2 | 2007-12-06 | |||
WO2008119353A1 | 2008-10-09 | |||
WO2009021754A2 | 2009-02-19 | |||
WO2009068630A1 | 2009-06-04 | |||
WO1991003493A1 | 1991-03-21 | |||
WO1993023537A1 | 1993-11-25 | |||
WO1994009131A1 | 1994-04-28 | |||
WO1994012625A2 | 1994-06-09 | |||
WO1995009917A1 | 1995-04-13 | |||
WO1996037621A2 | 1996-11-28 | |||
WO1999064460A1 | 1999-12-16 | |||
WO2021045836A1 | 2021-03-11 |
US5223409A | 1993-06-29 | |||
EP0184187A2 | 1986-06-11 | |||
EP0171496A2 | 1986-02-19 | |||
EP0173494A2 | 1986-03-05 | |||
US4816567A | 1989-03-28 | |||
EP0125023A1 | 1984-11-14 | |||
US5585089A | 1996-12-17 | |||
US5693761A | 1997-12-02 | |||
US5693762A | 1997-12-02 | |||
US5225539A | 1993-07-06 | |||
GB2188638A | 1987-10-07 | |||
EP0519596A1 | 1992-12-23 | |||
EP0388151A1 | 1990-09-19 | |||
US5624821A | 1997-04-29 | |||
US5648260A | 1997-07-15 | |||
US5731168A | 1998-03-24 | |||
US4433059A | 1984-02-21 | |||
US4444878A | 1984-04-24 | |||
US5273743A | 1993-12-28 | |||
US5534254A | 1996-07-09 | |||
US5582996A | 1996-12-10 | |||
US5591828A | 1997-01-07 | |||
US5635602A | 1997-06-03 | |||
US5637481A | 1997-06-10 | |||
US5837242A | 1998-11-17 | |||
US5837821A | 1998-11-17 | |||
US5844094A | 1998-12-01 | |||
US5864019A | 1999-01-26 | |||
US5869620A | 1999-02-09 | |||
US5910573A | 1999-06-08 | |||
US5932448A | 1999-08-03 | |||
US5959083A | 1999-09-28 | |||
US5989830A | 1999-11-23 | |||
US6005079A | 1999-12-21 | |||
US6239259B1 | 2001-05-29 | |||
US6294353B1 | 2001-09-25 | |||
US6333396B1 | 2001-12-25 | |||
US6476198B1 | 2002-11-05 | |||
US6511663B1 | 2003-01-28 | |||
US6670453B2 | 2003-12-30 | |||
US6743896B2 | 2004-06-01 | |||
US6809185B1 | 2004-10-26 | |||
US6833441B2 | 2004-12-21 | |||
US7129330B1 | 2006-10-31 | |||
US7183076B2 | 2007-02-27 | |||
US7521056B2 | 2009-04-21 | |||
US7527787B2 | 2009-05-05 | |||
US7534866B2 | 2009-05-19 | |||
US7612181B2 | 2009-11-03 | |||
US20020004587A1 | 2002-01-10 | |||
US20020076406A1 | 2002-06-20 | |||
US20020103345A1 | 2002-08-01 | |||
US20030207346A1 | 2003-11-06 | |||
US20030211078A1 | 2003-11-13 | |||
US20040219643A1 | 2004-11-04 | |||
US20040220388A1 | 2004-11-04 | |||
US20040242847A1 | 2004-12-02 | |||
US20050003403A1 | 2005-01-06 | |||
US20050004352A1 | 2005-01-06 | |||
US20050069552A1 | 2005-03-31 | |||
US20050079170A1 | 2005-04-14 | |||
US20050100543A1 | 2005-05-12 | |||
US20050136049A1 | 2005-06-23 | |||
US20050136051A1 | 2005-06-23 | |||
US20050163782A1 | 2005-07-28 | |||
US20050266425A1 | 2005-12-01 | |||
US20060083747A1 | 2006-04-20 | |||
US20060120960A1 | 2006-06-08 | |||
US20060204493A1 | 2006-09-14 | |||
US20060263367A1 | 2006-11-23 | |||
US20070004909A1 | 2007-01-04 | |||
US20070087381A1 | 2007-04-19 | |||
US20070128150A1 | 2007-06-07 | |||
US20070141049A1 | 2007-06-21 | |||
US20070154901A1 | 2007-07-05 | |||
US20070274985A1 | 2007-11-29 | |||
US20080050370A1 | 2008-02-28 | |||
US20080069820A1 | 2008-03-20 | |||
US20080152645A1 | 2008-06-26 | |||
US20080171855A1 | 2008-07-17 | |||
US20080241884A1 | 2008-10-02 | |||
US20080254512A1 | 2008-10-16 | |||
US20080260738A1 | 2008-10-23 | |||
US20090130106A1 | 2009-05-21 | |||
US20090148905A1 | 2009-06-11 | |||
US20090155275A1 | 2009-06-18 | |||
US20090162359A1 | 2009-06-25 | |||
US20090162360A1 | 2009-06-25 | |||
US20090175851A1 | 2009-07-09 | |||
US20090175867A1 | 2009-07-09 | |||
US20090232811A1 | 2009-09-17 | |||
US20090234105A1 | 2009-09-17 | |||
US20090263392A1 | 2009-10-22 | |||
US20090274649A1 | 2009-11-05 | |||
EP0346087A2 | 1989-12-13 | |||
US5208020A | 1993-05-04 | |||
US5475092A | 1995-12-12 | |||
US5585499A | 1996-12-17 | |||
US5846545A | 1998-12-08 |
LASSMANN ET AL., NUCLEIC ACIDS RES., vol. 37, no. 3, 2009, pages 858 - 65
KATOHSTANDLEY, MOL BIOL EVOL, vol. 30, no. 4, 2013, pages 772 - 80
EDGAR, NUCLEIC ACIDS RES., vol. 32, no. 5, 2004, pages 1792 - 7
BROWN ET AL., BIOINFORMATICS, vol. 14, no. 4, 1998, pages 380 - 1
LI ET AL., NUCLEIC ACIDS RES., vol. 43, no. W 1, 2015, pages W580 - 4
MCWILLIAM ET AL., NUCLEIC ACIDS RES., vol. 41, 2013, pages W597 - 600
NEEDLEMANWUNSCH, J MOL BIOL., vol. 48, no. 3, 1970, pages 443 - 53
MEYERSMILLER, COMPUT APPL BIOSCI., vol. 4, no. 1, 1988, pages 11 - 7
ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 10
ALTSCHUL ET AL., NUCLEIC ACIDS RES., vol. 25, 1997, pages 3389 - 3402
HUSE ET AL., SCIENCE, vol. 246, 1989, pages 1275 - 1281
"NCBI", Database accession no. YP_009724390
VERHOEYAN ET AL., SCIENCE, vol. 239, 1988, pages 1534 - 1043
HUSTON ET AL., PROC. NATL. ACAD SCI. USA, vol. 85, 1988, pages 5879 - 5883
COLCHER, D. ET AL., ANN N Y ACAD SCI, vol. 880, 1999, pages 263 - 80
REITER, Y., CLIN CANCER RES, vol. 2, 1996, pages 245 - 52
GARRAD ET AL., BIOITECHNOLOGY, vol. 9, 1991, pages 1373 - 1377
CHOTHIA, C. ET AL., J. MOL. BIOL., vol. 196, 1987, pages 901 - 917
"Antibody Engineering Lab Manual", SPRINGER-VERLAG, article "Protein Sequence and Structure Analysis of Antibody Variable Domains"
NORTH ET AL., J MOL BIOL., vol. 406, no. 2, 18 February 2011 (2011-02-18), pages 228 - 56
SALEH ET AL., CANCER LMMUNOL. IMMUNOTHER., vol. 32, 1990, pages 180 - 190
LOBUGLIO ET AL., HYBRIDOMA, vol. 5, 1986, pages 5117 - 5123
HAY ET AL., HUM ANTIBOD HYBRIDOMAS, vol. 3, 1992, pages 81 - 85
GRIFFTHS ET AL., EMBOJ, vol. 12, 1993, pages 725 - 734
HAWKINS ET AL., JMOL BIOL, vol. 226, 1992, pages 889 - 896
CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628
GRAM ET AL., PNAS, vol. 89, 1992, pages 3576 - 3580
HOOGENBOOM ET AL., NUC ACID RES, vol. 19, 1991, pages 4133 - 4137
BARBAS ET AL., PNAS, vol. 88, 1991, pages 7978 - 7982
LONBERG, N. ET AL., NATURE, vol. 368, 1994, pages 856 - 859
GREEN, L.L. ET AL., NATURE GENET., vol. 7, 1994, pages 13 - 21
MORRISON, S.L. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1994, pages 6851 - 6855
BRUGGEMAN ET AL., YEAR IMMUNOL, vol. 7, 1993, pages 33 - 40
TUAILLON ET AL., PNAS, vol. 90, 1993, pages 3720 - 3724
BRUGGEMAN ET AL., EURJ IMMUNOL, vol. 21, 1991, pages 1323 - 1326
SUN ET AL., PNAS, vol. 84, 1987, pages 3439 - 3443
LIU ET AL., J. IMMUNOL., vol. 139, 1987, pages 3521 - 3526
NISHIMURA ET AL., CANC. RES., vol. 47, 1987, pages 999 - 1005
WOOD ET AL., NATURE, vol. 314, 1985, pages 446 - 449
SHAW ET AL., J. NATL CANCER INST, vol. 80, 1988, pages 1553 - 1559
WINNAKER, FROM GENES TO CLONES, 1987
MORRISON, S. L., SCIENCE, vol. 229, 1985, pages 1202 - 1207
OI ET AL., BIOTECHNIQUES, vol. 4, 1986, pages 214
JONES ET AL., NATURE, vol. 321, 1986, pages 552 - 525
BEIDLER ET AL., J. IMMUNOL., vol. 141, 1988, pages 4053 - 4060
MUNOZ-FONTELA ET AL., NATURE, vol. 586, no. 7830, October 2020 (2020-10-01), pages 509 - 515
POWELL ET AL.: "Compendium of excipients for parenteral formulations", J PHARM SCI TECHNOL, vol. 52, 1998, pages 238 - 311, XP009119027
"ustained and Controlled Release Drug Delivery Systems", 1978, MARCEL DEKKER, INC.
WEINREICH ET AL., N ENGL J MED., vol. 384, no. 3, 21 January 2021 (2021-01-21), pages 238 - 251
KYRATSOUS ET AL., SCIENCE, vol. 370, no. 6520, 27 November 2020 (2020-11-27), pages 1110 - 1115
WEINREICH ET AL., MEDRXIV, 19 May 2021 (2021-05-19), pages 21257469
GUPTA ET AL., MEDRXIV, 27 May 2021 (2021-05-27), pages 21257096
TIAN ET AL., BIOMED PHARMACOTHER, vol. 137, May 2021 (2021-05-01), pages 111313
What is claimed is: 1. An antibody molecule capable of binding to a SARS-CoV-2 spike protein, comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises three heavy chain complementarity determining regions (HCDR1, HCDR2, and HCDR3), wherein the VL comprises three light chain complementarity determining regions (LCDR1, LCDR2, and LCDR3), and wherein the HCDR1 comprises an amino acid sequence of any of SEQ ID NOs: 43-49; the HCDR2 comprises an amino acid sequence of any of SEQ ID NOs: 50-55; the HCDR3 comprises an amino acid sequence of any of SEQ ID NOs: 56-63; the LCDR1 comprises an amino acid sequence of any of SEQ ID NOs: 64-68; the LCDR2 comprises an amino acid sequence of any of SEQ ID NOs: 69-72; the LCDR3 comprises an amino acid sequence of any of SEQ ID NOs: 73-77. 2. The antibody molecule of claim 1, comprising the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of any of mAb1.1, mAb1.2, mAb1.3, mAb1.4, mAb1.5, mAb1.6, mAb1.7, mAb1.8, mAb1.9, mAb1.10, mAb1.11, mAb1.12, mAb1.13, mAb1.14, mAb1.15, mAb1.16, mAb1.18, mAb1.19, mAb1.20, mAb1.21, mAb1.22, mAb1.23, mAb1.24, mAb1.25, mAb1.26, mAb1.27, mAb1.28, mAb1.29, mAb1.30, mAb1.31, mAb1.32, mAb1.33, mAb1.34, mAb1.35, mAb1.36, mAb1.37, mAb1.38, mAb1.39, mAb1.40, mAb1.41, mAb1.42, mAb1.43, mAb1.44, mAb1.45, mAb1.46, mAb1.47, mAb1.48, mAb1.49, mAb1.50, mAb1.51, mAb1.52, mAb1.53, mAb1.54, mAb1.55, mAb1.56, mAb1.57, mAb1.58, mAb1.59, mAb1.60, mAb1.61, mAb1.62, mAb1.63, mAb1.64, mAb1.65, mAb1.66, mAb1.67, mAb1.68, mAb1.69, mAb1.70, mAb1.71, mAb1.72, mAb1.73, mAb1.74, mAb1.75, mAb1.76, mAb1.77, mAb1.78, mAb1.79, mAb1.80, mAb1.81, mAb1.82, mAb1.83, mAb1.84, mAb1.85, mAb1.86, mAb1.87, mAb1.88, mAb1.89, mAb1.90, mAb1.91, mAb1.92, mAb1.93, mAb1.94, mAb1.95, mAb1.96, mAb1.97, mAb1.98, mAb1.99, mAb1.100, mAb1.101, mAb1.102, mAb1.103, mAb1.104, mAb1.105, mAb1.106, mAb1.107, mAb1.108, mAb1.109, mAb1.110, mAb1.111, mAb1.112, mAb1.113, mAb1.114, mAb1.115, mAb1.116, mAb1.117, mAb1.118, mAb1.119, mAb1.120, mAb1.121, mAb1.122, mAb1.123, mAb1.124, mAb1.125, mAb1.126, mAb1.127, mAb1.128, mAb1.129, mAb1.130, mAb1.131, mAb1.132, mAb1.133, mAb1.134, mAb1.135, mAb1.136, mAb1.137, mAb1.138, mAb1.139, mAb1.140, mAb1.141, or mAb1.142. 3. The antibody molecule of claim 1 or 2, wherein the VH comprises an amino acid sequence of any of SEQ ID NOs: 1-25, or an amino acid sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical thereto, or differs by no more than 1, 2, 3, 4, 5, 10, 15, 20, or 25 amino acids therefrom. 4. The antibody molecule of any of claims 1-3, wherein the VH comprises an amino acid sequence of any of SEQ ID NOs: 1-25. 5. The antibody molecule of any of claims 1-4, wherein the VL comprises an amino acid sequence of any of SEQ ID NOs: 26-42, or an amino acid sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical thereto, or differs by no more than 1, 2, 3, 4, 5, 10, 15, 20, or 25 amino acids therefrom. 6. The antibody molecule of any of claims 1-5, wherein the VL comprises an amino acid sequence of any of SEQ ID NOs: 26-42. 7. The antibody molecule of any of claims 1-6, wherein the VH comprises an amino acid sequence of any of SEQ ID NOs: 1-25, or an amino acid sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical thereto, or differs by no more than 1, 2, 3, 4, 5, 10, 15, 20, or 25 amino acids therefrom; and wherein the VL comprises an amino acid sequence of any of SEQ ID NOs: 26-42, or an amino acid sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical thereto, or differs by no more than 1, 2, 3, 4, 5, 10, 15, 20, or 25 amino acids therefrom. 8. The antibody molecule of any of claims 1-7, wherein the VH comprises an amino acid sequence of any of SEQ ID NOs: 1-25; and wherein the VL comprises an amino acid sequence of any of SEQ ID NOs: 26-42. 9. The antibody molecule of any of claims 1-8, comprising the VH and the VL of any of mAb1.1, mAb1.2, mAb1.3, mAb1.4, mAb1.5, mAb1.6, mAb1.7, mAb1.8, mAb1.9, mAb1.10, mAb1.11, mAb1.12, mAb1.13, mAb1.14, mAb1.15, mAb1.16, mAb1.18, mAb1.19, mAb1.20, mAb1.21, mAb1.22, mAb1.23, mAb1.24, mAb1.25, mAb1.26, mAb1.27, mAb1.28, mAb1.29, mAb1.30, mAb1.31, mAb1.32, mAb1.33, mAb1.34, mAb1.35, mAb1.36, mAb1.37, mAb1.38, mAb1.39, mAb1.40, mAb1.41, mAb1.42, mAb1.43, mAb1.44, mAb1.45, mAb1.46, mAb1.47, mAb1.48, mAb1.49, mAb1.50, mAb1.51, mAb1.52, mAb1.53, mAb1.54, mAb1.55, mAb1.56, mAb1.57, mAb1.58, mAb1.59, mAb1.60, mAb1.61, mAb1.62, mAb1.63, mAb1.64, mAb1.65, mAb1.66, mAb1.67, mAb1.68, mAb1.69, mAb1.70, mAb1.71, mAb1.72, mAb1.73, mAb1.74, mAb1.75, mAb1.76, mAb1.77, mAb1.78, mAb1.79, mAb1.80, mAb1.81, mAb1.82, mAb1.83, mAb1.84, mAb1.85, mAb1.86, mAb1.87, mAb1.88, mAb1.89, mAb1.90, mAb1.91, mAb1.92, mAb1.93, mAb1.94, mAb1.95, mAb1.96, mAb1.97, mAb1.98, mAb1.99, mAb1.100, mAb1.101, mAb1.102, mAb1.103, mAb1.104, mAb1.105, mAb1.106, mAb1.107, mAb1.108, mAb1.109, mAb1.110, mAb1.111, mAb1.112, mAb1.113, mAb1.114, mAb1.115, mAb1.116, mAb1.117, mAb1.118, mAb1.119, mAb1.120, mAb1.121, mAb1.122, mAb1.123, mAb1.124, mAb1.125, mAb1.126, mAb1.127, mAb1.128, mAb1.129, mAb1.130, mAb1.131, mAb1.132, mAb1.133, mAb1.134, mAb1.135, mAb1.136, mAb1.137, mAb1.138, mAb1.139, mAb1.140, mAb1.141, or mAb1.142. 10. An antibody molecule capable of binding to a SARS-CoV-2 spike protein, comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises three heavy chain complementarity determining regions (HCDR1, HCDR2, and HCDR3), wherein the VL comprises three light chain complementarity determining regions (LCDR1, LCDR2, and LCDR3), and wherein the HCDR1 comprises an amino acid sequence of any of SEQ ID NOs: 92-96; the HCDR2 comprises an amino acid sequence of any of SEQ ID NOs: 97-100; the HCDR3 comprises an amino acid sequence of any of SEQ ID NOs: 101-107; the LCDR1 comprises an amino acid sequence of any of SEQ ID NOs: 108-111; the LCDR2 comprises an amino acid sequence of any of SEQ ID NOs: 112-114; and the LCDR3 comprises an amino acid sequence of any of SEQ ID NOs: 115-118. 11. The antibody molecule of claim 10, comprising the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of any of mAb2.1, mAb2.2, mAb2.3, mAb2.4, mAb2.5, mAb2.6, mAb2.7, mAb2.8, mAb2.9, mAb2.10, mAb2.11, mAb2.12, mAb2.13, mAb2.14, mAb2.15, mAb2.16, mAb2.17, mAb2.18, mAb2.19, mAb2.20, mAb2.21, mAb2.22, mAb2.23, mAb2.24, mAb2.25, mAb2.26, mAb2.27, mAb2.28, mAb2.29, mAb2.30, mAb2.31, mAb2.32, mAb2.33, mAb2.34, mAb2.35, mAb2.36, mAb2.37, mAb2.38, mAb2.39, mAb2.40, mAb2.41, mAb2.42, mAb2.43, mAb2.44, or mAb2.45. 12. The antibody molecule of claim 10 or 11, wherein the VH comprises an amino acid sequence of any of SEQ ID NOs: 78-86, or an amino acid sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical thereto, or differs by no more than 1, 2, 3, 4, 5, 10, 15, 20, or 25 amino acids therefrom. 13. The antibody molecule of any of claims 10-12, wherein the VH comprises an amino acid sequence of any of SEQ ID NOs: 78-86. 14. The antibody molecule of any of claims 10-13, wherein the VL comprises an amino acid sequence of any of SEQ ID NOs: 87-91, or an amino acid sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical thereto, or differs by no more than 1, 2, 3, 4, 5, 10, 15, 20, or 25 amino acids therefrom. 15. The antibody molecule of any of claims 10-14, wherein the VL comprises an amino acid sequence of any of SEQ ID NOs: 87-91. 16. The antibody molecule of any of claims 10-15, wherein the VH comprises an amino acid sequence of any of SEQ ID NOs: 78-86, or an amino acid sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical thereto, or differs by no more than 1, 2, 3, 4, 5, 10, 15, 20, or 25 amino acids therefrom; and wherein the VL comprises an amino acid sequence of any of SEQ ID NOs: 87-91, or an amino acid sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical thereto, or differs by no more than 1, 2, 3, 4, 5, 10, 15, 20, or 25 amino acids therefrom. 17. The antibody molecule of any of claims 10-16, wherein the VH comprises an amino acid sequence of any of SEQ ID NOs: 78-86; and wherein the VL comprises an amino acid sequence of any of SEQ ID NOs: 87-91. 18. The antibody molecule of any of claims 10-17, comprising the VH and the VL of any of mAb2.1, mAb2.2, mAb2.3, mAb2.4, mAb2.5, mAb2.6, mAb2.7, mAb2.8, mAb2.9, mAb2.10, mAb2.11, mAb2.12, mAb2.13, mAb2.14, mAb2.15, mAb2.16, mAb2.17, mAb2.18, mAb2.19, mAb2.20, mAb2.21, mAb2.22, mAb2.23, mAb2.24, mAb2.25, mAb2.26, mAb2.27, mAb2.28, mAb2.29, mAb2.30, mAb2.31, mAb2.32, mAb2.33, mAb2.34, mAb2.35, mAb2.36, mAb2.37, mAb2.38, mAb2.39, mAb2.40, mAb2.41, mAb2.42, mAb2.43, mAb2.44, or mAb2.45. 19. An antibody molecule capable of binding to a SARS-CoV-2 spike protein, comprising: (a) a VH comprising: (i) an HCDR1 comprising the amino acid sequence: AASGFX1X2SSX3YMS wherein: X1 is I, N, or T; X2 is I, N, or V; and X3 is S or N; (SEQ ID NO: 119); (ii) an HCDR2 comprising the amino acid sequence: VIYX1GX2X3X4Y wherein: X1 is S or T; X2 is S, G, or R; X3 is S or T; and X5 is S or T; (SEQ ID NO: 120); and (iii) an HCDR3 comprising the amino acid sequence: AX1EX2YX3X4X5X6 wherein: X1 is R or Y; X2 is P, A, L, or I; X3 is G or E; X4 is M or L; X5 is D or I; and X6 is V or I; (SEQ ID NO: 121); and (b) a VL comprising: (i) an LCDR1 comprising the amino acid sequence: RAX1QGX2X3X4YLA wherein: X1 is S or T; X2 is V or I; X3 is S or N; and X4 is S or N; (SEQ ID NO: 122); (v) an LCDR2 comprising the amino acid sequence: YX1ASX2LQX3 wherein: X1 is S or A; X2 is S or T; and X3 is S or T; (SEQ ID NO: 123); and (iii) an LCDR3 comprising the amino acid sequence: X1QX2NX3YPPX4T wherein: X1 is Q or S; X2 is V or L; X3 is S or R; and X4 is F or Y (SEQ ID NO: 124). 20. The antibody molecule of claim 19, comprising the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of any of mAb1.1, mAb1.2, mAb1.3, mAb1.4, mAb1.5, mAb1.6, mAb1.7, mAb1.8, mAb1.9, mAb1.10, mAb1.11, mAb1.12, mAb1.13, mAb1.14, mAb1.15, mAb1.16, mAb1.18, mAb1.19, mAb1.20, mAb1.21, mAb1.22, mAb1.23, mAb1.24, mAb1.25, mAb1.26, mAb1.27, mAb1.28, mAb1.29, mAb1.30, mAb1.31, mAb1.32, mAb1.33, mAb1.34, mAb1.35, mAb1.36, mAb1.37, mAb1.38, mAb1.39, mAb1.40, mAb1.41, mAb1.42, mAb1.43, mAb1.44, mAb1.45, mAb1.46, mAb1.47, mAb1.48, mAb1.49, mAb1.50, mAb1.51, mAb1.52, mAb1.53, mAb1.54, mAb1.55, mAb1.56, mAb1.57, mAb1.58, mAb1.59, mAb1.60, mAb1.61, mAb1.62, mAb1.63, mAb1.64, mAb1.65, mAb1.66, mAb1.67, mAb1.68, mAb1.69, mAb1.70, mAb1.71, mAb1.72, mAb1.73, mAb1.74, mAb1.75, mAb1.76, mAb1.77, mAb1.78, mAb1.79, mAb1.80, mAb1.81, mAb1.82, mAb1.83, mAb1.84, mAb1.85, mAb1.86, mAb1.87, mAb1.88, mAb1.89, mAb1.90, mAb1.91, mAb1.92, mAb1.93, mAb1.94, mAb1.95, mAb1.96, mAb1.97, mAb1.98, mAb1.99, mAb1.100, mAb1.101, mAb1.102, mAb1.103, mAb1.104, mAb1.105, mAb1.106, mAb1.107, mAb1.108, mAb1.109, mAb1.110, mAb1.111, mAb1.112, mAb1.113, mAb1.114, mAb1.115, mAb1.116, mAb1.117, mAb1.118, mAb1.119, mAb1.120, mAb1.121, mAb1.122, mAb1.123, mAb1.124, mAb1.125, mAb1.126, mAb1.127, mAb1.128, mAb1.129, mAb1.130, mAb1.131, mAb1.132, mAb1.133, mAb1.134, mAb1.135, mAb1.136, mAb1.137, mAb1.138, mAb1.139, mAb1.140, mAb1.141, or mAb1.142. 21. The antibody molecule of claim 19 or 20, comprising the VH and the VL of any of mAb1.1, mAb1.2, mAb1.3, mAb1.4, mAb1.5, mAb1.6, mAb1.7, mAb1.8, mAb1.9, mAb1.10, mAb1.11, mAb1.12, mAb1.13, mAb1.14, mAb1.15, mAb1.16, mAb1.18, mAb1.19, mAb1.20, mAb1.21, mAb1.22, mAb1.23, mAb1.24, mAb1.25, mAb1.26, mAb1.27, mAb1.28, mAb1.29, mAb1.30, mAb1.31, mAb1.32, mAb1.33, mAb1.34, mAb1.35, mAb1.36, mAb1.37, mAb1.38, mAb1.39, mAb1.40, mAb1.41, mAb1.42, mAb1.43, mAb1.44, mAb1.45, mAb1.46, mAb1.47, mAb1.48, mAb1.49, mAb1.50, mAb1.51, mAb1.52, mAb1.53, mAb1.54, mAb1.55, mAb1.56, mAb1.57, mAb1.58, mAb1.59, mAb1.60, mAb1.61, mAb1.62, mAb1.63, mAb1.64, mAb1.65, mAb1.66, mAb1.67, mAb1.68, mAb1.69, mAb1.70, mAb1.71, mAb1.72, mAb1.73, mAb1.74, mAb1.75, mAb1.76, mAb1.77, mAb1.78, mAb1.79, mAb1.80, mAb1.81, mAb1.82, mAb1.83, mAb1.84, mAb1.85, mAb1.86, mAb1.87, mAb1.88, mAb1.89, mAb1.90, mAb1.91, mAb1.92, mAb1.93, mAb1.94, mAb1.95, mAb1.96, mAb1.97, mAb1.98, mAb1.99, mAb1.100, mAb1.101, mAb1.102, mAb1.103, mAb1.104, mAb1.105, mAb1.106, mAb1.107, mAb1.108, mAb1.109, mAb1.110, mAb1.111, mAb1.112, mAb1.113, mAb1.114, mAb1.115, mAb1.116, mAb1.117, mAb1.118, mAb1.119, mAb1.120, mAb1.121, mAb1.122, mAb1.123, mAb1.124, mAb1.125, mAb1.126, mAb1.127, mAb1.128, mAb1.129, mAb1.130, mAb1.131, mAb1.132, mAb1.133, mAb1.134, mAb1.135, mAb1.136, mAb1.137, mAb1.138, mAb1.139, mAb1.140, mAb1.141, or mAb1.142. 22. An antibody molecule capable of binding to a SARS-CoV-2 spike protein, comprising: (a) a VH comprising: (i) an HCDR1 comprising the amino acid sequence: KASGYTFX1X2YX3MH wherein: X1 is S or T; X2 is G, S, or D; and X3 is W or Y; (SEQ ID NO: 125); (ii) an HCDR2 comprising the amino acid sequence: RIX1PX2X3GGTN wherein: X1 is S or N; X2 is S or N; and X3 is S or T; (SEQ ID NO: 126); (iii) an HCDR3 comprising the amino acid sequence: ARVPYCSSTX1CX2X3X4WX5FDX6 wherein: X1 is S or T; X2 is H or Y; X3 is R or S; X4 is D or E; X5 is W or Y; and X6 is L or I; (SEQ ID NO: 127); and (b) a VL comprising: (i) an LCDR1 comprising the amino acid sequence: X1SSQSX2LDSDDX3NTYLD wherein: X1 is K or R; X2 is L or I; and X3 is G or S; (SEQ ID NO: 128); (ii) an LCDR2 comprising the amino acid sequence: YX1X2SYRAS wherein: X1 is S or T; and X2 V or L; (SEQ ID NO: 129); and (iii) an LCDR3 comprising the amino acid sequence: MQRX1EX2PLT wherein: X1 is L or I; and X2 is F or W (SEQ ID NO: 130). 23. The antibody molecule of claim 22, comprising the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3 of any of mAb2.1, mAb2.2, mAb2.3, mAb2.4, mAb2.5, mAb2.6, mAb2.7, mAb2.8, mAb2.9, mAb2.10, mAb2.11, mAb2.12, mAb2.13, mAb2.14, mAb2.15, mAb2.16, mAb2.17, mAb2.18, mAb2.19, mAb2.20, mAb2.21, mAb2.22, mAb2.23, mAb2.24, mAb2.25, mAb2.26, mAb2.27, mAb2.28, mAb2.29, mAb2.30, mAb2.31, mAb2.32, mAb2.33, mAb2.34, mAb2.35, mAb2.36, mAb2.37, mAb2.38, mAb2.39, mAb2.40, mAb2.41, mAb2.42, mAb2.43, mAb2.44, or mAb2.45. 24. The antibody molecule of claim 22 or 23, comprising the VH and the VL of any of mAb2.1, mAb2.2, mAb2.3, mAb2.4, mAb2.5, mAb2.6, mAb2.7, mAb2.8, mAb2.9, mAb2.10, mAb2.11, mAb2.12, mAb2.13, mAb2.14, mAb2.15, mAb2.16, mAb2.17, mAb2.18, mAb2.19, mAb2.20, mAb2.21, mAb2.22, mAb2.23, mAb2.24, mAb2.25, mAb2.26, mAb2.27, mAb2.28, mAb2.29, mAb2.30, mAb2.31, mAb2.32, mAb2.33, mAb2.34, mAb2.35, mAb2.36, mAb2.37, mAb2.38, mAb2.39, mAb2.40, mAb2.41, mAb2.42, mAb2.43, mAb2.44, or mAb2.45. 25. The antibody molecule of any of the preceding claims, which comprises an antigen- binding fragment. 26. The antibody molecule of claim 25, wherein the antigen-binding fragment comprises a Fab, F(ab')2, Fv, scFv, or sc(Fv)2. 27. The antibody molecule of any of the preceding claims, which comprises a heavy chain constant region chosen from the heavy chain constant regions of IgG1, IgG2, IgG3, or IgG4. 28. The antibody molecule of any of the preceding claims, which comprises a light chain constant region chosen from the light chain constant regions of kappa or lambda. 29. The antibody molecule of any of the preceding claims, which comprises an Fc region. 30. The antibody molecule of claim 29, wherein the Fc region comprises a mutation. 31. The antibody molecule of any of the preceding claims, wherein said antibody molecule is a monoclonal antibody molecule, an isolated antibody molecule, a humanized antibody molecule, or a synthetic antibody molecule. 32. The antibody molecule of any of the preceding claims, wherein said antibody molecule is a monospecific antibody molecule or a multispecific antibody molecule, e.g., a bispecific antibody molecule. 33. An antibody molecule that competes for binding to a SARS-CoV-2 spike protein with an antibody molecule of any of claims 1-32. 34. An antibody molecule that binds to the same or overlapping epitope as the epitope recognized by an antibody molecule of any of claims 1-32. 35. A composition (e.g., pharmaceutical composition) comprising an antibody molecule of any of claims 1-34, and optionally a pharmaceutically acceptable carrier, excipient or stabilizer. 36. A formulation comprising an antibody molecule of any of claims 1-34 and one or more excipients. 37. The formulation of claim 36, wherein the one or more excipients comprise one, two, three, four, or all of a buffer, a salt, a surfactant, a carbohydrate, an amino acid, or an antioxidant. 38. The formulation of claim 36 or 37, wherein the buffer comprises acetate, citrate, histidine, succinate, phosphate, or Tris. 39. The formulation of any of claims 36-38, wherein the salt comprises sodium. 40. The formulation of any of claims 36-39, wherein the surfactant comprises polysorbate 80, polysorbate 20, or poloxamer 188. 41. The formulation of any of claims 36-40, wherein the carbohydrate comprises sucrose, mannitol, sorbitol, trehalose, or dextran 40. 42. The formulation of any of claims 36-41, wherein the amino acid comprises glycine or arginine. 43. The formulation of any of claims 36-42, wherein the antioxidant comprises ascorbic acid, methionine, or ethylenediaminetetraacetic acid (EDTA). 44. The formulation of any of claims 36-43, wherein the antibody molecule is present at a concentration of 1 mg/mL to 300 mg/mL. 45. The formulation of any of claims 36-44, which has a pH of 5 to 8. 46. The formulation of any of claims 36-45, wherein the formulation is suitable for intravenous, subcutaneous, or intramuscular administration. 47. The formulation of any of claims 36-46, which is a liquid formulation, a lyophilized formulation, or a reconstituted formulation. 48. The formulation of any of claims 36-47, comprising 25 mg/mL to 35 mg/mL of the antibody molecule of any of claims 1-39, 15 mM to 25 mM Na-Acetate, 6% to 10% (w/v) sucrose, and 0.03% to 0.05% (w/v) polysorbate 80, at a pH of 5 to 6. 49. The formulation of claim 48, comprising 30 mg/mL of an antibody molecule described herein, 20 mM Na-Acetate, 8% (w/v) sucrose, and 0.04 % (w/v) polysorbate 80, at a pH of 5.5. 50. The formulation of any of claims 36-47, comprising 25 mg/mL to 35 mg/mL of the antibody molecule of any of claims 1-39, 15 mM to 25 mM Na-Citrate, 6% to 10% (w/v) sucrose, and 0.03% to 0.05% (w/v) polysorbate 80, at a pH of 5 to 6. 51. The formulation of claim 50, comprising 30 mg/mL of an antibody molecule described herein, 20 mM Na-Acetate, 8% (w/v) sucrose, and 0.04 % (w/v) polysorbate 80, at a pH of 5.5. 52. A container (e.g., a vial) comprising an antibody molecule of any of claims 1-34, the composition of claim 35, or the formulation of any of claims 36-51. 53. The container of claim 52, which is a 10R, single use, Type 1 glass vial, e.g., sealed with a 20 mm push-fit cap. 54. The container of claim 52 or 53, which is suitable for storage at -20°C ± 5°C, e.g., for at least 3, 6, 9, 12, 15, 18, 21, or 24 months. 55. A kit comprising an antibody molecule of any of claims 1-34, the composition of claim 35, or the formulation of any of claims 36-51, and instructions for use. 56. A nucleic acid encoding the VH, VL, or both, of an antibody molecule of any of claims 1-34. 57. A vector (e.g., expression vector) comprising the nucleic acid of claim 56. 58. A cell (e.g., host cell) comprising the nucleic acid of claim 56 or the vector of claim 57. 59. A method of producing an antibody molecule, comprising culturing the cell of claim 58 under conditions that allow expression of the antibody molecule. 60. A method of inhibiting SARS-CoV-2, comprising contacting SARS-CoV-2 with an antibody molecule of any of claims 1-34, the composition of claim 35, or the formulation of any of claims 36-51. 61. The method of claim 60, wherein the contacting step occurs in vitro, ex vivo, or in vivo. 62. A method of treating or preventing a SARS-CoV-2 infection, comprising administering to a subject in need thereof an effective amount of an antibody molecule of any of claims 1-34, the composition of claim 35, or the formulation of any of claims 36-51. 63. A method of treating or preventing COVID-19, or a symptom thereof, comprising administering to a subject in need thereof an effective amount of an antibody molecule of any of claims 1-34, the composition of claim 35, or the formulation of any of claims 36-51. 64. A method of treating or preventing a disorder associated with SARS-CoV-2, comprising administering to a subject in need thereof an effective amount of an effective amount of an antibody molecule of any of claims 1-34, the composition of claim 35, or the formulation of any of claims 36-51. 65. An antibody molecule of any of claims 1-34, the composition of claim 35, or the formulation of any of claims 36-51, for use in a method of treating or preventing a SARS-CoV-2 infection in a subject. 66. An antibody molecule of any of claims 1-34, the composition of claim 35, or the formulation of any of claims 36-51, for use in a method of treating or preventing COVID-19, or a symptom thereof, in a subject. 67. An antibody molecule of any of claims 1-34, the composition of claim 35, or the formulation of any of claims 36-51, for use in a method of treating or preventing a disorder associated with SARS-CoV-2 in a subject. 68. Use of an antibody molecule of any of claims 1-34, the composition of claim 35, or the formulation of any of claims 36-51, in the manufacture of a medicament for treating or preventing a SARS-CoV-2 infection in a subject. 69. Use of an antibody molecule of any of claims 1-34, the composition of claim 35, or the formulation of any of claims 36-51, in the manufacture of a medicament for treating or preventing COVID-19, or a symptom thereof, in a subject. 70. Use of an antibody molecule of any of claims 1-34, the composition of claim 35, or the formulation of any of claims 36-51, in the manufacture of a medicament for treating or preventing a disorder associated with SARS-CoV-2 in a subject. 71. The method of any of claims 62-64, the antibody molecule, composition, or formulation for use of any of claims 65-67, or the use of any of claims 68-70, wherein the antibody molecule, composition, or formulation is administered intravenously, subcutaneously, or intramuscularly. 72. The method of any of claims 62-64 or 71, the antibody molecule, composition, or formulation for use of any of claims 65-67 or 71, or the use of any of claims 68-71, wherein the antibody molecule, composition, or formulation is administered at a dose of 0.5 mg/kg to 30 mg/kg, e.g., 0.5 mg/kg, 2.5 mg/kg, 5 mg/kg, 7.5 mg/kg, 15 mg/kg, or 30 mg/kg. 73. The method of any of claims 62-64 or 71-72, the antibody molecule, composition, or formulation for use of any of claims 65-67 or 71-72, or the use of any of claims 68-72, wherein the antibody molecule, composition, or formulation is administered or used in combination with a second therapeutic agent or modality. 74. The method of claim 73, the antibody molecule, composition, or formulation for use of claim 73, or the use of claim 73, wherein the antibody molecule, composition, or formulation is administered or used prior to, concurrently with, or after the administration or use of the second therapeutic agent or modality. 75. The method of claim 73 or 74, the antibody molecule, composition, or formulation for use of claim 73 or 74, or the use of claim 73 or 74, wherein the second therapeutic agent or modality comprises a second antibody molecule, e.g., a second antibody molecule that binds to SARS-CoV-2. 75. The method of any of claims 62-64 or 71-74, the antibody molecule, composition, or formulation for use of any of claims 65-67 or 71-74, or the use of any of claims 68-74, wherein the SARS-CoV-2 is a SARS-CoV-2 variant, or wherein the COVID-19 is caused by a SARS-CoV-2 variant, optionally wherein the SARS-CoV-2 variant is an alpha variant, a beta variant, a gamma variant, or a delta variant. 77. A method of detecting SARS-CoV-2, comprising (i) contacting a sample or a subject with an antibody molecule of any of claims 1-34 under conditions that allow interaction of the antibody molecule and SARS-CoV-2 to occur, and (ii) detecting formation of a complex between the antibody molecule and the sample or subject. 78. A plurality of antibody molecules comprising a first antibody molecule of any of claims 1-34 and a second antibody molecule, e.g., a second antibody molecule that binds to SARS- CoV-2, e.g., provided (e.g., formulated separately and premixed together prior to administration). 79. The plurality of antibody molecules of claim 78, wherein the first antibody molecule is an antibody molecule of any of claims 1-9 and the second antibody molecule is an antibody molecule of any of claims 10-18. 80. The plurality of antibody molecules of claim 78, wherein the first antibody molecule is an antibody molecule of any of claims 1-9 and the second antibody molecule is an antibody molecule of any of claims 1-9. 81. The plurality of antibody molecules of claim 78, wherein the first antibody molecule is an antibody molecule of any of claims 10-18 and the second antibody molecule is an antibody molecule of any of claims 10-18. 82. The plurality of antibody molecules of any of claims 78-81, wherein the first antibody molecule and/or the second antibody molecule comprises an antigen-binding fragment. 83. The plurality of antibody molecules of claim 82, wherein the antigen-binding fragment comprises a Fab, F(ab')2, Fv, scFv, or sc(Fv)2. 84. The plurality of antibody molecules of any of claims 78-83, wherein the first antibody molecule and/or the second antibody molecule comprises a heavy chain constant region chosen from the heavy chain constant regions of IgG1, IgG2, IgG3, or IgG4. 85. The plurality of antibody molecules of any of claims 78-84, wherein the first antibody molecule and/or the second antibody molecule comprises a light chain constant region chosen from the light chain constant regions of kappa or lambda. 86. The plurality of antibody molecules of any of claims 78-85, wherein the first antibody molecule and/or the second antibody molecule comprises an Fc region. 87. The plurality of antibody molecules of claim 86, wherein the Fc region comprises a mutation. 88. The plurality of antibody molecules of any of claims 78-87, wherein said antibody molecule is a monoclonal antibody molecule, an isolated antibody molecule, a humanized antibody molecule, or a synthetic antibody molecule. 89. The plurality of antibody molecules of any of claims 78-88, wherein said antibody molecule is a monospecific antibody molecule or a multispecific antibody molecule, e.g., a bispecific antibody molecule. 90. A composition (e.g., pharmaceutical composition) comprising a plurality of antibody molecules of any of claims 78-89, and optionally a pharmaceutically acceptable carrier, excipient or stabilizer. 91. A formulation comprising a plurality of antibody molecules of any of claims 78-89 and one or more excipients. 92. A container (e.g., a vial) comprising a plurality of antibody molecules of any of claims 78-89, the composition of claim 90, or the formulation of claim 91. 93. A kit comprising a plurality of antibody molecules of any of claims 78-89, the composition of claim 90, or the formulation of claim 91, and instructions for use. 94. A method of inhibiting SARS-CoV-2, comprising contacting SARS-CoV-2 with a plurality of antibody molecules of any of claims 78-89, the composition of claim 90, or the formulation of claim 91. 95. The method of claim 94, wherein the contacting step occurs in vitro, ex vivo, or in vivo. 96. A method of treating or preventing a SARS-CoV-2 infection, comprising administering to a subject in need thereof an effective amount of a plurality of antibody molecules of any of claims 78-89, the composition of claim 90, or the formulation of claim 91. 97. A method of treating or preventing COVID-19, or a symptom thereof, comprising administering to a subject in need thereof an effective amount of a plurality of antibody molecules of any of claims 78-89, the composition of claim 90, or the formulation of claim 91. 98. A method of treating or preventing a disorder associated with SARS-CoV-2, comprising administering to a subject in need thereof an effective amount of a plurality of antibody molecules of any of claims 78-89, the composition of claim 90, or the formulation of claim 91. 99. A plurality of antibody molecules of any of claims 78-89, the composition of claim 90, or the formulation of claim 91, for use in a method of treating or preventing a SARS-CoV-2 infection in a subject. 100. A plurality of antibody molecules of any of claims 78-89, the composition of claim 90, or the formulation of claim 91, for use in a method of treating or preventing COVID-19, or a symptom thereof, in a subject. 101. A plurality of antibody molecules of any of claims 78-89, the composition of claim 90, or the formulation of claim 91, for use in a method of treating or preventing a disorder associated with SARS-CoV-2 in a subject. 102. Use of a plurality of antibody molecules of any of claims 78-89, the composition of claim 90, or the formulation of claim 91, in the manufacture of a medicament for treating or preventing a SARS-CoV-2 infection in a subject. 103. Use of a plurality of antibody molecules of any of claims 78-89, the composition of claim 90, or the formulation of claim 91, in the manufacture of a medicament for treating or preventing COVID-19, or a symptom thereof, in a subject. 104. Use of a plurality of antibody molecules of any of claims 78-89, the composition of claim 90, or the formulation of claim 91, in the manufacture of a medicament for treating or preventing a disorder associated with SARS-CoV-2 in a subject. 105. The method of any of claims 96-98, the plurality of antibody molecules, composition, or formulation for use of any of claims 99-101, or the use of any of claims 102-104, wherein the plurality of antibody molecules, composition, or formulation is administered intravenously, subcutaneously, or intramuscularly. 106. The method of any of claims 96-98 or 105, the plurality of antibody molecules, composition, or formulation for use of any of claims 99-101 or 105, or the use of any of claims 102- 105, wherein the plurality of antibody molecules, composition, or formulation is administered or used in combination with an additional therapeutic agent or modality. 107. The method of claim 106, the plurality of antibody molecules, composition, or formulation for use of claim 106, or the use of claim 106, wherein the plurality of antibody molecules, composition, or formulation is administered or used prior to, concurrently with, or after the administration or use of the additional therapeutic agent or modality. 108. The method of any of claims 96-98 or 105-107, the plurality of antibody molecules, composition, or formulation for use of any of claims 99-101 or 105-107, or the use of any of claims 102-107, wherein the SARS-CoV-2 is a SARS-CoV-2 variant, or wherein the COVID-19 is caused by a SARS-CoV-2 variant, optionally wherein the SARS-CoV-2 variant is an alpha variant, a beta variant, a gamma variant, or a delta variant. |
In an embodiment, the antibody molecule comprises one or more (e.g., two, three, four, five, or all) of the CDRs of mAb1.1, mAb1.2, mAb1.3, mAb1.4, mAb1.5, mAb1.6, mAb1.7, mAb1.8, mAb1.9, mAb1.10, mAb1.11, mAb1.12, mAb1.13, mAb1.14, mAb1.15, mAb1.16, mAb1.18, mAb1.19, mAb1.20, mAb1.21, mAb1.22, mAb1.23, mAb1.24, mAb1.25, mAb1.26, mAb1.27, mAb1.28, mAb1.29, mAb1.30, mAb1.31, mAb1.32, mAb1.33, mAb1.34, mAb1.35, mAb1.36, mAb1.37, mAb1.38, mAb1.39, mAb1.40, mAb1.41, mAb1.42, mAb1.43, mAb1.44, mAb1.45, mAb1.46, mAb1.47, mAb1.48, mAb1.49, mAb1.50, mAb1.51, mAb1.52, mAb1.53, mAb1.54, mAb1.55, mAb1.56, mAb1.57, mAb1.58, mAb1.59, mAb1.60, mAb1.61, mAb1.62, mAb1.63, mAb1.64, mAb1.65, mAb1.66, mAb1.67, mAb1.68, mAb1.69, mAb1.70, mAb1.71, mAb1.72, mAb1.73, mAb1.74, mAb1.75, mAb1.76, mAb1.77, mAb1.78, mAb1.79, mAb1.80, mAb1.81, mAb1.82, mAb1.83, mAb1.84, mAb1.85, mAb1.86, mAb1.87, mAb1.88, mAb1.89, mAb1.90, mAb1.91, mAb1.92, mAb1.93, mAb1.94, mAb1.95, mAb1.96, mAb1.97, mAb1.98, mAb1.99, mAb1.100, mAb1.101, mAb1.102, mAb1.103, mAb1.104, mAb1.105, mAb1.106, mAb1.107, mAb1.108, mAb1.109, mAb1.110, mAb1.111, mAb1.112, mAb1.113, mAb1.114, mAb1.115, mAb1.116, mAb1.117, mAb1.118, mAb1.119, mAb1.120, mAb1.121, mAb1.122, mAb1.123, mAb1.124, mAb1.125, mAb1.126, mAb1.127, mAb1.128, mAb1.129, mAb1.130, mAb1.131, mAb1.132, mAb1.133, mAb1.134, mAb1.135, mAb1.136, mAb1.137, mAb1.138, mAb1.139, mAb1.140, mAb1.141, or mAb1.142. In an embodiment, the antibody molecule comprises one or more (e.g., two, three, four, five, or all) of the CDRs of mAb2.1, mAb2.2, mAb2.3, mAb2.4, mAb2.5, mAb2.6, mAb2.7, mAb2.8, mAb2.9, mAb2.10, mAb2.11, mAb2.12, mAb2.13, mAb2.14, mAb2.15, mAb2.16, mAb2.17, mAb2.18, mAb2.19, mAb2.20, mAb2.21, mAb2.22, mAb2.23, mAb2.24, mAb2.25, mAb2.26, mAb2.27, mAb2.28, mAb2.29, mAb2.30, mAb2.31, mAb2.32, mAb2.33, mAb2.34, mAb2.35, mAb2.36, mAb2.37, mAb2.38, mAb2.39, mAb2.40, mAb2.41, mAb2.42, mAb2.43, mAb2.44, or mAb2.45. In an embodiment, the antibody molecule comprises one or both of: (a) a VH comprising one, two, or all of: (i) an HCDR1 comprising the amino acid sequence: AASGFX 1 X 2 SSX 3 YMS wherein: X 1 is I, N, or T; X 2 is I, N, or V; and X 3 is S or N; (SEQ ID NO: 119); (ii) an HCDR2 comprising the amino acid sequence: VIYX 1 GX 2 X 3 X 4 Y wherein: X 1 is S or T; X 2 is S, G, or R; X 3 is S or T; and X 5 is S or T;(SEQ ID NO: 120); and (iii) an HCDR3 comprising the amino acid sequence: AX 1 EX 2 YX 3 X 4 X 5 X 6 wherein: X 1 is R or Y; X 2 is P, A, L, or I; X 3 is G or E; X 4 is M or L; X 5 is D or I; and X 6 is V or I; (SEQ ID NO: 121); and (b) a VL comprising one, two, or all of: (i) an LCDR1 comprising the amino acid sequence: RAX 1 QGX 2 X 3 X 4 YLA wherein: X 1 is S or T; X 2 is V or I; X 3 is S or N; and X4 is S or N; (SEQ ID NO: 122); (v) an LCDR2 comprising the amino acid sequence: YX 1 ASX 2 LQX 3 wherein: X 1 is S or A; X 2 is S or T; and X 3 is S or T; (SEQ ID NO: 123); and (iii) an LCDR3 comprising the amino acid sequence: X 1 QX 2 NX 3 YPPX 4 T wherein: X 1 is Q or S; X 2 is V or L; X 3 is S or R; and X 4 is F or Y (SEQ ID NO: 124). In an embodiment, the antibody molecule does not comprise all of the following at the same time: the HCDR1 of SEQ ID NO: 46, the HCDR2 of SEQ ID NO: 51, the HCDR3 of SEQ ID NO: 58, the LCDR1 of SEQ ID NO: 67, the LCDR2 of SEQ ID NO: 70, and the LCDR3 of SEQ ID NO: 74. In an embodiment, the antibody molecule having the consensus sequences above does not comprise both of the following at the same time: the VH of SEQ ID NO: 9 and the VL of SEQ ID NO: 30. In some embodiments, the antibody molecule comprises one or both of: (a) a VH comprising one, two, or all of: (i) an HCDR1 comprising the amino acid sequence: KASGYTFX 1 X 2 YX 3 MH wherein: X 1 is S or T; X 2 is G, S, or D; and X 3 is W or Y; (SEQ ID NO: 125); (ii) an HCDR2 comprising the amino acid sequence: RIX 1 PX 2 X 3 GGTN wherein: X 1 is S or N; X 2 is S or N; and X 3 is S or T; (SEQ ID NO: 126); (iii) an HCDR3 comprising the amino acid sequence: ARVPYCSSTX 1 CX 2 X 3 X 4 WX 5 FDX 6 wherein: X 1 is S or T; X 2 is H or Y; X 3 is R or S; X 4 is D or E; X 5 is W or Y; and X 6 is L or I; (SEQ ID NO: 127); and (b) a VL comprising one, two, or all of: (i) an LCDR1 comprising the amino acid sequence: X 1 SSQSX 2 LDSDDX 3 NTYLD wherein: X 1 is K or R; X 2 is L or I; and X 3 is G or S; (SEQ ID NO: 128); (ii) an LCDR2 comprising the amino acid sequence: YX 1 X 2 SYRAS wherein: X 1 is S or T; and X 2 V or L; (SEQ ID NO: 129); and (iii) an LCDR3 comprising the amino acid sequence: MQRX 1 EX 2 PLT wherein: X 1 is L or I; and X 2 is F or W (SEQ ID NO: 130). In an embodiment, the antibody molecule comprises one or both of: (i) a VH comprising one, two, or all of the following: (a) an HCDR1 comprising an amino acid sequence that differs by no more than 1, 2, or 3 amino acid residues from, or has at least 85, 90, 95, 99 or 100% homology with, an amino acid sequence of any of SEQ ID NOs: 43-49; (b) an HCDR2 comprising an amino acid sequence that differs by no more than 1, 2, or 3 amino acid residues from, or has at least 85, 90, 95, 99 or 100% homology with, an amino acid sequence of any of SEQ ID NOs: 50-55; or (c) an HCDR3 comprising an amino acid sequence that differs by no more than 1, 2, or 3 amino acid residues from, or has at least 85, 90, 95, 99 or 100% homology with, an amino acid sequence of any of SEQ ID NOs: 56-63, or (ii) a VL comprising one, two, or all of the following: (a) an LCDR1 comprising an amino acid sequence that differs by no more than 1, 2, or 3 amino acid residues from, or has at least 85, 90, 95, 99 or 100% homology with, an amino acid sequence of any of SEQ ID NOs: 64-68; (b) an LCDR2 comprising an amino acid sequence that differs by no more than 1, 2, or 3 amino acid residues from, or has at least 85, 90, 95, 99 or 100% homology with, an amino acid sequence of any of SEQ ID NOs: 69-72; or (c) an LCDR3 comprising an amino acid sequence that differs by no more than 1, 2, or 3 amino acid residues from, or has at least 85, 90, 95, 99 or 100% homology with, an amino acid sequence of any of SEQ ID NOs: 73-77. In an embodiment, the antibody molecule comprises one or both of: (i) a VH comprising: (a) an HCDR1 comprising an amino acid sequence that differs by no more than 1, 2, or 3 amino acid residues from, or has at least 85, 90, 95, 99 or 100% homology with, an amino acid sequence of any of SEQ ID NOs: 43-49; (b) an HCDR2 comprising an amino acid sequence that differs by no more than 1, 2, or 3 amino acid residues from, or has at least 85, 90, 95, 99 or 100% homology with, an amino acid sequence of any of SEQ ID NOs: 50-55; and (c) an HCDR3 comprising an amino acid sequence that differs by no more than 1, 2, or 3 amino acid residues from, or has at least 85, 90, 95, 99 or 100% homology with, an amino acid sequence of any of SEQ ID NOs: 56-63, or (ii) a VL comprising: (a) an LCDR1 comprising an amino acid sequence that differs by no more than 1, 2, or 3 amino acid residues from, or has at least 85, 90, 95, 99 or 100% homology with, an amino acid sequence of any of SEQ ID NOs: 64-68; (b) an LCDR2 comprising an amino acid sequence that differs by no more than 1, 2, or 3 amino acid residues from, or has at least 85, 90, 95, 99 or 100% homology with, an amino acid sequence of any of SEQ ID NOs: 69-72; and (c) an LCDR3 comprising an amino acid sequence that differs by no more than 1, 2, or 3 amino acid residues from, or has at least 85, 90, 95, 99 or 100% homology with, an amino acid sequence of any of SEQ ID NOs: 73-77. In an embodiment, the antibody molecule comprises one or both of: (i) a VH comprising: (a) an HCDR1 comprising an amino acid sequence of any of SEQ ID NOs: 43-49; (b) an HCDR2 comprising an amino acid sequence of any of SEQ ID NOs: 50-55; and (c) an HCDR3 comprising an amino acid sequence of any of SEQ ID NOs: 56-63, or (ii) a VL comprising: (a) an LCDR1 comprising an amino acid sequence of any of SEQ ID NOs: 64-68; (b) an LCDR2 comprising an amino acid sequence of any of SEQ ID NOs: 69-72; and (c) an LCDR3 comprising an amino acid sequence of any of SEQ ID NOs: 73-77. In an embodiment, the antibody molecule comprises: (i) a VH comprising: (a) an HCDR1 comprising an amino acid sequence of any of SEQ ID NOs: 43-49; (b) an HCDR2 comprising an amino acid sequence of any of SEQ ID NOs: 50-55; and (c) an HCDR3 comprising an amino acid sequence of any of SEQ ID NOs: 56-63, and (ii) a VL comprising: (a) an LCDR1 comprising an amino acid sequence of any of SEQ ID NOs: 64-68; (b) an LCDR2 comprising an amino acid sequence of any of SEQ ID NOs: 69-72; and (c) an LCDR3 comprising an amino acid sequence of any of SEQ ID NOs: 73-77. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 43; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 50; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 56, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 64; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 69; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 73. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 43; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 50; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 57, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 64; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 69; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 73. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 44; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 50 ; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 56, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 64; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 69; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 73. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 44; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 50; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 57, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 64; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 69; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 73. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 43; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 50; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 56, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 65; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 69; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 73. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 43; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 50; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 57, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 65; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 69; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 73. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 44; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 50; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 56, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 65; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 69; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 73. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 44; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 50; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 57, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 65; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 69; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 73. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 45; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 66; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 45; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 66; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 46; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 52; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 66; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 46; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 59, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 66; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 45; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 75. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 46; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 52; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 75. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 46; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 59, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 75. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 45; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 53; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 56, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 68; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 71; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 76. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 45; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 53; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 60, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 68; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 71; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 76. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 45; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 53; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 61, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 68; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 71; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 76. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 47; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 53; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 56, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 68; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 71; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 76. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 47; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 53; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 60, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 68; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 71; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 76. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 47; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 53; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 61, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 68; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 71; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 76. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 45; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 53; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 56, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 68; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 71; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 77. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 45; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 53; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 60, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 68; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 71; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 77. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 45; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 53; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 61, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 68; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 71; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 77. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 47; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 53; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 56, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 68; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 71; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 77. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 47; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 53; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 60, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 68; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 71; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 77. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 47; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 53; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 61, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 68; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 71; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 77. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 46; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 71; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 48; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 71; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 45; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 54; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 71; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 45; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 62, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 71; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 46; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 71; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 44; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 71; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 49; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 71; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 46; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 50; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 71; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 46; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 55; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 71; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 46; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 57, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 71; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 46; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 63, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 71; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 46; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 69; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 48; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 69; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 45; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 54; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 69; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 45; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 62, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 69; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 46; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 69; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 44; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 69; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 49; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 69; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 46; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 50; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 69; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 46; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 55; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 69; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 46; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 57, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 69; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 46; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 63, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 69; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 46; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 48; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 45; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 54; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 45; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 62, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 46; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 44; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 49; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 46; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 50; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 46; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 55; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 46; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 57, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 46; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 63, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 46; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 64; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 48; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 64; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 45; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 54; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 64; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 45; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 62, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 64; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 46; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 64; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 44; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 64; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 49; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 64; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 46; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 50; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 64; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 46; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 55; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 64; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 46; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 57, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 64; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 46; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 63, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 64; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 46; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 68; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 48; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 68; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 45; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 54; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 68; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 45; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 62, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 68; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 46; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 68; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 44; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 68; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 49; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 68; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 46; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 50; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 68; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 46; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 55; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 68; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 46; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 57, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 68; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 46; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 63, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 68; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 46; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 69; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 48; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 69; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 45; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 54; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 69; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 45; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 62, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 69; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 46; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 69; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 44; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 69; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 49; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 69; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 46; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 50; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 69; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 46; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 55; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 69; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 46; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 57, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 69; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 46; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 63, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 69; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 46; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 72; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 48; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 72; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 45; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 54; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 72; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 45; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 62, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 72; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 46; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 72; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 44; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 72; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 49; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 72; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 46; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 50; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 72; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 46; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 55; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 72; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 46; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 57, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 72; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 46; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 63, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 72; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 46; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 76. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 48; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 76. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 45; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 54; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 76. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 45; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 62, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 76. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 46; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 76. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 44; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 76. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 49; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 76. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 46; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 50; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 76. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 46; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 55; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 76. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 46; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 57, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 76. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 46; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 63, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 76. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 46; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 77. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 48; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 77. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 45; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 54; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 77. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 45; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 62, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 77. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 46; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 77. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 44; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 77. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 49; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 77. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 46; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 50; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 77. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 46; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 55; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 77. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 46; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 57, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 77. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 46; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 63, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 77. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 48; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 45; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 54; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 45; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 62, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 46; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 44; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 49; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 46; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 50; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 46; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 55; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 46; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 57, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 46; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 63, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 70; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 45; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 72; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 46; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 52; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 58, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 72; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence selected from SEQ ID NO: 46; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 51; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 59, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of the LCDR1 of SEQ ID NO: 67; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 72; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 74. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 1. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 26. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 1; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 26. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 1; and a VL comprising the amino acid sequence of SEQ ID NO: 26. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 2. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 26. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 2; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 26. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 2; and a VL comprising the amino acid sequence of SEQ ID NO: 26. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 3. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 26. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 3; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 26. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 3; and a VL comprising the amino acid sequence of SEQ ID NO: 26. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 4. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 26. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 4; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 26. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 4; and a VL comprising the amino acid sequence of SEQ ID NO: 26. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 1. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 27. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 1; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 27. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 1; and a VL comprising the amino acid sequence of SEQ ID NO: 27. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 2. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 27. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 2; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 27. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 2; and a VL comprising the amino acid sequence of SEQ ID NO: 27. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 3. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 27. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 3; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 27. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 3; and a VL comprising the amino acid sequence of SEQ ID NO: 27. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 4. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 27. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 4; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 27. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 4; and a VL comprising the amino acid sequence of SEQ ID NO: 27. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 5. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 28. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 5; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 28. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 5; and a VL comprising the amino acid sequence of SEQ ID NO: 28. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 6. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 28. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 6; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 28. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 6; and a VL comprising the amino acid sequence of SEQ ID NO: 28. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 7. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 28. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 7; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 28. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 7; and a VL comprising the amino acid sequence of SEQ ID NO: 28. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 8. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 28. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 8; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 28. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 8; and a VL comprising the amino acid sequence of SEQ ID NO: 28. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 5. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 29. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 5; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 29. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 5; and a VL comprising the amino acid sequence of SEQ ID NO: 29. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 6. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 29. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 6; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 29. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 6; and a VL comprising the amino acid sequence of SEQ ID NO: 29. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 7. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 29. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 7; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 29. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 7; and a VL comprising the amino acid sequence of SEQ ID NO: 29. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 8. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 29. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 8; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 29. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 8; and a VL comprising the amino acid sequence of SEQ ID NO: 29. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 5. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 42. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 5; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 42. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 5; and a VL comprising the amino acid sequence of SEQ ID NO: 42. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 6. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 42. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 6; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 42. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 6; and a VL comprising the amino acid sequence of SEQ ID NO: 42. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 7. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 42. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 7; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 42. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 7; and a VL comprising the amino acid sequence of SEQ ID NO: 42. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 8. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 42. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 8; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 42. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 8; and a VL comprising the amino acid sequence of SEQ ID NO: 42. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 10. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 31. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 10; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 31. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 10; and a VL comprising the amino acid sequence of SEQ ID NO: 31. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 11. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 31. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 11; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 31. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 11; and a VL comprising the amino acid sequence of SEQ ID NO: 31. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 12. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 31. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 12; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 31. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 12; and a VL comprising the amino acid sequence of SEQ ID NO: 31. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 13. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 31. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 13; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 31. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 13; and a VL comprising the amino acid sequence of SEQ ID NO: 31. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 14. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 31. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 14; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 31. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 14; and a VL comprising the amino acid sequence of SEQ ID NO: 31. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 15. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 31. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 15; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 31. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 15; and a VL comprising the amino acid sequence of SEQ ID NO: 31. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 10. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 32. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 10; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 32. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 10; and a VL comprising the amino acid sequence of SEQ ID NO: 32. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 11. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 32. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 11; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 32. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 11; and a VL comprising the amino acid sequence of SEQ ID NO: 32. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 12. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 32. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 12; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 32. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 12; and a VL comprising the amino acid sequence of SEQ ID NO: 32. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 13. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 32. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 13; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 32. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 13; and a VL comprising the amino acid sequence of SEQ ID NO: 32. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 14. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 32. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 14; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 32. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 14; and a VL comprising the amino acid sequence of SEQ ID NO: 32. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 15. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 32. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 15; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 32. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 15; and a VL comprising the amino acid sequence of SEQ ID NO: 32. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 16. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 30. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 16; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 30. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 16; and a VL comprising the amino acid sequence of SEQ ID NO: 30. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 17. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 30. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 17; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 30. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 17; and a VL comprising the amino acid sequence of SEQ ID NO: 30. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 18. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 30. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 18; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 30. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 18; and a VL comprising the amino acid sequence of SEQ ID NO: 30. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 19. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 30. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 19; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 30. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 19; and a VL comprising the amino acid sequence of SEQ ID NO: 30. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 20. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 30. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 20; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 30. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 20; and a VL comprising the amino acid sequence of SEQ ID NO: 30. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 21. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 30. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 21 and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 30. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 21; and a VL comprising the amino acid sequence of SEQ ID NO: 30. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 22. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 30. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 22; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 30. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 22; and a VL comprising the amino acid sequence of SEQ ID NO: 30. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 23. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 30. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 23; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 30. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 23; and a VL comprising the amino acid sequence of SEQ ID NO: 30. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 24. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 30. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 24; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 30. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 24; and a VL comprising the amino acid sequence of SEQ ID NO: 30. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 25. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 30. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 25; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 30. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 25; and a VL comprising the amino acid sequence of SEQ ID NO: 30. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 9. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 33. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 9; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 33. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 9; and a VL comprising the amino acid sequence of SEQ ID NO: 33. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 16. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 33. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 16; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 33. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 16; and a VL comprising the amino acid sequence of SEQ ID NO: 33. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 17. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 33. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 17; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 33. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 17; and a VL comprising the amino acid sequence of SEQ ID NO: 33. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 18. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 33. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 18; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 33. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 18; and a VL comprising the amino acid sequence of SEQ ID NO: 33. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 19. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 33. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 19; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 33. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 19; and a VL comprising the amino acid sequence of SEQ ID NO: 33. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 20. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 33. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 20; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 33. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 20; and a VL comprising the amino acid sequence of SEQ ID NO: 33. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 21. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 33. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 21; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 33. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 21; and a VL comprising the amino acid sequence of SEQ ID NO: 33. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 22. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 33. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 22; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 33. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 33; and a VL comprising the amino acid sequence of SEQ ID NO: 33. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 23. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 33. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 23; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 33. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 23; and a VL comprising the amino acid sequence of SEQ ID NO: 33. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 24. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 33. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 24; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 33. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 24; and a VL comprising the amino acid sequence of SEQ ID NO: 33. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 25. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 33. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 25; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 33. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 25; and a VL comprising the amino acid sequence of SEQ ID NO: 33. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 9. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 34. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 9; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 34. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 9; and a VL comprising the amino acid sequence of SEQ ID NO: 34. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 16. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 34. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 16; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 34. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 16; and a VL comprising the amino acid sequence of SEQ ID NO: 34. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 17. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 34. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 17; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 34. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 17; and a VL comprising the amino acid sequence of SEQ ID NO: 34. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 18. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 34. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 18; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 34. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 18; and a VL comprising the amino acid sequence of SEQ ID NO: 34. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 19. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 34. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 19; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 34. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 19; and a VL comprising the amino acid sequence of SEQ ID NO: 34. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 20. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 34. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 20; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 34. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 20; and a VL comprising the amino acid sequence of SEQ ID NO: 34. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 21. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 34. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 21; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 34. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 21; and a VL comprising the amino acid sequence of SEQ ID NO: 34. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 22. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 34. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 22; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 34. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 22; and a VL comprising the amino acid sequence of SEQ ID NO: 34. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 23. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 34. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 23; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 34. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 23; and a VL comprising the amino acid sequence of SEQ ID NO: 34. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 24. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 34. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 24; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 34. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 24; and a VL comprising the amino acid sequence of SEQ ID NO: 34. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 25. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 34. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 25; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 34. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 25; and a VL comprising the amino acid sequence of SEQ ID NO: 34.In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 9. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 35. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 9; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 35. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 9; and a VL comprising the amino acid sequence of SEQ ID NO: 35. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 16. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 35. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 16; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 35. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 16; and a VL comprising the amino acid sequence of SEQ ID NO: 35. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 17. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 35. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 17; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 35. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 17; and a VL comprising the amino acid sequence of SEQ ID NO: 35. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 18. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 35. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 18; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 35. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 18; and a VL comprising the amino acid sequence of SEQ ID NO: 35. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 19. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 35. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 19; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 35. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 19; and a VL comprising the amino acid sequence of SEQ ID NO: 35. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 20. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 35. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 20; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 35. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 20; and a VL comprising the amino acid sequence of SEQ ID NO: 35. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 21. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 35. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 21; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 35. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 21; and a VL comprising the amino acid sequence of SEQ ID NO: 35. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 22. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 35. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 22; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 35. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 22; and a VL comprising the amino acid sequence of SEQ ID NO: 35. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 23. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 35. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 23; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 35. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 23; and a VL comprising the amino acid sequence of SEQ ID NO: 35. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 24. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 35. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 24; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 35. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 24; and a VL comprising the amino acid sequence of SEQ ID NO: 35. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 25. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 35. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 25; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 35. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 25; and a VL comprising the amino acid sequence of SEQ ID NO: 35. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 9. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 36. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 9; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 36. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 9; and a VL comprising the amino acid sequence of SEQ ID NO: 36. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 16. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 36. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 16; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 36. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 16; and a VL comprising the amino acid sequence of SEQ ID NO: 36. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 17. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 36. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 17; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 36. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 17; and a VL comprising the amino acid sequence of SEQ ID NO: 36. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 18. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 36. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 18; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 36. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 18; and a VL comprising the amino acid sequence of SEQ ID NO: 36. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 19. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 36. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 19; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 36. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 19; and a VL comprising the amino acid sequence of SEQ ID NO: 36. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 20. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 36. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 20; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 36. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 20; and a VL comprising the amino acid sequence of SEQ ID NO: 36. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 21. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 36. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 21; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 36. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 21; and a VL comprising the amino acid sequence of SEQ ID NO: 36. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 22. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 36. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 22; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 36. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 22; and a VL comprising the amino acid sequence of SEQ ID NO: 36. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 23. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 36. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 23; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 36. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 23; and a VL comprising the amino acid sequence of SEQ ID NO: 36. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 24. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 36. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 24; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 36. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 24; and a VL comprising the amino acid sequence of SEQ ID NO: 36. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 25. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 36. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 25; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 36. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 25; and a VL comprising the amino acid sequence of SEQ ID NO: 36. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 9. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 37. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 9; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 37. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 9; and a VL comprising the amino acid sequence of SEQ ID NO: 37. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 16. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 37. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 16; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 37. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 16; and a VL comprising the amino acid sequence of SEQ ID NO: 37. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 17. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 37. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 17; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 37. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 17; and a VL comprising the amino acid sequence of SEQ ID NO: 37. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 18. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 37. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 18; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 37. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 18; and a VL comprising the amino acid sequence of SEQ ID NO: 37. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 19. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 37. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 19; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 37. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 19; and a VL comprising the amino acid sequence of SEQ ID NO: 37. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 20. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 37. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 20; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 37. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 20; and a VL comprising the amino acid sequence of SEQ ID NO: 37. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 21. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 37. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 21; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 37. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 21; and a VL comprising the amino acid sequence of SEQ ID NO: 37. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 22. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 37. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 22; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 37. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 22; and a VL comprising the amino acid sequence of SEQ ID NO: 37. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 23. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 37. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 23; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 37. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 23; and a VL comprising the amino acid sequence of SEQ ID NO: 37. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 24. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 37. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 24; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 37. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 24; and a VL comprising the amino acid sequence of SEQ ID NO: 37. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 25. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 37. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 25; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 37. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 25; and a VL comprising the amino acid sequence of SEQ ID NO: 37. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 9. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 38. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 9; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 38. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 9; and a VL comprising the amino acid sequence of SEQ ID NO: 38. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 16. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 38. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 16; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 38. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 16; and a VL comprising the amino acid sequence of SEQ ID NO: 38. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 17. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 38. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 17; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 38. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 17; and a VL comprising the amino acid sequence of SEQ ID NO: 38. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 18. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 38. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 18; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 38. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 18; and a VL comprising the amino acid sequence of SEQ ID NO: 38. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 19. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 38. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 19; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 38. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 19; and a VL comprising the amino acid sequence of SEQ ID NO: 38. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 20. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 38. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 20; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 38. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 20; and a VL comprising the amino acid sequence of SEQ ID NO: 38. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 21. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 38. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 21; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 38. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 21; and a VL comprising the amino acid sequence of SEQ ID NO: 38. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 22. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 38. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 22; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 38. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 22; and a VL comprising the amino acid sequence of SEQ ID NO: 38. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 23. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 38. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 23; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 38. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 23; and a VL comprising the amino acid sequence of SEQ ID NO: 38. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 24. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 38. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 24; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 38. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 24; and a VL comprising the amino acid sequence of SEQ ID NO: 38. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 25. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 38. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 25; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 38. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 25; and a VL comprising the amino acid sequence of SEQ ID NO: 38. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 9. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 39. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 9; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 39. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 9; and a VL comprising the amino acid sequence of SEQ ID NO: 39. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 16. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 39. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 16; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 39. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 16; and a VL comprising the amino acid sequence of SEQ ID NO: 39. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 17. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 39. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 17; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 39. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 17; and a VL comprising the amino acid sequence of SEQ ID NO: 39. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 18. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 39. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 18; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 39. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 18; and a VL comprising the amino acid sequence of SEQ ID NO: 39. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 19. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 39. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 19; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 39. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 19; and a VL comprising the amino acid sequence of SEQ ID NO: 39. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 20. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 39. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 20; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 39. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 20; and a VL comprising the amino acid sequence of SEQ ID NO: 39. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 21. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 39. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 21; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 39. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 21; and a VL comprising the amino acid sequence of SEQ ID NO: 39. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 22. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 39. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 22; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 39. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 22; and a VL comprising the amino acid sequence of SEQ ID NO: 39. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 23. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 39. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 23; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 39. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 23; and a VL comprising the amino acid sequence of SEQ ID NO: 39. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 24. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 39. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 24; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 39. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 24; and a VL comprising the amino acid sequence of SEQ ID NO: 39. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 25. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 39. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 25; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 39. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 25; and a VL comprising the amino acid sequence of SEQ ID NO: 39. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 9. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 40. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 9; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 40. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 9; and a VL comprising the amino acid sequence of SEQ ID NO: 40. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 16. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 40. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 16; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 40. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 16; and a VL comprising the amino acid sequence of SEQ ID NO: 40. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 17. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 40. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 17; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 40. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 17; and a VL comprising the amino acid sequence of SEQ ID NO: 40. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 18. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 40. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 18; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 40. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 18; and a VL comprising the amino acid sequence of SEQ ID NO: 40. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 19. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 40. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 19; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 40. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 19; and a VL comprising the amino acid sequence of SEQ ID NO: 40. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 20. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 40. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 20; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 40. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 20; and a VL comprising the amino acid sequence of SEQ ID NO: 40. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 21. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 40. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 21; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 40. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 21; and a VL comprising the amino acid sequence of SEQ ID NO: 40. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 22. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 40. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 22; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 40. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 22; and a VL comprising the amino acid sequence of SEQ ID NO: 40. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 23. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 40. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 23; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 40. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 23; and a VL comprising the amino acid sequence of SEQ ID NO: 40. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 24. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 40. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 24; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 40. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 24; and a VL comprising the amino acid sequence of SEQ ID NO: 40. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 25. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 40. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 25; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 40. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 25; and a VL comprising the amino acid sequence of SEQ ID NO: 40. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 9. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 41. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 9; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 41. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 9; and a VL comprising the amino acid sequence of SEQ ID NO: 41. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 16. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 41. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 16; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 41. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 16; and a VL comprising the amino acid sequence of SEQ ID NO: 41. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 17. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 41. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 17; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 41. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 17; and a VL comprising the amino acid sequence of SEQ ID NO: 41. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 18. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 41. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 18; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 41. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 18; and a VL comprising the amino acid sequence of SEQ ID NO: 41. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 19. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 41. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 19; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 41. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 19; and a VL comprising the amino acid sequence of SEQ ID NO: 41. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 20. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 41. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 20; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 41. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 20; and a VL comprising the amino acid sequence of SEQ ID NO: 41. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 21. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 41. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 21; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 41. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 21; and a VL comprising the amino acid sequence of SEQ ID NO: 41. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 22. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 41. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 22; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 41. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 22; and a VL comprising the amino acid sequence of SEQ ID NO: 41. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 23. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 41. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 23; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 41. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 23; and a VL comprising the amino acid sequence of SEQ ID NO: 41. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 24. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 41. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 24; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 41. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 24; and a VL comprising the amino acid sequence of SEQ ID NO: 41. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 25. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 41. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 25; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 41. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 25; and a VL comprising the amino acid sequence of SEQ ID NO: 41. In an embodiment, the antibody molecule comprises one or both of: (i) a VH comprising one, two, or all of the following: (a) an HCDR1 comprising an amino acid sequence that differs by no more than 1, 2, or 3 amino acid residues from, or has at least 85, 90, 95, 99 or 100% homology with, an amino acid sequence of any of SEQ ID NOs: 92-96; (b) an HCDR2 comprising an amino acid sequence that differs by no more than 1, 2, or 3 amino acid residues from, or has at least 85, 90, 95, 99 or 100% homology with, an amino acid sequence of any of SEQ ID NOs 97-100; or (c) an HCDR3 comprising an amino acid sequence that differs by no more than 1, 2, or 3 amino acid residues from, or has at least 85, 90, 95, 99 or 100% homology with, the amino acid sequence selected from SEQ ID NO: 101-107, or (ii) a VL comprising one, two, or all of the following: (a) an LCDR1 comprising an amino acid sequence that differs by no more than 1, 2, or 3 amino acid residues from, or has at least 85, 90, 95, 99 or 100% homology with, an amino acid sequence of any of SEQ ID NOs: 108-111; (b) an LCDR2 comprising an amino acid sequence that differs by no more than 1, 2, or 3 amino acid residues from, or has at least 85, 90, 95, 99 or 100% homology with, an amino acid sequence of any of SEQ ID NOs: 112-114; or (c) an LCDR3 comprising an amino acid sequence that differs by no more than 1, 2, or 3 amino acid residues from, or has at least 85, 90, 95, 99 or 100% homology with, an amino acid sequence of any of SEQ ID NOs: 115-118. In an embodiment, the antibody molecule comprises one or both of: (i) a VH comprising: (a) an HCDR1 comprising an amino acid sequence that differs by no more than 1, 2, or 3 amino acid residues from, or has at least 85, 90, 95, 99 or 100% homology with, an amino acid sequence of any of SEQ ID NOs: 92-96; (b) an HCDR2 comprising an amino acid sequence that differs by no more than 1, 2, or 3 amino acid residues from, or has at least 85, 90, 95, 99 or 100% homology with, an amino acid sequence of any of SEQ ID NOs 97-100; and (c) an HCDR3 comprising an amino acid sequence that differs by no more than 1, 2, or 3 amino acid residues from, or has at least 85, 90, 95, 99 or 100% homology with, an amino acid sequence of any of SEQ ID NOs: 101-107, or (ii) a VL comprising: (a) an LCDR1 comprising an amino acid sequence that differs by no more than 1, 2, or 3 amino acid residues from, or has at least 85, 90, 95, 99 or 100% homology with, an amino acid sequence of any of SEQ ID NOs: 108-111; (b) an LCDR2 comprising an amino acid sequence that differs by no more than 1, 2, or 3 amino acid residues from, or has at least 85, 90, 95, 99 or 100% homology with, an amino acid sequence of any of SEQ ID NOs: 112-114; and (c) an LCDR3 comprising an amino acid sequence that differs by no more than 1, 2, or 3 amino acid residues from, or has at least 85, 90, 95, 99 or 100% homology with, an amino acid sequence of any of SEQ ID NOs: 115-118. In an embodiment, the antibody molecule comprises one or both of: (i) a VH comprising: (a) an HCDR1 comprising an amino acid sequence of any of SEQ ID NOs: 92-96; (b) an HCDR2 comprising an amino acid sequence of any of SEQ ID NOs 97-100; and (c) an HCDR3 comprising an amino acid sequence of any of SEQ ID NOs: 101-107, or (ii) a VL comprising: (a) an LCDR1 comprising an amino acid sequence of any of SEQ ID NOs: 108-111; (b) an LCDR2 comprising an amino acid sequence of any of SEQ ID NOs: 112-114; and (c) an LCDR3 comprising an amino acid sequence of any of SEQ ID NOs: 115-118. In an embodiment, the antibody molecule comprises: (i) a VH comprising: (a) an HCDR1 comprising an amino acid sequence of any of SEQ ID NOs: 92-96; (b) an HCDR2 comprising an amino acid sequence of any of SEQ ID NOs: 97-100; and (c) an HCDR3 comprising an amino acid sequence of any of SEQ ID NOs: 101-107, and (ii) a VL comprising: (a) an LCDR1 comprising an amino acid sequence of any of SEQ ID NOs: 108-111; (b) an LCDR2 comprising an amino acid sequence of any of SEQ ID NOs: 112-114; and (c) an LCDR3 comprising an amino acid sequence of any of SEQ ID NOs: 115-118. In an embodiment, the antibody molecule comprises: (i) a VH comprising an HCDR1 comprising the amino acid sequence of SEQ ID NO: 92; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 97; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 101, and (ii) a VL comprising an LCDR1 comprising the amino acid sequence of SEQ ID NO: 108; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 112; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 115. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence of SEQ ID NO: 93; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 97; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 102, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of SEQ ID NO: 108; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 112; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 115. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence of SEQ ID NO: 93; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 98; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 103, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of SEQ ID NO: 108; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 112; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 115. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence of SEQ ID NO: 92; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 99; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 104, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of SEQ ID NO: 108; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 112; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 115. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence of SEQ ID NO: 92; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 98; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 105, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of SEQ ID NO: 108; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 112; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 115. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence of SEQ ID NO: 94; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 100; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 102, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of SEQ ID NO: 108; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 112; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 115. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence of SEQ ID NO: 92; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 100; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 104, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of SEQ ID NO: 108; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 112; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 115. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence of SEQ ID NO: 95; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 97; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 106, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of SEQ ID NO: 108; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 112; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 115. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence of SEQ ID NO: 96; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 97; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 107, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of SEQ ID NO: 108; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 112; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 115. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence of SEQ ID NO: 92; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 97; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 101, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of SEQ ID NO: 109; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 113; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 115. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence of SEQ ID NO: 93; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 97; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 102, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of SEQ ID NO: 109; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 113; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 115. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence of SEQ ID NO: 93; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 98; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 103, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of SEQ ID NO: 109; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 113; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 115. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence of SEQ ID NO: 92; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 99; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 104, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of SEQ ID NO: 109; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 113; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 115. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence of SEQ ID NO: 92; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 98; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 105, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of SEQ ID NO: 109; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 113; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 115. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence of SEQ ID NO: 94; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 100; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 102, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of SEQ ID NO: 109; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 113; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 115. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence of SEQ ID NO: 92; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 100; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 104, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of SEQ ID NO: 109; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 113; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 115. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence of SEQ ID NO: 95; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 97; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 106, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of SEQ ID NO: 109; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 113; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 115. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence of SEQ ID NO: 96; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 97; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 107, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of SEQ ID NO: 109; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 113; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 115. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence of SEQ ID NO: 92; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 97; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 101, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of SEQ ID NO: 108; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 114; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 116. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence of SEQ ID NO: 93; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 97; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 102, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of SEQ ID NO: 108; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 114; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 116. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence of SEQ ID NO: 93; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 98; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 103, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of SEQ ID NO: 108; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 114; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 116. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence of SEQ ID NO: 92; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 99; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 104, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of SEQ ID NO: 108; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 114; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 116. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence of SEQ ID NO: 92; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 98; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 105, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of SEQ ID NO: 108; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 114; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 116. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence of SEQ ID NO: 94; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 100; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 102, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of SEQ ID NO: 108; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 114; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 116. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence of SEQ ID NO: 92; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 100; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 104, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of SEQ ID NO: 108; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 114; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 116. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence of SEQ ID NO: 95; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 97; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 106, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of SEQ ID NO: 108; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 114; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 116. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence of SEQ ID NO: 96; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 97; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 107, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of SEQ ID NO: 108; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 114; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 116. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence of SEQ ID NO: 92; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 97; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 101, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of SEQ ID NO: 110; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 112; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 117. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence of SEQ ID NO: 93; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 97; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 102, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of SEQ ID NO: 110; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 112; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 117. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence of SEQ ID NO: 93; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 98; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 103, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of SEQ ID NO: 110; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 112; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 117. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence of SEQ ID NO: 92; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 99; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 104, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of SEQ ID NO: 110; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 112; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 117. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence of SEQ ID NO: 92; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 98; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 105, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of SEQ ID NO: 110; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 112; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 117. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence of SEQ ID NO: 94; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 100; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 102, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of SEQ ID NO: 110; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 112; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 117. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence of SEQ ID NO: 92; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 100; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 104, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of SEQ ID NO: 110; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 112; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 117. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence of SEQ ID NO: 95; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 97; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 106, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of SEQ ID NO: 110; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 112; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 117. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence of SEQ ID NO: 96; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 97; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 107, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of SEQ ID NO: 110; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 112; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 117. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence of SEQ ID NO: 92; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 97; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 101, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of SEQ ID NO: 111; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 112; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 118. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence of SEQ ID NO: 93; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 97; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 102, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of SEQ ID NO: 111; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 112; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 118. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence of SEQ ID NO: 93; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 98; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 103, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of SEQ ID NO: 111; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 112; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 118. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence of SEQ ID NO: 92; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 99; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 104, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of SEQ ID NO: 111; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 112; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 118. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence of SEQ ID NO: 92; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 98; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 105, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of SEQ ID NO: 111; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 112; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 118. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence of SEQ ID NO: 94; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 100; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 102, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of SEQ ID NO: 111; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 112; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 118. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence of SEQ ID NO: 92; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 100; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 104, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of SEQ ID NO: 111; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 112; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 118. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence of SEQ ID NO: 95; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 97; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 106, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of SEQ ID NO: 111; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 112; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 118. In an embodiment, the antibody molecule comprises: (i) a VH comprising: an HCDR1 comprising the amino acid sequence of SEQ ID NO: 96; an HCDR2 comprising the amino acid sequence of SEQ ID NO: 97; and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 107, and (ii) a VL comprising: an LCDR1 comprising the amino acid sequence of SEQ ID NO: 111; an LCDR2 comprising the amino acid sequence of SEQ ID NO: 112; and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 118. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 78. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 87. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 78; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 87. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 78; and a VL comprising the amino acid sequence of SEQ ID NO: 87. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 79. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 87. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 79; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 87. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 79; and a VL comprising the amino acid sequence of SEQ ID NO: 87. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 80. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 87. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 80; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 87. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 80; and a VL comprising the amino acid sequence of SEQ ID NO: 87. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 81. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 87. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 81; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 87. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 81; and a VL comprising the amino acid sequence of SEQ ID NO: 87. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 82. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 87. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 82; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 87. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 82; and a VL comprising the amino acid sequence of SEQ ID NO: 87. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 83. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 87. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 83; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 87. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 83; and a VL comprising the amino acid sequence of SEQ ID NO: 87. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 84. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 87. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 84; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 87. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 84; and a VL comprising the amino acid sequence of SEQ ID NO: 87. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 85. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 87. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 85; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 87. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 85; and a VL comprising the amino acid sequence of SEQ ID NO: 87. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 86. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 87. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 86; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 87. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 86; and a VL comprising the amino acid sequence of SEQ ID NO: 87. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 78. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 88. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 78; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 88. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 78; and a VL comprising the amino acid sequence of SEQ ID NO: 88. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 79. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 88. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 79; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 88. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 79; and a VL comprising the amino acid sequence of SEQ ID NO: 88. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 80. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 88. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 80; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 88. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 80; and a VL comprising the amino acid sequence of SEQ ID NO: 88. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 81. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 88. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 81; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 88. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 81; and a VL comprising the amino acid sequence of SEQ ID NO: 88. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 82. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 88. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 82; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 88. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 82; and a VL comprising the amino acid sequence of SEQ ID NO: 88. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 83. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 88. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 83; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 88. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 83; and a VL comprising the amino acid sequence of SEQ ID NO: 88. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 84. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 88. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 84; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 88. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 84; and a VL comprising the amino acid sequence of SEQ ID NO: 88. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 85. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 88. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 85; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 88. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 85; and a VL comprising the amino acid sequence of SEQ ID NO: 88. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 86. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 88. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 86; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 88. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 86; and a VL comprising the amino acid sequence of SEQ ID NO: 88. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 78. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 89. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 78; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 89. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 78; and a VL comprising the amino acid sequence of SEQ ID NO: 89. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 79. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 89. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 79; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 89. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 79; and a VL comprising the amino acid sequence of SEQ ID NO: 89. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 80. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 89. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 80; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 89. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 80; and a VL comprising the amino acid sequence of SEQ ID NO: 89. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 81. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 89. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 81; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 89. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 81; and a VL comprising the amino acid sequence of SEQ ID NO: 89. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 82. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 89. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 82; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 89. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 82; and a VL comprising the amino acid sequence of SEQ ID NO: 89. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 83. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 89. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 83; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 89. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 83; and a VL comprising the amino acid sequence of SEQ ID NO: 89. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 84. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 89. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 84; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 89. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 84; and a VL comprising the amino acid sequence of SEQ ID NO: 89. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 85. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 89. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 85; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 89. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 85; and a VL comprising the amino acid sequence of SEQ ID NO: 89. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 86. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 89. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 86; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 89. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 86; and a VL comprising the amino acid sequence of SEQ ID NO: 89. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 78. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 90. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 78; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 90. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 78; and a VL comprising the amino acid sequence of SEQ ID NO: 90. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 79. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 90. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 79; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 90. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 79; and a VL comprising the amino acid sequence of SEQ ID NO: 90. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 80. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 90. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 80; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 90. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 80; and a VL comprising the amino acid sequence of SEQ ID NO: 90. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 81. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 90. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 81; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 90. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 81; and a VL comprising the amino acid sequence of SEQ ID NO: 90. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 82. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 90. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 82; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 90. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 82; and a VL comprising the amino acid sequence of SEQ ID NO: 90. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 83. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 90. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 83; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 90. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 83; and a VL comprising the amino acid sequence of SEQ ID NO: 90. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 84. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 90. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 84; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 90. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 84; and a VL comprising the amino acid sequence of SEQ ID NO: 90. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 85. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 90. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 85; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 90. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 85; and a VL comprising the amino acid sequence of SEQ ID NO: 90. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 86. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 90. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 86; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 90. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 86; and a VL comprising the amino acid sequence of SEQ ID NO: 90. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 78. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 91. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 78; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 91. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 78; and a VL comprising the amino acid sequence of SEQ ID NO: 91. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 79. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 91. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 79; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 91. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 79; and a VL comprising the amino acid sequence of SEQ ID NO: 91. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 80. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 91. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 80; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 91. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 80; and a VL comprising the amino acid sequence of SEQ ID NO: 91. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 81. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 91. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 81; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 91. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 81; and a VL comprising the amino acid sequence of SEQ ID NO: 91. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 82. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 91. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 82; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 91. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 82; and a VL comprising the amino acid sequence of SEQ ID NO: 91. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 83. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 91. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 83; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 91. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 83; and a VL comprising the amino acid sequence of SEQ ID NO: 91. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 84. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 91. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 84; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 91. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 84; and a VL comprising the amino acid sequence of SEQ ID NO: 91. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 85. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 91. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 85; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 91. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 85; and a VL comprising the amino acid sequence of SEQ ID NO: 91. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 86. In an embodiment, the antibody molecule comprises a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 91. In an embodiment, the antibody molecule comprises a VH comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 86; and a VL comprising an amino acid sequence that differs by no more than 1, 5, 10, 15, or 20 amino acid residues from, or has at least 85%, 90%, 95%, 99%, or 100% homology with, the amino acid sequence of SEQ ID NO: 91. In an embodiment, the antibody molecule comprises a VH comprising the amino acid sequence of SEQ ID NO: 86; and a VL comprising the amino acid sequence of SEQ ID NO: 91. In an embodiment, the antibody molecule comprises one or both of (a) a VH comprising an amino acid sequence of any of SEQ ID NOs: 1-25, or an amino acid sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical thereto, or differs by no more than 1, 2, 3, 4, 5, 10, 15, 20, or 25 amino acids therefrom; or (b) a VL comprising an amino acid sequence of any of SEQ ID NOs: 26-42, or an amino acid sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical thereto, or differs by no more than 1, 2, 3, 4, 5, 10, 15, 20, or 25 amino acids therefrom. In an embodiment, the antibody molecule further comprises a heavy chain constant region (e.g., a heavy chain constant region described herein), a light chain constant region (e.g., a light chain constant region described herein), or both. In an embodiment, the antibody molecule comprises one or both of the VH or VL of any of mAb1.1, mAb1.2, mAb1.3, mAb1.4, mAb1.5, mAb1.6, mAb1.7, mAb1.8, mAb1.9, mAb1.10, mAb1.11, mAb1.12, mAb1.13, mAb1.14, mAb1.15, mAb1.16, mAb1.18, mAb1.19, mAb1.20, mAb1.21, mAb1.22, mAb1.23, mAb1.24, mAb1.25, mAb1.26, mAb1.27, mAb1.28, mAb1.29, mAb1.30, mAb1.31, mAb1.32, mAb1.33, mAb1.34, mAb1.35, mAb1.36, mAb1.37, mAb1.38, mAb1.39, mAb1.40, mAb1.41, mAb1.42, mAb1.43, mAb1.44, mAb1.45, mAb1.46, mAb1.47, mAb1.48, mAb1.49, mAb1.50, mAb1.51, mAb1.52, mAb1.53, mAb1.54, mAb1.55, mAb1.56, mAb1.57, mAb1.58, mAb1.59, mAb1.60, mAb1.61, mAb1.62, mAb1.63, mAb1.64, mAb1.65, mAb1.66, mAb1.67, mAb1.68, mAb1.69, mAb1.70, mAb1.71, mAb1.72, mAb1.73, mAb1.74, mAb1.75, mAb1.76, mAb1.77, mAb1.78, mAb1.79, mAb1.80, mAb1.81, mAb1.82, mAb1.83, mAb1.84, mAb1.85, mAb1.86, mAb1.87, mAb1.88, mAb1.89, mAb1.90, mAb1.91, mAb1.92, mAb1.93, mAb1.94, mAb1.95, mAb1.96, mAb1.97, mAb1.98, mAb1.99, mAb1.100, mAb1.101, mAb1.102, mAb1.103, mAb1.104, mAb1.105, mAb1.106, mAb1.107, mAb1.108, mAb1.109, mAb1.110, mAb1.111, mAb1.112, mAb1.113, mAb1.114, mAb1.115, mAb1.116, mAb1.117, mAb1.118, mAb1.119, mAb1.120, mAb1.121, mAb1.122, mAb1.123, mAb1.124, mAb1.125, mAb1.126, mAb1.127, mAb1.128, mAb1.129, mAb1.130, mAb1.131, mAb1.132, mAb1.133, mAb1.134, mAb1.135, mAb1.136, mAb1.137, mAb1.138, mAb1.139, mAb1.140, mAb1.141, or mAb1.142. In an embodiment, the antibody molecule further comprises a heavy chain constant region (e.g., a heavy chain constant region described herein), a light chain constant region (e.g., a light chain constant region described herein), or both. In an embodiment, the antibody molecule comprises one or both of (a) a VH comprising an amino acid sequence of any of SEQ ID NOs: 78-86, or an amino acid sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical thereto, or differs by no more than 1, 2, 3, 4, 5, 10, 15, 20, or 25 amino acids therefrom; or (b) a VL comprising an amino acid sequence of any of SEQ ID NOs: 87-91, or an amino acid sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical thereto, or differs by no more than 1, 2, 3, 4, 5, 10, 15, 20, or 25 amino acids therefrom. In an embodiment, the antibody molecule further comprises a heavy chain constant region (e.g., a heavy chain constant region described herein), a light chain constant region (e.g., a light chain constant region described herein), or both. In an embodiment, the antibody molecule comprises one or both of the VH or VL of any of mAb2.1, mAb2.2, mAb2.3, mAb2.4, mAb2.5, mAb2.6, mAb2.7, mAb2.8, mAb2.9, mAb2.10, mAb2.11, mAb2.12, mAb2.13, mAb2.14, mAb2.15, mAb2.16, mAb2.17, mAb2.18, mAb2.19, mAb2.20, mAb2.21, mAb2.22, mAb2.23, mAb2.24, mAb2.25, mAb2.26, mAb2.27, mAb2.28, mAb2.29, mAb2.30, mAb2.31, mAb2.32, mAb2.33, mAb2.34, mAb2.35, mAb2.36, mAb2.37, mAb2.38, mAb2.39, mAb2.40, mAb2.41, mAb2.42, mAb2.43, mAb2.44, or mAb2.45. In an embodiment, the antibody molecule further comprises a heavy chain constant region (e.g., a heavy chain constant region described herein), a light chain constant region (e.g., a light chain constant region described herein), or both. In an embodiment, the antibody molecule further comprises a heavy chain constant region, e.g., a heavy chain constant region described herein. In an embodiment, the antibody molecule further comprises a light chain constant region, e.g., a light chain constant region described herein. In an embodiment, the antibody molecule further comprises a heavy chain constant region, e.g., a heavy chain constant region described herein, and a light chain constant region, e.g., a light chain constant region described herein. In an embodiment, the antibody molecule binds to a coronavirus spike protein (e.g., a SARS- CoV-2 spike protein), or a fragment thereof (e.g., a fragment comprising an RBD), with high affinity, e.g., with a dissociation constant (K D ) of 100 nM or less, e.g., 50 nM or less, 20 nM or less, 10 nM or less, 5 nM or less, 2 nM or less, 1 nM or less, 0.5 nM or less, 0.2 nM or less, 0.1 nM or less, 0.09 nM or less, 0.08 nM or less, 0.07 nM or less, 0.06 nM or less, 0.05 nM or less, 0.04 nM or less, 0.03 nM or less, 0.02 nM or less, 0.01 nM or less, 0.005 nM or less, 0.002 nM or less, or 0.001 nM or less, e.g., between 0.001 nM and 100 nM, between 0.01 nM and 100 nM, between 0.1 nM and 100 nM, between 1 nM and 100 nM, between 10 nM and 100 nM, between 0.001 nM and 1 nM, between 0.002 nM and 0.5 nM, between 0.005 nM and 0.2 nM, between 0.01 nM and 0.1 nM, between 0.02 nM and 0.05 nM, between 0.001 nM and 0.5 nM, between 0.001 nM and 0.2 nM, between 0.001 nM and 0.1 nM, between 0.001 nM and 0.05 nM, between 0.001 nM and 0.02 nM, between 0.001 nM and 0.01 nM, between 0.001 nM and 0.005 nM, between 0.5 nM and 1 nM, between 0.2 nM and 1 nM, between 0.1 nM and 1 nM, between 0.05 nM and 1 nM, between 0.02 nM and 1 nM, between 0.01 nM and 1 nM, between 0.005 nM and 1 nM, between 0.002 nM and 1 nM, between 0.002 nM and 0.01 nM, between 0.005 nM and 0.02 nM, between 0.01 nM and 0.05 nM, between 0.02 nM and 0.1 nM, between 0.05 nM and 0.2 nM, or between 0.1 nM and 0.5 nM, e.g., between 0.02 nM and 0.1 nM, between 0.04 nM and 0.1 nM, between 0.043 nM and 0.095 nM, between 0.02 nM and 0.03 nM, between 0.04 nM and 0.05 nM, or between 0.09 nM and 0.1 nM, e.g., 0.0216nM, 0.043 nM, or 0.095 nM, e.g., as determined by a method described herein (e.g., in Examples). In an embodiment, the antibody molecule binds to a coronavirus spike protein (e.g., a SARS- CoV-2 spike protein), or fragment thereof (e.g., a fragment comprising an RBD), with high affinity, e.g., with a half maximal effective concentration (EC 50 ) of 10 µg/mL or less, e.g., 5 µg/mL or less, 2 µg/mL or less, 1 µg/mL or less, 0.5 µg/mL or less, 0.2 µg/mL or less, 100 ng/mL or less, 50 ng/mL or less, 20 ng/mL or less, 15 ng/mL or less, 10 ng/mL or less, 9 ng/mL or less, 8 ng/mL or less, 7 ng/mL or less, 6 ng/mL or less, 5 ng/mL or less, 4 ng/mL or less, 3 ng/mL or less, 2 ng/mL or less, 1 ng/mL or less, 0.5 ng/mL or less, 0.2 ng/mL or less, or 0.1 ng/mL or less, e.g., less, 5 ng/mL or less, 4 ng/mL or less, 3 ng/mL or less, 2 ng/mL or less, 1 ng/mL or less, 0.5 ng/mL or less, 0.2 ng/mL or less, or 0.1 ng/mL or less, e.g., between 0.1 ng/mL to 10 µg/mL, between 1 ng/mL to 10 µg/mL, between 10 ng/mL to 10 µg/mL, between 100 ng/mL to 10 µg/mL, between 1 µg/mL to 10 µg/mL, between 0.1 ng/mL and 100 ng/mL, between 0.2 ng/mL and 50 ng/mL, between 0.5 ng/mL and 20 ng/mL, between 1 ng/mL and 10 ng/mL, between 2 ng/mL and 5 ng/mL, between 0.1 ng/mL and 50 ng/mL, between 0.1 ng/mL and 20 ng/mL, between 0.1 ng/mL and 10 ng/mL, between 0.1 ng/mL and 5 ng/mL, between 0.1 ng/mL and 2 ng/mL, between 0.1 ng/mL and 1 ng/mL, between 0.1 ng/mL and 0.5 ng/mL, between 0.1 ng/mL and 0.2 ng/mL, between 50 ng/mL and 100 ng/mL, between 20 ng/mL and 100 ng/mL, between 10 ng/mL and 100 ng/mL, between 5 ng/mL and 100 ng/mL, between 2 ng/mL and 100 ng/mL, between 1 ng/mL and 100 ng/mL, between 0.5 ng/mL and 100 ng/mL, between 0.2 ng/mL and 100 ng/mL, between 0.2 ng/mL and 1 ng/mL, between 0.5 ng/mL and 2 ng/mL, between 1 ng/mL and 5 ng/mL, between 2 ng/mL and 10 ng/mL, between 5 ng/mL and 20 ng/mL, or between 10 ng/mL and 50 ng/mL, e.g., between 1 ng/mL and 15 ng/mL, between 6 ng/mL and 15 ng/mL, between 1 ng/mL and 9 ng/mL, between 1 ng/mL and 2 ng/mL, between 3 ng/mL and 4 ng/mL, between 6 ng/mL and 7 ng/mL, between 8 ng/mL and 9 ng/mL, between 14 ng/mL and 15 ng/mL, e.g., , 1.39 ng/mL, 3.25 ng/mL, 6.4 ng/mL, 8.47 ng/mL, or 14.2 ng/mL, e.g., as determined by a method described herein (e.g., in Examples). In an embodiment, the antibody molecule binds to a coronavirus spike protein (e.g., a SARS- CoV-2 spike protein), or fragment thereof (e.g., a fragment comprising an RBD), with high affinity, e.g., with a half maximal effective concentration (EC 50 ) of 100 nM or less, e.g., 50 nM or less, 20 nM or less, 10 nM or less, 5 nM or less, 2 nM or less, 1 nM or less, 500 pM or less, 200 pM or less, 100 pM or less, 50 pM or less, 20 pM or less, 10 pM or less, 5 pM or less, 2 pM or less, or 1 pM or less, e.g., between 1 pM and 100 nM, between 10 pM and 100 nM, between 0.1 nM and 100 nM, between 1 nM and 100 nM, between 10 nM and 100 nM, between 1 pM and 500 pM, between 2 pM and 200 pM, between 5 pM and 100 pM, between 10 pM and 50 pM, between 1 pM and 200 pM, between 1 pM and 100 pM, between 1 pM and 50 pM, between 1 pM and 20 pM, between 1 pM and 10 pM, between 1 pM and 5 pM, between 200 pM and 500 pM, between 100 pM and 500 pM, between 50 pM and 500 pM, between 20 pM and 500 pM, between 10 pM and 500 pM, between 5 pM and 500 pM, between 2 pM and 500 pM, between 2 pM and 10 pM, between 5 pM and 20 pM, between 10 pM and 50 pM, between 20 pM and 100 pM, between 50 pM and 200 pM, e.g., between 9 pM and 60 pM, between 8 pM and 10 pM, between 20 pM and 24 pM, between 55 pM and 58 pM, e.g., 9.26 pM, 21.6 pM, or 56.4 pM, e.g., as determined by a method described herein (e.g., in Examples). In an embodiment, the antibody molecule reduces (e.g., inhibits or blocks) the binding of a coronavirus spike protein (e.g., a SARS-CoV-2 spike protein), or a fragment thereof (e.g., a fragment comprising an RBD), to an ACE receptor, at a half maximal inhibitory concentration (IC 50 ) of 100 µg/ml or less, e.g., 50 µg/ml or less, 20 µg/ml or less, 10 µg/ml or less, 9 µg/ml or less, 8 µg/ml or less, 7 µg/ml or less, 6 µg/ml or less, 5 µg/ml or less, 4 µg/ml or less, 3 µg/ml or less, 2 µg/ml or less, 1 µg/ml or less, 0.9 µg/ml or less, 0.8 µg/ml or less, 0.7 µg/ml or less, 0.6 µg/ml or less, 0.5 µg/ml or less, 0.4 µg/ml or less, 0.3 µg/ml or less, 0.2 µg/ml or less, 0.1 µg/ml or less, 0.05 µg/ml or less, 0.02 µg/ml or less, or 0.01 µg/ml or less, e.g., between 0.01 µg/ml and 100 µg/ml, between 0.02 µg/ml and 50 µg/ml, between 0.05 µg/ml and 20 µg/ml, between 0.1 µg/ml and 10 µg/ml, between 0.2 µg/ml and 5 µg/ml, between 0.5 µg/ml and 2 µg/ml, between 0.02 µg/ml and 100 µg/ml, between 0.05 µg/ml and 100 µg/ml, between 0.1 µg/ml and 100 µg/ml, between 0.1 µg/ml and 50 µg/ml, between 0.1 µg/ml and 20 µg/ml, between 0.1 µg/ml and 10 µg/ml, between 0.1 µg/ml and 5 µg/ml, between 0.1 µg/ml and 2 µg/ml, between 0.1 µg/ml and 1 µg/ml, between 0.1 µg/ml and 0.5 µg/ml, between 0.1 µg/ml and 0.2 µg/ml, between 20 µg/ml and 100 µg/ml, between 10 µg/ml and 100 µg/ml, between 5 µg/ml and 100 µg/ml, between 2 µg/ml and 100 µg/ml, between 1 µg/ml and 100 µg/ml, between 0.5 µg/ml and 100 µg/ml, between 0.2 µg/ml and 100 µg/ml, between 0.1 µg/ml and 100 µg/ml, between 0.05 µg/ml and 100 µg/ml, 0.02 µg/ml and 100 µg/ml, between 0.02 µg/ml and 0.1 µg/ml, between 0.05 µg/ml and 0.2 µg/ml, between 0.1 µg/ml and 0.5 µg/ml, between 0.2 µg/ml and 1 µg/ml, between 0.5 µg/ml and 2 µg/ml, between 1 µg/ml and 5 µg/ml, between 2 µg/ml and 10 µg/ml, between 5 µg/ml and 20 µg/ml, or between 10 µg/ml and 50 µg/ml, e.g., between 0.1 µg/ml and 15 µg/ml, between 0.1 µg/ml and 2.5 µg/ml, between 1 µg/ml and 15 µg/ml, between 0.5 µg/ml and 3.5 µg/ml, between 0.3 µg/ml and 1.2 µg/ml, 1.2 µg/ml and 3 µg/ml, between 0.3 µg/ml and 0.4 µg/ml, between 0.9 µg/ml and 1 µg/ml, between 1 µg/ml and 1.2 µg/ml, between 2 µg/ml and 2.2 µg/ml, between 3.1 µg/ml and 3.2 µg/ml, e.g., 0.17 µg/ml, 0.24 µg/ml, 0.33 µg/ml, 0.66 µg/ml, 0.974 µg/ml, 1.05 µg/ml, 1.7 µg/ml, 1.99 µg/ml, 2.15 µg/ml, 2.3 µg/ml, 3.16 µg/ml, 3.29 µg/ml, 3.63 µg/ml, 3.85 µg/ml, 4.28 µg/ml, 5.89 µg/ml, 7.38 µg/ml, 7.53 µg/ml, or 9.55 µg/ml, e.g., as determined by a method described herein (e.g., in Examples). In an embodiment, the antibody molecule reduces (e.g., inhibits or blocks) the binding of a coronavirus spike protein (e.g., a SARS-CoV-2 spike protein), or a fragment thereof (e.g., a fragment comprising an RBD), to an ACE receptor, at a half maximal inhibitory concentration (IC 50 ) of 200 nM or less, e.g., 150 nM or less, 100 nM or less, 50 nM or less, 25 nM or less, 20 nM or less, 15 nM or less, 10 nM or less, 5 nM or less, 2 nM or less, 1 nM or less, 0.5 nM or less, 0.2 nM or less, or 0.1 nM or less, e.g., between 0.1 nM and 200 nM, between 0.2 nM and 100 nM, between 0.5 nM and 50 nM, between 1 nM and 20 nM, between 2 nM and 10 nM, between 0.1 nM and 100 nM, between 0.1 nM and 50 nM, between 0.1 nM and 20 nM, between 0.1 nM and 10 nM, between 0.1 nM and 5 nM, between 0.1 nM and 2 nM, between 0.1 nM and 1 nM, between 0.1 nM and 0.5 nM, between 0.1 nM and 0.2 nM, between 100 nM and 200 nM, between 50 nM and 200 nM, between 20 nM and 200 nM, between 10 nM and 200 nM, between 5 nM and 200 nM, between 2 nM and 200 nM, between 1 nM and 200 nM, between 0.5 nM and 200 nM, between 0.2 nM and 200 nM, between 0.2 nM and 1 nM, between 0.5 nM and 2 nM, between 1 nM and 5 nM, between 2 nM and 10 nM, between 5 nM and 20 nM, between 10 nM and 50 nM, between 20 nM and 100 nM, e.g., between 2 nM and 25 nM, between 6 nM and 7 nM, between 14 nM and 15 nM, between 21 nM and 22 nM, e.g., 6.5 nM, 14.3 nM, or 21.1 nM, e.g., as determined by a method described herein (e.g., in Examples). In an embodiment, the antibody molecule reduces (e.g., inhibits or neutralizes) a coronavirus (e.g., SARS-CoV-2) infection at a half maximal inhibitory concentration (IC 50 ) of 10 µg/ml or less, e.g., 5 µg/ml or less, 2 µg/ml or less, 1 µg/ml or less, 0.9 µg/ml or less, 0.8 µg/ml or less, 0.7 µg/ml or less, 0.6 µg/ml or less, 0.5 µg/ml or less, 0.4 µg/ml or less, 0.3 µg/ml or less, 0.2 µg/ml or less, 0.1 µg/ml or less, 0.05 µg/ml or less, 0.02 µg/ml or less, or 0.01 µg/ml or less, e.g., between 0.01 µg/ml and 10 µg/ml, between 0.1 µg/ml and 10 µg/ml, between 1 µg/ml and 10 µg/ml, between 0.01 µg/ml and 5 µg/ml, between 0.02 µg/ml and 2 µg/ml, between 0.05 µg/ml and 1 µg/ml, between 0.1 µg/ml and 0.5 µg/ml, between 0.01 µg/ml and 0.02 µg/ml, between 0.01 µg/ml and 0.05 µg/ml, between 0.01 µg/ml and 0.1 µg/ml, between 0.01 µg/ml and 0.2 µg/ml, between 0.01 µg/ml and 0.5 µg/ml, between 0.01 µg/ml and 1 µg/ml, between 0.01 µg/ml and 2 µg/ml, between 2 µg/ml and 5 µg/ml, between 1 µg/ml and 5 µg/ml, between 0.5 µg/ml and 5 µg/ml, between 0.2 µg/ml and 5 µg/ml, between 0.1 µg/ml and 5 µg/ml, between 0.05 µg/ml and 5 µg/ml, between 0.02 µg/ml and 5 µg/ml, between 0.02 µg/ml and 0.1 µg/ml, between 0.05 µg/ml and 0.2 µg/ml, between 0.1 µg/ml and 0.5 µg/ml, between 0.2 µg/ml and 1 µg/ml, or between 0.5 µg/ml and 2 µg/ml, e.g., between 0.3 µg/ml and 1.2 µg/ml, between 0.354 µg/ml and 1.14 µg/ml, between 0.3 µg/ml and 0.4 µg/ml, between 1.1 µg/ml and 1.2 µg/ml, e.g., 0.354 µg/ml or 1.14 µg/ml, as determined by a method described herein (e.g., in Examples). In an embodiment, the antibody molecule reduces (e.g., inhibits or neutralizes) a coronavirus (e.g., SARS-CoV-2) infection at a half maximal inhibitory concentration (IC 50 ) of 100 nM or less, e.g., 50 nM or less, 20 nM or less, 10 nM or less, 9 nM or less, 8 nM or less, 7 nM or less, 6 nM or less, 5 nM or less, 4 nM or less, 3 nM or less, 2 nM or less, 1 nM or less, 0.5 nM or less, 0.2 nM or less, 0.1 nM or less, e.g., between 0.1 nM and 100 nM, between 1 nM and 100 nM, between 0.1 nM and 50 nM, between 0.2 nM and 20 nM, between 0.5 nM and 10 nM, between 1 nM and 5 nM, between 0.1 nM and 0.2 nM, between 0.1 nM and 0.5 nM, between 0.1 nM and 1 nM, between 0.1 nM and 2 nM, between 0.1 nM and 5 nM, between 0.1 nM and 10 nM, between 0.1 nM and 20 nM, between 20 nM and 50 nM, between 10 nM and 50 nM, between 5 nM and 50 nM, between 1 nM and 50 nM, between 0.5 nM and 50 nM, between 0.2 nM and 50 nM, between 0.2 nM and 1 nM, between 0.5 nM and 2 nM, between 1 nM and 5 nM, between 2 nM and 10 nM, or between 5 nM and 20 nM, e.g., between 2 nM and 8 nM, between 2.4 nM and 7.6 nM, between 2 nM and 3 nM, between 7 nM and 8 nM, e.g., 2.4 nM or 7.6 nM, as determined by a method described herein; In an embodiment, the antibody molecule reduces (e.g., inhibits or neutralizes) a coronavirus (e.g., SARS-CoV-2) infection at a PRNT 50 of 100 µg/mL or less, e.g., 20 µg/mL or less, 10 µg/mL or less, 9 µg/mL or less, 8 µg/mL or less, 7 µg/mL or less, 6 µg/mL or less, 5 µg/mL or less, 4 µg/mL or less, 3 µg/mL or less, 2 µg/mL or less, 1 µg/mL or less, 0.5 µg/mL or less, 0.2 µg/mL or less, 0.1 µg/mL or less, e.g., between 0.1 µg/mL and 100 µg/mL, between 1 µg/mL and 100 µg/mL, between 10 µg/mL and 100 µg/mL, between 0.1 µg/mL and 50 µg/mL, between 0.2 µg/mL and 20 µg/mL, between 0.5 µg/mL and 10 µg/mL, between, 1 µg/mL and 5 µg/mL, between 0.1 µg/mL and 20 µg/mL, between 0.1 µg/mL and 10 µg/mL, between 0.1 µg/mL and 5 µg/mL, between 0.1 µg/mL and 2 µg/mL, between 0.1 µg/mL and 1 µg/mL, between 0.1 µg/mL and 0.5 µg/mL, between 0.1 µg/mL and 0.2 µg/mL, between 20 µg/mL and 50 µg/mL, between 10 µg/mL and 50 µg/mL, between 5 µg/mL and 50 µg/mL, between 2 µg/mL and 50 µg/mL, between 1 µg/mL and 50 µg/mL, between 0.5 µg/mL and 50 µg/mL, between 0.2 µg/mL and 50 µg/mL, between 0.2 µg/mL and 1 µg/mL, between 0.5 µg/mL and 2 µg/mL, between 1 µg/mL and 5 µg/mL, between 2 µg/mL and 10 µg/mL, between 5 µg/mL and 20 µg/mL, e.g., between 2 µg/mL and 8 µg/mL, between 2 µg/mL and 3 µg/mL, between 3 µg/mL and 4 µg/mL, between 4 µg/mL and 5 µg/mL, between 7 µg/mL and 8 µg/mL, e.g., 2.82 µg/mL, 3.68 µg/mL, 3.97 µg/mL, 4.03 µg/mL, or 7.04 µg/mL, e.g., as determined by a plaque reduction neutralization test (PRNT) (e.g., as shown in Examples). In an embodiment, the antibody molecule reduces (e.g., inhibits or neutralizes) a coronavirus (e.g., SARS-CoV-2) infection at a PRNT 50 of 500 nM or less, e.g., 200 nM or less, 100 nM or less, 50 nM or less, 40 nM or less, 30 nM or less, 20 nM or less, 10 nM or less, 5 nm or less, 2 nM or less, or 1 nM or less, e.g., between 1 nM and 500 nM, between 10 nM and 500 nM, between 100 nM and 500 nM, between 1 nM and 200 nM, between 2 nM and 100 nM, between 5 nM and 50 nM, between 10 nM and 20 nM, between 1 nM and 100 nM, between 1 nM and 50 nM, between 1 nM and 20 nM, between 1 nM and 10 nM, between 1 nM and 5 nM, between 1 nM and 2 nM, between 100 nM and 200 nM, between 50 nM and 200 nM, 20 nM and 200 nM, 10 nM and 200 nM, 5 nM and 200 nM, 2 nM and 200 nM, 2 nM and 10 nM, 5 nM and 20 nM, 10 nM and 50 nM, 20 nM and 100 nM, e.g., between 15 nM and 50 nM, between 18 nM and 19 nM, between 24 nM and 25 nM, between 26 nM and 27 nM, between 46 nM and 47 nM, e.g., 18.8 nM, 24.5 nM, 26.5 nM, 26.9 nM, or 46.9 nM, e.g., as determined by a plaque reduction neutralization test (PRNT) (e.g., as shown in Examples). In an embodiment, the antibody molecule reduces (e.g., inhibits, blocks, or neutralizes) one or more biological activities of a coronavirus spike protein (e.g., a SARS-CoV-2 spike protein), in vitro, ex vivo, or in vivo. In an embodiment, the antibody molecule binds specifically to an epitope on a coronavirus spike protein (e.g., a SARS-CoV-2 spike protein), or a fragment thereof (e.g., a fragment comprising an RBD), e.g., the same, similar, or overlapping epitope as the epitope recognized by a monoclonal antibody described in any of Tables 1-4. In an embodiment, the antibody molecule shows the same or similar binding affinity or specificity, or both, as a monoclonal antibody described in any of Tables 1-4. In an embodiment, the antibody molecule shows the same or similar binding affinity or specificity, or both, as an antibody molecule comprising one or more (e.g., two or three) heavy chain CDRs and/or one or more (e.g., two or three) light chain CDRs described in Table 3 or 4. In an embodiment, the antibody molecule shows the same or similar binding affinity or specificity, or both, as an antibody molecule comprising a heavy chain variable region (VH) and/or a light chain variable region (VL) described in Table 1 or 2. In an embodiment, the antibody molecule inhibits, e.g., competitively inhibits, the binding of a second antibody molecule to a coronavirus spike protein (e.g., a SARS-CoV-2 spike protein), or a fragment thereof, wherein the second antibody molecule is a monoclonal antibody described in any of Tables 1-4. In an embodiment, the antibody molecule competes for binding with a second antibody molecule to a coronavirus spike protein (e.g., a SARS-CoV-2 spike protein), or a fragment thereof, wherein the second antibody molecule is a monoclonal antibody selected from any of Tables 1-4. In an embodiment, the antibody molecule has one or more biological properties of a monoclonal antibody described in any of Tables 1-4. In an embodiment, the antibody molecule has one or more structural properties of a monoclonal antibody described in any of Tables 1-4. In an embodiment, the antibody molecule has one or more pharmacokinetic properties of a monoclonal antibody described in any of Tables 1-4. In an embodiment, the antibody molecule binds to a coronavirus spike protein (e.g., a SARS- CoV-2 spike protein), or a fragment thereof (e.g., a fragment comprising an RBD), with high affinity, wherein the coronavirus spike protein (e.g., SARS-CoV-2 spike protein) comprises an amino acid sequence of SEQ ID NO: 131, 132 or 133. In an embodiment, the antibody molecule binds specifically to a coronavirus spike protein (e.g., a SARS-CoV-2 spike protein), or a fragment thereof (e.g., a fragment comprising an RBD), with high affinity, wherein the coronavirus spike protein (e.g., SARS-CoV-2 spike protein) comprises one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more) mutations chosen from D839Y, A829T, D480A/G, L452R, D614G, S13I, W152C, A67V, 69del, 70del, 144del, E484K, Q677H, F888L, L5F, (D80G*), T95I, (Y144-*), (F157S*), D253G, (L452R*), (S477N*), A701V, (T859N*), (D950H*), (Q957R*), (T95I), G142D, E154K, E484Q, P681R, Q1071H, T19R, D950N, (E484K*), (S494P*), N501Y, A570D, P681H, T716I, S982A, D1118H, (K1191N*), D80A, D215G, 241del, 242del, 243del, K417N, (V70F*), E156-, F157-, R158G, (A222V*), (W258L*), (K417N*), T478K, L18F, T20N, P26S, D138Y, R190S, K417T, H655Y, or T1027I. In an embodiment, the antibody molecule reduces (e.g., inhibits or neutralizes) an infection caused by a coronavirus variant (e.g., a SARS-CoV-2 variant), e.g., one or more of SARS-CoV-2 variants alpha (B.1.1.7, UK variant), beta (B.1.351, B.1.351.2, B.1.351.3, South Africa variant), gamma (P.1, P.1.1, P.1.2, Brazil variant), delta (B.1.617.2, AY.1, AY.2, AY.3, India variant), eta (B.1.525), Iota (B.1.526), kappa (B.1.617.1), or lambda (C.37). In an embodiment, the antibody molecule reduces (e.g., inhibits or neutralizes) an infection caused by a coronavirus variant (e.g., a SARS-CoV-2 variant comprising one or more (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more) mutations in the spike protein chosen from D839Y, A829T, D480A/G, L452R, D614G, S13I, W152C, A67V, 69del, 70del, 144del, E484K, Q677H, F888L, L5F, (D80G*), T95I, (Y144-*), (F157S*), D253G, (L452R*), (S477N*), A701V, (T859N*), (D950H*), (Q957R*), (T95I), G142D, E154K, E484Q, P681R, Q1071H, T19R, D950N, (E484K*), (S494P*), N501Y, A570D, P681H, T716I, S982A, D1118H, (K1191N*), D80A, D215G, 241del, 242del, 243del, K417N, (V70F*), E156-, F157-, R158G, (A222V*), (W258L*), (K417N*), T478K, L18F, T20N, P26S, D138Y, R190S, K417T, H655Y, or T1027I;. Animal Models The antibody molecules described herein can be evaluated in vivo, e.g., using various animal models. For example, an animal model can be used to test the efficacy of an antibody molecule described herein in inhibiting binding of a coronavirus spike protein (e.g., a SARS-CoV-2 spike protein), in treating or preventing a coronavirus (e.g., a SARS-CoV-2) infection, and/or in treating or preventing a disorder associated with a coronavirus (e.g., a SARS-CoV-2), e.g., COVID-19. Exemplary animal models that can be used for evaluating an antibody molecule described herein are known in the art, e.g., as described in Muñoz-Fontela et al., Nature.2020 Oct; 586(7830):509-515, which is incorporated by reference in its entirety. For example, the suitable animal models include, but are not limited to, mouse models, Syrian hamster model, ferret models, and non-human-primate models. Additional exemplary animal models include, e.g., mink, cats, dogs, pigs, chickens, ducks, and fruit bats. Pharmaceutical Compositions The antibody molecules described herein can be included in pharmaceutical compositions. In an aspect, this disclosure provides a composition, e.g., a pharmaceutically acceptable composition, which includes an antibody molecule described herein, formulated together with a pharmaceutically acceptable carrier. Therapeutic compositions in accordance with the disclosure can comprise one or more antibody molecules, e.g., an antibody molecule as disclosed herein, with suitable carriers, excipients, and other agents that are incorporated into formulations to provide improved transfer, delivery, tolerance, and the like. These formulations include, for example, powders, pastes, ointments, jellies, waxes, oils, lipids, lipid (cationic or anionic) containing vesicles (such as LIPOFECTIN™), DNA conjugates, anhydrous absorption pastes, oil-in-water and water-in-oil emulsions, emulsions carbowax (polyethylene glycols of various molecular weights), semi-solid gels, and semi-solid mixtures containing carbowax. See, e.g., Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa.; and Powell et al. “Compendium of excipients for parenteral formulations” PDA (1998) J Pharm Sci Technol 52:238-311. As used herein, “pharmaceutically acceptable carrier” includes any and all solvents, dispersion media, isotonic and absorption delaying agents, and the like that are physiologically compatible. The carrier can be suitable for intravenous, intramuscular, subcutaneous, parenteral, rectal, spinal or epidermal administration (e.g., by injection or infusion). In an embodiment, less than about 5%, e.g., less than about 4%, 3%, 2%, or 1% of the antibody molecules in the pharmaceutical composition are present as aggregates. In other embodiments, at least about 95%, e.g., at least about 96%, 97%, 98%, 98.5%, 99%, 99.5%, 99.8%, or more of the antibody molecules in the pharmaceutical composition are present as monomers. In an embodiment, the level of aggregates or monomers is determined by chromatography, e.g., high performance size exclusion chromatography (HP-SEC). The compositions set out herein may be in a variety of forms. These include, for example, liquid, semi-solid and solid dosage forms, such as liquid solutions (e.g., injectable and infusible solutions), dispersions or suspensions, liposomes, and suppositories. A suitable form depends on the intended mode of administration and therapeutic application. Typical suitable compositions are in the form of injectable or infusible solutions. One suitable mode of administration is parenteral (e.g., intravenous, subcutaneous, intraperitoneal, intramuscular). In an embodiment, the antibody molecule is administered by intravenous infusion or injection. In an embodiment, the antibody is administered by intramuscular or subcutaneous injection. The phrases “parenteral administration” and “administered parenterally” as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural and intrasternal injection and infusion. Therapeutic compositions typically should be sterile and stable under the conditions of manufacture and storage. The composition can be formulated as a solution, microemulsion, dispersion, liposome, or other ordered structure suitable to high antibody concentration. Sterile injectable solutions can be prepared by incorporating the active compound (i.e., antibody or antibody portion) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying that yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof. The proper fluidity of a solution can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prolonged absorption of injectable compositions can be brought about by including in the composition an agent that delays absorption, for example, monostearate salts and gelatin. The antibody molecules described herein can be administered by a variety of methods. Several are known in the art, and for many therapeutic, prophylactic, or diagnostic applications, an appropriate route/mode of administration is intravenous injection or infusion. For example, the antibody molecules can be administered by intravenous infusion at a rate of less than 10mg/min; preferably less than or equal to 5 mg/min to reach a dose of about 1 to 100 mg/m 2 , preferably about 5 to 50 mg/m 2 , about 7 to 25 mg/m 2 and more preferably, about 10 mg/m 2 . As will be appreciated by the skilled artisan, the route and/or mode of administration will vary depending upon the desired results. In an embodiment, the active compound may be prepared with a carrier that will protect the compound against rapid release, such as a controlled release formulation, including implants, transdermal patches, and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Many methods for the preparation of such formulations are patented or generally known to those skilled in the art. See, e.g., Sustained and Controlled Release Drug Delivery Systems, J. R. Robinson, ed., Marcel Dekker, Inc., New York, 1978. In an embodiment, an antibody molecule can be orally administered, for example, with an inert diluent or an assimilable edible carrier. The antibody molecule (and other ingredients, if desired) may also be enclosed in a hard- or soft-shell gelatin capsule, compressed into tablets, or incorporated directly into the subject’s diet. For oral therapeutic administration, the antibody molecule may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. To administer an antibody molecule by other than parenteral administration, it may be necessary to coat the compound with, or co-administer the compound with, a material to prevent its inactivation. Therapeutic, prophylactic, or diagnostic compositions can also be administered with medical devices, and several are known in the art. Dosage regimens are adjusted to provide the desired response (e.g., a therapeutic, prophylactic, or diagnostic response). For example, a single bolus may be administered, several divided doses may be administered over time or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subjects to be treated; each unit contains a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms are dictated by and directly dependent on (a) the unique characteristics of the antibody molecule and the particular therapeutic, prophylactic, or diagnostic effect to be achieved, and (b) the limitations inherent in the art of compounding such an antibody molecule for the treatment of sensitivity in individuals. An exemplary, non-limiting range for a therapeutically, prophylactically, or diagnostically effective amount of an antibody molecule is about 0.1-200 mg/kg body weight of a subject, e.g., about 0.1-100 mg/kg, e.g., about 0.1-50, .2-40, 03- 30, 0.4- 20, 05- 15, 1-30, 1-15, 1-10, 1-5, 5-10, or 1-3 mg/kg, e.g., about 0.4, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50, 100, or 200 mg/kg. The antibody molecule can be administered by intravenous infusion at a rate of less than 10 mg/min, e.g., less than or equal to 5 mg/min to reach a dose of about 1 to 100 mg/m 2 , e.g., about 5 to 50 mg/m 2 , about 7 to 25 mg/m 2 , e.g., about 10 mg/m 2 . In an embodiment, a therapeutically, prophylactically, or diagnostically effective amount of an antibody molecule is between 5 mg to 10,000 mg, e.g., between 10 mg to 9,000 mg, 15 mg to 8,500 mg, 20 mg to 8,250 mg, 25 mg to 8,000 mg, 30 mg to 7,500 mg, 35 mg to 7,000 mg, 40 mg to 6,500 mg, 50 mg to 8, 000 mg, 75 mg to 8,000 mg, 100 mg to 8,000 mg, 150 mg to 6,000 mg, 100 mg to 9,000 mg, 150 mg to 8,500 mg, 200 mg to 8,000 mg, 250 mg to 7,500 mg, 300 mg to 7,000 mg, 350 mg to 7, 000 mg, 400 mg to 6,500 mg, 450 mg to 6,000 mg, 500 mg to 5,500 mg, 100 mg to 5,000 mg, 150 mg to 4,500 mg, 200 mg to 4,000 mg, 200 mg to 3,500 mg, 200 mg to 2,000 mg, 200 mg to 1000 mg, 50 mg to 900 mg, 100 mg to 850 mg, 125 mg to 800 mg, 150 mg to 750 mg, 175 mg to 700 mg, 200 mg to 600 mg, 150 mg to 500 mg, or 200 mg to 400 mg. It is to be noted that dosage values may vary with the type and severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that dosage ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed compositions. A “prophylactically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result. Typically, since a prophylactic dose is used in subjects prior to or at an earlier stage of disease, the prophylactically effective amount will be less than the therapeutically effective amount. A “diagnostically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired diagnostic result. Typically, a diagnostically effective amount is one in which a disorder, e.g., a disorder described herein, e.g., IgA nephropathy, can be diagnosed in vitro, ex vivo, or in vivo. Formulations The antibody molecules described herein can be formulated into various formulations for therapeutic and/or prophylactic use. In an aspect, the disclosure provides a formulation comprises an antibody molecule described herein. In an embodiment, the formulation is a drug substance formulation. In an embodiment, the formulation is a liquid formulation. In an embodiment, the formulation is a lyophilized formulation. In an embodiment, the formulation is a reconstituted formulation. In an embodiment, the formulation is suitable for intravenous administration. In an embodiment, the formulation is suitable for subcutaneous administration. In an embodiment, the formulation is suitable for intramuscular administration. In an embodiment, the formulation further comprises one or more excipients, e.g., one, two, three, four, or all of a buffer, a salt, a surfactant, a carbohydrate, an amino acid, or an antioxidant. In an embodiment, the buffer comprises acetate, citrate, histidine, succinate, phosphate, or Tris. In an embodiment, the salt comprises sodium. In an embodiment, the surfactant comprises polysorbate 80, polysorbate 20, or poloxamer 188. In an embodiment, the carbohydrate comprises sucrose, mannitol, sorbitol, trehalose, or dextran 40. In an embodiment, the amino acid comprises glycine or arginine. In an embodiment, the antioxidant comprises ascorbic acid, methionine, or ethylenediaminetetraacetic acid (EDTA). In an embodiment, the antibody molecule is present at a concentration of 1 mg/mL to 300 mg/mL, e.g., 2 mg/mL to 250 mg/mL, 5 mg/mL to 200 mg/mL, 10 mg/mL to 150 mg/mL, 20 mg/mL to 100 mg/mL, 25 mg/mL to 50 mg/mL, 1 mg/mL to 250 mg/mL, 1 mg/mL to 200 mg/mL, 1 mg/mL to 150 mg/mL, 1 mg/mL to 100 mg/mL, 1 mg/mL to 50 mg/mL, 1 mg/mL to 20 mg/mL, 1 mg/mL to 10 mg/mL, 1 mg/mL to 5 mg/mL, 1 mg/mL to 2 mg/mL, 250 mg/mL to 300 mg/mL, 200 mg/mL to 300 mg/mL, 150 mg/mL to 300 mg/mL, 100 mg/mL to 300 mg/mL, 50 mg/mL to 300 mg/mL, 20 mg/mL to 300 mg/mL, 5 mg/mL to 300 mg/mL, 2 mg/mL to 300 mg/mL, 2 mg/mL to 10 mg/mL, 5 mg/mL to 20 mg/mL, 10 mg/mL to 50 mg/mL, 50 mg/mL to 200 mg/mL, or 100 mg/mL to 250 mg/mL. In an embodiment, the formulation has a pH of 5 to 8, e.g., 5.5 to 7.5, 6 to 7, 5 to 7.5, 5 to 7, 5 to 6.5, 5 to 6, 5 to 5.5, 7.5 to 8, 7 to 8, 6.5 to 8, 6 to 8, 5.5 to 8, 5 to 6, 5.5 to 6.5, 6 to 7, 6.5 to 7.5, or 7 to 8, e.g., 5, 5.5, 6, 6.5, 7,5, or 8. In an embodiment, the formulation comprises 25 mg/mL to 35 mg/mL of the antibody molecule, 15 mM to 25 mM Na-Acetate, 6% to 10% (w/v) sucrose, and 0.03% to 0.05% (w/v) polysorbate 80, at a pH of 5 to 6. In an embodiment, the formulation comprises 30 mg/mL of an antibody molecule described herein, 20 mM Na-Acetate, 8% (w/v) sucrose, and 0.04 % (w/v) polysorbate 80, at a pH of 5.5. In an embodiment, the formulation comprises 25 mg/mL to 35 mg/mL of the antibody molecule, 15 mM to 25 mM Na-Citrate, 6% to 10% (w/v) sucrose, and 0.03% to 0.05% (w/v) polysorbate 80, at a pH of 5 to 6. In an embodiment, the formulation comprises 30 mg/mL of an antibody molecule described herein, 20 mM Na-Citrate, 8% (w/v) sucrose, and 0.04 % (w/v) polysorbate 80, at a pH of 5.5. In an embodiment, the antibody molecule is present at a concentration of 15 mg/mL to 50 mg/mL, e.g., 20 mg/mL to 40 mg/mL, or 25 mg/mL to 35 mg/mL. In an embodiment, the antibody molecule is present at a concentration of 25 mg/mL to 35 mg/mL, e.g., 30 mg/mL. In an embodiment, the formulation comprises a buffer comprising Na-Acetate (e.g., Na- Acetate buffer). In an embodiment, the buffer is (e.g., Na-Acetate buffer) is present at a concentration of 10 mM to 50 mM, e.g., 10 mM to 40 mM or 15 mM to 25 mM. In an embodiment, the buffer (e.g., Na-Acetate buffer) is present at a concentration of 15 mM to 25 mM, e.g., 20 mM. In an embodiment, the formulation comprises a buffer comprising Na-Citrate (e.g., Na-Citrate buffer). In an embodiment, the buffer is (e.g., Na-Citrate buffer) is present at a concentration of 10 mM to 50 mM, e.g., 10 mM to 40 mM or 15 mM to 25 mM. In an embodiment, the buffer (e.g., Na- Citrate buffer) is present at a concentration of 15 mM to 25 mM, e.g., 20 mM. In an embodiment, the formulation further comprises a carbohydrate (e.g., sucrose). In an embodiment, the carbohydrate or sucrose is present at a concentration of 5% to 15% (w/v), e.g., 6% to 12% or 6% to 10% (w/v). In an embodiment, the carbohydrate or sucrose is present at a concentration of 6% to 10% (w/v), e.g., 8% (w/v). In an embodiment, the formulation further comprises a surfactant (e.g., polysorbate 80). In an embodiment, the surfactant or polysorbate 80 is present at a concentration of 0.02% to 0.08% (w/v), e.g., 0.02% to 0.06% (w/v) or 0.03% to 0.05% (w/v). In an embodiment, the surfactant or polysorbate is present at a concentration of 0.03% to 0.05% (w/v), e.g., 0.04% (w/v). In an embodiment, the formulation has a pH of 4.5 to 6.5, e.g., 5 to 6. In an embodiment, the formulation has a pH of 5.5. In an embodiment, the pharmaceutical composition comprises 25 mg/mL to 35 mg/mL of the antibody molecule, 15 mM to 25 mM Na-Acetate, 6% to 10% (w/v) sucrose, and 0.03% to 0.05% (w/v) polysorbate 80, at a pH of 5 to 6. In an embodiment, the pharmaceutical composition or formulation comprises 30 mg/mL of an antibody molecule described herein, 20 mM Na-Acetate, 8% (w/v) sucrose, and 0.04 % (w/v) polysorbate 80, at a pH of 5.5. In an embodiment, the pharmaceutical composition comprises 25 mg/mL to 35 mg/mL of the antibody molecule, 15 mM to 25 mM Na-Citrate, 6% to 10% (w/v) sucrose, and 0.03% to 0.05% (w/v) polysorbate 80, at a pH of 5 to 6. In an embodiment, the pharmaceutical composition or formulation comprises 30 mg/mL of an antibody molecule described herein, 20 mM Na-Citrate, 8% (w/v) sucrose, and 0.04 % (w/v) polysorbate 80, at a pH of 5.5. In an embodiment, the pharmaceutical composition is placed or stored in a container, e.g., a glass vial. In an embodiment, the container is a 10R, single use, Type 1 glass vial, e.g., sealed with a 20 mm push-fit cap. In an embodiment, 1 mL to 6 mL (e.g., 2 mL to 5 mL or 3 mL to 4 mL) of the formulation is filled per container (e.g., vial). In an embodiment, 3 mL to 4 mL (e.g., 3.33 mL) of the formulation is filled per container (e.g., vial). Other exemplary buffering agents that can be used in the formulation described herein include, but are not limited to, an arginine buffer, a citrate buffer, or a phosphate buffer. Other exemplary carbohydrates that can be used in the formulation described herein include, but are not limited to, trehalose, mannitol, sorbitol, or a combination thereof. The formulation described herein may also contain a tonicity agent, e.g., sodium chloride, and/or a stabilizing agent, e.g., an amino acid (e.g., glycine, arginine, methionine, or a combination thereof). Kits The antibody molecules described herein can also be placed in kits. In an aspect, the disclosure provides kit that comprises an antibody molecule described herein or a composition (e.g., pharmaceutical composition) described herein. The kit can include one or more other elements including: instructions for use; other reagents, e.g., a label, a therapeutic agent, or an agent useful for chelating, or otherwise coupling, an antibody molecule to a label or therapeutic agent, or a radioprotective composition; devices or other materials for preparing the antibody molecule for administration; pharmaceutically acceptable carriers; and devices or other materials for administration to a subject. Nucleic Acids The disclosure also features nucleic acids comprising nucleotide sequences that encode the antibody molecules (e.g., heavy and/or light chain variable regions, CDRs of the antibody molecules), as described herein. For example, the present disclosure features a first and second nucleic acid encoding heavy and light chain variable regions, respectively, of an antibody molecule chosen from one or more of the antibody molecules disclosed herein, e.g., an antibody molecule of Table 1 or 2, or a portion of an antibody molecule, e.g., the variable regions of Table 1 or 2. The nucleic acid can comprise a nucleotide sequence encoding any one of the amino acid sequences in the tables herein, or a sequence substantially identical thereto (e.g., a sequence at least about 85%, 90%, 95%, 99% or more identical thereto, or which differs by no more than 3, 6, 15, 30, or 45 nucleotides from the sequences shown in the tables herein). In an embodiment, the nucleic acid can comprise a nucleotide sequence encoding at least one, two, or three CDRs from a heavy chain variable region having an amino acid sequence as set forth in the tables herein, or a sequence substantially homologous thereto (e.g., a sequence at least about 85%, 90%, 95%, 99% or more identical thereto, and/or having one or more substitutions, e.g., conserved substitutions). In an embodiment, the nucleic acid can comprise a nucleotide sequence encoding at least one, two, or three CDRs from a light chain variable region having an amino acid sequence as set forth in the tables herein, or a sequence substantially homologous thereto (e.g., a sequence at least about 85%, 90%, 95%, 99% or more identical thereto, and/or having one or more substitutions, e.g., conserved substitutions). In an embodiment, the nucleic acid can comprise a nucleotide sequence encoding at least one, two, three, four, five, or six CDRs from heavy and light chain variable regions having an amino acid sequence as set forth in the tables herein, or a sequence substantially homologous thereto (e.g., a sequence at least about 85%, 90%, 95%, 99% or more identical thereto, and/or having one or more substitutions, e.g., conserved substitutions). In an embodiment, the nucleic acid can comprise a nucleotide sequence encoding at least one, two, or three CDRs from a heavy chain variable region having the nucleotide sequence as set forth in Table 5, a sequence substantially homologous thereto (e.g., a sequence at least about 85%, 90%, 95%, 99% or more identical thereto, and/or capable of hybridizing under the stringency conditions described herein). In an embodiment, the nucleic acid can comprise a nucleotide sequence encoding at least one, two, or three CDRs from a light chain variable region having the nucleotide sequence as set forth in Table 5, or a sequence substantially homologous thereto (e.g., a sequence at least about 85%, 90%, 95%, 99% or more identical thereto, and/or capable of hybridizing under the stringency conditions described herein). In an embodiment, the nucleic acid can comprise a nucleotide sequence encoding at least one, two, three, four, five, or six CDRs from heavy and light chain variable regions having the nucleotide sequence as set forth in Table 5, or a sequence substantially homologous thereto (e.g., a sequence at least about 85%, 90%, 95%, 99% or more identical thereto, and/or capable of hybridizing under the stringency conditions described herein). In an embodiment, the nucleic acid comprises a nucleotide sequence as set forth in Table 5 or a sequence substantially homologous thereto (e.g., a sequence at least about 85%, 90%, 95%, 99% or more identical thereto, and/or capable of hybridizing under the stringency conditions described herein). In an embodiment, the nucleic acid comprises a portion of a nucleotide sequence as set forth in Table 5 or a sequence substantially homologous thereto (e.g., a sequence at least about 85%, 90%, 95%, 99% or more identical thereto, and/or capable of hybridizing under the stringency conditions described herein). The portion may encode, for example, a variable region (e.g., VH or VL); one, two, or three or more CDRs; or one, two, three, or four or more framework regions. The nucleic acids disclosed herein include deoxyribonucleotides or ribonucleotides, or analogs thereof. The polynucleotide may be either single-stranded or double-stranded, and if single- stranded may be the coding strand or non-coding (antisense) strand. A polynucleotide may comprise modified nucleotides, such as methylated nucleotides and nucleotide analogs. The sequence of nucleotides may be interrupted by non-nucleotide components. A polynucleotide may be further modified after polymerization, such as by conjugation with a labeling component. The nucleic acid may be a recombinant polynucleotide, or a polynucleotide of genomic, cDNA, semisynthetic, or synthetic origin which either does not occur in nature or is linked to another polynucleotide in a non- natural arrangement. In an aspect, the application features host cells and vectors containing the nucleic acids described herein. The nucleic acids may be present in a single vector or separate vectors present in the same host cell or separate host cell, as described in more detail below. Vectors The disclosure also provides vectors that comprise a nucleotide sequence encoding an antibody molecule described herein. In an embodiment, the vector comprises a nucleotide sequence encoding an antibody molecule described herein, e.g., as described in any of Tables 1-4. The vectors include, but are not limited to, a virus, plasmid, cosmid, lambda phage or a yeast artificial chromosome (YAC). Numerous vector systems can be employed. For example, vectors can utilize DNA elements or RNA elements derived from animal viruses. Exemplary viral vectors include, but are not limited to, those derived from bovine papilloma virus, polyoma virus, adenovirus, adeno-associated virus, vaccinia virus, baculovirus, retrovirus, lentivirus, SV40 virus, Semliki Forest virus, eastern equine encephalitis virus, and flaviviruses. Additionally, cells which have stably integrated the DNA into their chromosomes may be selected by introducing one or more markers which allow for the selection of transfected host cells. The marker may provide, for example, prototropy to an auxotrophic host, biocide resistance (e.g., antibiotics), or resistance to heavy metals such as copper, or the like. The selectable marker gene can be either directly linked to the DNA sequences to be expressed or introduced into the same cell by cotransformation. Additional elements may also be needed for optimal synthesis of mRNA. These elements may include splice signals, as well as transcriptional promoters, enhancers, and termination signals. Once the expression vector or DNA sequence containing the constructs has been prepared for expression, the expression vectors may be transfected or introduced into an appropriate host cell. Various techniques may be employed to achieve this, such as, for example, protoplast fusion, calcium phosphate precipitation, electroporation, retroviral transduction, viral transfection, gene gun, lipid based transfection or other conventional techniques. In the case of protoplast fusion, the cells are grown in media and screened for the appropriate activity. Methods and conditions for culturing the resulting transfected cells and for recovering the antibody molecule produced are known to those skilled in the art and may be varied or optimized depending upon the specific expression vector and mammalian host cell employed, based upon the present description. Cells The present disclosure also provides cells (e.g., host cells) comprising a nucleic acid encoding an antibody molecule as described herein. In some embodiments, the cell comprises a nucleic acid described herein. Additionally, the cells may comprise a nucleic acid molecule encoding an amino acid sequence of any of Table 1-4, a sequence substantially homologous thereto (e.g., a sequence at least about 80%, 85%, 90%, 95%, 99% or more identical thereto), or a portion of one of said sequences. The disclosure also provides cells comprising a vector described herein. In an embodiment, the cell is an isolated cell. In an embodiment, the cell is genetically engineered to comprise a nucleic acid encoding an antibody molecule described herein. In an embodiment, the cell is genetically engineered by using an expression cassette. The phrase “expression cassette,” refers to nucleotide sequences, which are capable of affecting expression of a gene in hosts compatible with such sequences. Such cassettes may include a promoter, an open reading frame with or without introns, and a termination signal. Additional factors necessary or helpful in effecting expression may also be used, such as, for example, an inducible promoter. The cell can be, but is not limited to, a eukaryotic cell, a bacterial cell, an insect cell, or a human cell. Suitable eukaryotic cells include, but are not limited to, Vero cells, HeLa cells, COS cells, CHO cells, HEK293 cells, BHK cells and MDCKII cells. Suitable insect cells include, but are not limited to, Sf9 cells. In an embodiment, the cell (e.g., host cell) is an isolated cell. Uses of Antibody Molecules The antibody molecules disclosed herein, as well as the pharmaceutical compositions disclosed herein, have in vitro, ex vivo, and in vivo therapeutic, prophylactic, and/or diagnostic utilities. In an embodiment, the antibody molecule reduces (e.g., inhibits, blocks, or neutralizes) one or more biological activities of a coronavirus spike protein (e.g., a SARS-CoV2 spike protein), or a fragment thereof (e.g., a fragment comprising an RBD). For example, these antibodies molecules can be administered to cells in culture, in vitro or ex vivo, or to a subject, e.g., a human subject, e.g., in vivo, to reduce (e.g., inhibits, blocks, or neutralizes) an infection caused by a coronavirus (e.g., SARS- CoV-2). In an embodiment, the antibody molecule inhibits, or substantially inhibit, binding of a coronavirus spike protein (e.g., a SARS-CoV-2 spike protein) to an ACE receptor expressed in a cell surface, e.g., mammalian cell surface, e.g., human cell surface. Accordingly, in an aspect, the disclosure provides a method of treating, preventing, or diagnosing a disorder, e.g., a disorder described herein (e.g., COVID-19), in a subject, comprising administering to the subject an antibody molecule described herein, such that the disorder is treated, prevented, or diagnosed. For example, the disclosure provides a method comprising contacting the antibody molecule described herein with cells in culture, e.g., in vitro or ex vivo, or administering the antibody molecule described herein to a subject, e.g., in vivo, to treat, prevent, or diagnose a disorder, e.g., a disorder described herein (e.g., COVID-19). As used herein, the term “subject” is intended to include human and non-human animals. In an embodiment, the subject is a human subject, e.g., a human patient having a coronavirus-associated disorder (e.g., a SARS-CoV-2-associated disorder), or at risk of having a coronavirus-associated disorder (e.g., a SARS-CoV-2-associated disorder). The term “non-human animals” includes mammals and non-mammals, such as non-human primates. In an embodiment, the subject is a human. The antibody molecules and pharmaceutical compositions described herein are suitable for treating various coronavirus-associated disorders (e.g., SARS-CoV-2-associated disorders) in subjects (e.g., human subjects). Coronavirus-associated disorders (e.g., SARS-CoV-2-associated disorders) include, e.g., disorders that caused by coronavirus (e.g., SARS-CoV-2) directly or indirectly. For example, coronavirus-associated disorders can include coronavirus infections (e.g., SARS-CoV-2 infections) or disorders following coronavirus infections (e.g., SARS-CoV-2 infections). Subjects (e.g., patients) having a coronavirus-associated disorder associated (e.g., a SARS-CoV-2-associated disorder) include those who have developed the disorder, but are (at least temporarily) asymptomatic, patients who have exhibited a symptom of the disorder, or patients having another disorder related to or associated with the disorder. In an embodiment, the subject has, or is at risk of having, a coronavirus infection (e.g., a SARS-CoV-2 infection). In an embodiment, the subject has, or is at risk of having, COVID-19. Subjects that are at risk of having a coronavirus infection (e.g., a SARS-CoV-2 infection) include, but are not limited to, subjects with compromised immune systems, subjects with forms of anemia that deplete or destroy white blood cells, subjects afflicted with human immunodeficiency syndrome (HIV) or acquired immune deficiency syndrome (AIDS), subjects receiving immunosuppressive therapy (e.g., following organ transplant), subjects afflicted with a neoplasia disorder, subjects afflicted with a respiratory disorder, e.g., asthma, subjects receiving radiation or chemotherapy, or subjects afflicted with an inflammatory disorder. In an embodiment, subjects of young age (e.g., 5 years of age or younger) or old age (e.g., 65 years of age or older) may be at increased risk. In an embodiment, a subject may be at risk of contracting a coronavirus infection (e.g., SARS-CoV-2 infection) due to proximity to an outbreak of the disease, e.g., subject resides in a densely-populated location or in close proximity to subjects having confirmed or suspected infections of a coronavirus (e.g., SARS- CoV-2), or choice of employment (e.g., hospital worker, pharmaceutical researcher, traveler to infected area, or frequent flier). In an embodiment, the subject has, is at risk of having, a disorder following a coronavirus infection (e.g., a SARS-CoV-2 infection). Exemplary disorders that may follow a coronavirus infection (e.g., a SARS-CoV-2 infection) include, but are not limited to, multisystem inflammatory syndrome (IMS), e.g., pediatric inflammatory syndrome (PIMS), Guillain–Barré Syndrome, Kawasaki disease, autoimmune diseases, inflammatory diseases, and central nervous system complications. Methods of Treating or Preventing Disorders The antibody molecules described herein can be used to treat or prevent a coronavirus infection (e.g., a SARS-CoV-2 infection), or a coronavirus-associated disorder (e.g., a SARS-CoV-2- associated disorder, e.g., COVID-19), or a symptom thereof. In an aspect, the disclosure provides a method of treating or preventing a coronavirus infection (e.g., a SARS-CoV-2 infection) or a symptom thereof. The method comprises administering to a subject in need thereof an effective amount of an antibody molecule described herein. In an embodiment, the subject has a coronavirus infection (e.g., a SARS-CoV-2 infection). In an embodiment, the subject is at risk of having a coronavirus infection (e.g., a SARS-CoV-2 infection). In an embodiment, the subject has exhibited a symptom of a coronavirus infection (e.g., a SARS-CoV-2 infection). In an embodiment, the subject has not exhibited a symptom of a coronavirus infection (e.g., a SARS-CoV-2 infection). In an aspect, the disclosure provides a method of treating or preventing a coronavirus- associated disorder (e.g., a SARS-CoV-2-associated disorder, e.g., COVID-19), or a symptom thereof. The method comprises administering to a subject in need thereof an effective amount of an antibody molecule described herein. In an embodiment, the subject has a coronavirus-associated disorder (e.g., a SARS-CoV-2- associated disorder, e.g., COVID-19). In an embodiment, the subject is at risk of having a coronavirus-associated disorder (e.g., a SARS-CoV-2-associated disorder, e.g., COVID-19). In an embodiment, the subject has exhibited a symptom of a coronavirus-associated disorder (e.g., a SARS- CoV-2-associated disorder, e.g., COVID-19). In an embodiment, the subject has not exhibited a symptom of a coronavirus-associated disorder (e.g., a SARS-CoV-2-associated disorder, e.g., COVID-19). Exemplary symptoms of a coronavirus infection (e.g., a SARS-CoV-2 infection), or a coronavirus-associated disorder (e.g., a SARS-CoV-2-associated disorder, e.g., COVID-19), include, but are not limited to, fever or chills, cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting, and diarrhea. Exemplary coronavirus-associated disorders (e.g., SARS-CoV-2-associated disorders) include, but are not limited to, multisystem inflammatory syndrome (IMS), e.g., pediatric inflammatory syndrome (PIMS), Guillain–Barré Syndrome, Kawasaki disease, acute respiratory distress syndrome (ARDS), lung injuries (e.g., diffuse alveolar damage in the lung, lung fibrosis, dilated pulmonary vessels), pneumonias, autoimmune diseases, inflammatory diseases, and central nervous system complications. The antibody molecules described herein are typically administered at a frequency that keeps a therapeutically effective level of antibody molecules in the patient’s system until the patient recovers. For example, the antibody molecules may be administered at a frequency that achieves a serum concentration sufficient for at least about 1, 2, 5, 10, 20, 30, or 40 antibody molecules to bind each coronavirus spike protein (e.g., SARS-CoV-2 spike protein). In an embodiment, the antibody molecules are administered every 1, 2, 3, 4, 5, 6, or 7 days, every 1, 2, 3, 4, 5, or 6 weeks, or every 1, 2, 3, 4, 5, or 6 months. Methods of administering antibody molecules are known in the art. Suitable dosages of the antibody molecules used typically depend on the age and weight of the subject and the particular drug used. In an embodiment, the antibody molecule is administered to the subject (e.g., a human subject) intravenously. In an embodiment, the antibody molecule is administered to the subject at a dose between 0.01 mg/kg and 500 mg/kg, e.g., between 0.05 mg/kg and 200 mg/kg, between 0.1 mg/kg and 100 mg/kg, between 0.2 mg/kg and 50 mg/kg, between 0.5 mg/kg and 20 mg/kg, 1 mg/kg and 10 mg/kg, between 2 mg/kg and 5 mg/kg, between 1 mg/kg and 10 mg/kg, between 1 mg/kg and 5 mg/kg, between 0.5 mg/kg and 30 mg/kg, between 2.5 mg/kg and 15 mg/kg, between 5 mg/kg and 7.5 mg/kg, between 0.2 mg/kg and 1 mg/kg, between 2 mg/kg and 3 mg/kg, between 2 mg/kg and 10 mg/kg, between 5 mg/kg and 10 mg/kg, between 10 mg/kg and 20 mg/kg, between 25 mg/kg and 35 mg/kg, e.g., 0.5 mg/kg, 1 mg/kg, 2.5 mg/kg, 5 mg/kg, 7.5 mg/kg, 10 mg/kg, 15 mg/kg, 20 mg/kg, 25 mg/kg, or 30 mg/kg. In an embodiment, the antibody molecule is administered once a day, once a week, twice a week, once every two weeks, once every three weeks, once every four weeks, once every eight weeks, once a month, once every two months, or once every three months, or on as needed basis based on subject condition. In an embodiment, the antibody molecule may be administered at an initial dose, followed by one or more secondary doses. In certain embodiments, the initial dose may be followed by administration of a second or a plurality of subsequent doses of antibody molecule in an amount that can be approximately the same or less than that of the initial dose, wherein the subsequent doses are separated by at least 1 day to 3 days, at least one week, at least 2 weeks, at least 3 weeks, at least 4 weeks, at least 5 weeks, at least 6 weeks, at least 7 weeks, at least 8 weeks, at least 9 weeks, at least 10 weeks, at least 12 weeks, or at least 14 weeks. The antibody molecules described herein can be used by themselves or conjugated to a second agent, e.g., a bacterial agent, toxin, or protein, e.g., a second antibody molecule. This method includes: administering the antibody molecule, alone or conjugated to a second agent, to a subject requiring such treatment. The antibody molecules described herein can be used to deliver a variety of therapeutic agents, e.g., a toxin, or mixtures thereof. In an embodiment, a method described herein reduces one or more symptoms of a coronavirus infection (e.g., a SARS-CoV-2 infection), or a coronavirus-associated disorder (e.g., a SARS-CoV-2-associated disorder, e.g., COVID-19) in a subject for 12 hours, 15 hours, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, or longer, compared to a subject who has not been treated by a method described herein. Combination Therapies The antibody molecules described herein can be used in combination with other therapies. In an aspect, the disclosure provides a combination therapy comprising an antibody molecule described herein and a second therapeutic agent or modality. In an embodiment, the antibody molecule is administered or used in combination with a second therapeutic agent or modality to treat or prevent a coronavirus infection (e.g., a SARS-CoV-2 infection) or a coronavirus-associated disorder (e.g., a SARS-CoV-2-associated disorder), e.g., COVID-19. In an embodiment, the combination therapy comprises an antibody molecule described herein co-formulated with, and/or co-administered with, one or more additional therapeutic agents or modalities e.g., one or more additional therapeutic agents or modalities described herein. Such combination therapies may advantageously utilize lower dosages of the administered or used therapeutic agents or modalities, thus avoiding possible toxicities or complications associated with the various monotherapies. Administered “in combination”, as used herein, means that two (or more) different treatments are delivered to the subject before, or during the course of the subject's affliction with a disorder. In an embodiment, two or more treatments are delivered prophylactically, e.g., before the subject has the disorder or is diagnosed with the disorder. In another embodiment, the two or more treatments are delivered after the subject has developed or diagnosed with the disorder. In an embodiment, the delivery of one treatment is still occurring when the delivery of the second begins, so that there is overlap. This is sometimes referred to herein as "simultaneous" or "concurrent delivery." In other embodiments, the delivery of one treatment ends before the delivery of the other treatment begins. This is sometimes referred to herein as "sequential delivery." In an embodiment of either case, the treatment is more effective because of combined administration. For example, the second treatment is more effective, e.g., an equivalent effect is seen with less of the second treatment, or the second treatment reduces symptoms to a greater extent, than would be seen if the second treatment were administered in the absence of the first treatment, or the analogous situation is seen with the first treatment. In an embodiment, delivery is such that the reduction in a symptom, or other parameter related to the disorder is greater than what would be observed with one treatment delivered in the absence of the other. The effect of the two treatments can be partially additive, wholly additive, or greater than additive. The delivery can be such that an effect of the first treatment delivered is still detectable when the second is delivered. In an embodiment, the additional agent is a second antibody molecule, e.g., an antibody molecule different from a first antibody molecule. Exemplary antibody molecules that can be used in combination include, but are not limited to, any combination of the antibody molecules described in any of Tables 1-4. In an embodiment, the first antibody molecule is an antibody molecule described in Table 1 or 3 and the second antibody molecule is an antibody molecule described in Table 2 or 4. In an embodiment, the first and second antibody molecules are described in Table 1 or 3. In an embodiment, the first and second antibody molecules are described in Table 2 or 4. In an embodiment, the first antibody molecule is described in Table 1 or 3, and the second antibody molecule is an antibody molecule different from an antibody molecule described in any of Tables 1-4. In an embodiment, the first antibody molecule is described in Table 2 or 4, and the second antibody molecule is an antibody molecule different from an antibody molecule described in any of Tables 1-4. In an embodiment, the second antibody molecule is capable of binding to a coronavirus spike protein (e.g., a SARS-CoV-2 spike protein). In an embodiment, the second antibody molecule comprises one or more of sotrovimab (VIR-7831), VIR-7832, casirivimab, imdevimab, bamlanivimab (LY-CoV555), etesevimab (LY-CoV016), CT-P59, AZD8895, AZD1061, TY027, BRII-196, BRII- 198, MAD0004J08, JMB2002, LY-CovMab, C144-LS, C135-LS, ABBV-47D11, HFB30132A, ADM03820, DXP604, ZRC-3308, HLX70, COR-101, COVI-AMG, LY-CoV1404, LY3853113, DXP593, JS016, LY3832479, LY-CoV016, MW33, SCTA01, ADG20, TY027, AZD8895, AZD1061, CT-P59, or a combination thereof. Other exemplary antibody molecules that are capable of binding to a coronavirus spike protein (e.g., a SARS-CoV-2 spike protein) are also described, e.g., in WO2021/045836, Kyratsous et al. N Engl J Med.2021 Jan 21;384(3):238-251, Kyratsous et al. Science.2020 Nov 27;370(6520):1110-1115, Ho et al (2021), Weinreich et al. N Engl J Med.2021 Jan 21;384(3):238- 251, Weinreich et al. medRxiv 2021.05.19.21257469; Gupta et al. medRxiv 2021.05.27.21257096; (2021), Mahase, BMJ 2020;371:m4362, Chinese Clinical Trial Register (ChiCTR) 2100042150, ClinicalTrials.gov Identifiers: NCT04932850, NCT04700163, NCT04644120, NCT04590430, NCT04592549, NCT04669262, NCT04561076, NCT04674566, NCT04746183, NCT04634409, NCT04734860, NCT04532294, NCT04551898, NCT04441918, NCT04441931, NCT04427501, NCT04627584, NCT04533048, NCT04700163, NCT04483375, NCT04644185, NCT04805671, NCT04859517, NCT04479631, NCT04479644, NCT04429529, NCT04649515, NCT04507256, NCT04625725, NCT04625972, NCT04525079, NCT04593641, NCT04602000, NCT04545060, NCT04411628, NCT04427501, NCT04497987, NCT04501978, and NCT04518410, which are incorporated by reference in their entirety. In an embodiment, the additional agent is a small molecule. Exemplary small molecules that can be used in combination with an antibody molecule described herein include, but are not limited to, an RdRp inhibitor (e.g., remdesivir (GS-5734), favipirair, ribavirin, penciclovir), a 3CL pro inhibitor (e.g., AG7088, AG7404, lopinavir, ritonavir, darunavir, cobicistat, ASC09 F), a PL pro inhibitor (e.g., 6-mercaptopurine (6MP), 6-thioguanine (6TG), biltricide, cinacalcet, procainamide, terbinafine, pethidine, labetalol, tetrahydrozoline, ticlopidine, ethoheptazine, formoterol, amitriptyline, naphazoline, levamisole, benzylpenicillin, CQ, HCQ, chlorothiazide), a dihydroorotate dehydrogenase (DHODH) inhibitor (e.g., S312, S416), thalidomide, pentoxifylline, oxypurinol, an S-phase kinase- associated protein 2 (SKP2) inhibitor, a TMPRSS2 inhibitor (e.g., camostat mesylate, namostat mesylate, MI-432, MI-1900), a furin inhibitor (MI-1851, MI-1148, diminazene, CMK), an S protein inhibitor (e.g., arbidol), and a corticosteroid. Other small molecule therapeutics are described, e.g., in Tian et al. Biomed Pharmacother.2021 May;137:111313, which is incorporated by reference in its entirety. Other exemplary second therapeutic agents or modalities that can be used in the combination therapies described herein include, but are not limited to, vaccine (e.g., a COVID-19 vaccine), paracetamol, NSAID, fluid therapy, oxygen support, prone positioning, glucocorticoid dexamethasone, noninvasive ventilation, mechanical ventilation, extracorporeal membrane oxygenation (ECMO), hydroxychloroquine, lopinavir, ritonavir, and remdesivir. Methods of Diagnosis The antibody molecules described herein can be used to detect a coronavirus infection (e.g., a SARS-CoV-2 infection) and/or to diagnose a coronavirus-associated disorder (e.g., a SARS-CoV-2- associated disorder) In an aspect, the disclosure provides a method for detecting the presence of a coronavirus (e.g., SARS-CoV-2) in vitro (e.g., in a sample) or in vivo (e.g., in vivo imaging in a subject). The method includes: (i) contacting a sample with an antibody molecule described herein, or administering to a subject an antibody molecule described herein; (optionally) (ii) contacting a reference sample with the antibody molecule, or administering to a reference subject the antibody molecule; and (iii) detecting formation of a complex between the antibody molecule and the coronavirus (e.g., SARS-CoV2) in the sample or subject, or in the control sample or subject, wherein a change, e.g., a statistically significant change, in the formation of the complex in the sample or subject relative to the control sample or subject is indicative of the presence of the coronavirus (e.g., SARS-CoV2) in the sample or subject. In another aspect, the disclosure provides a diagnostic method for detecting the presence of a coronavirus spike protein (e.g., a SARS-CoV2 spike protein) or a fragment thereof (e.g., a fragment comprising an RBD) in vitro (e.g., in a sample) or in vivo (e.g., in vivo imaging in a subject). The method includes: (i) contacting a sample with an antibody molecule described herein, or administering to a subject an antibody molecule described herein; (optionally) (ii) contacting a reference sample with the antibody molecule, or administering to a reference subject the antibody molecule; and (iii) detecting formation of a complex between the antibody molecule and the coronavirus spike protein (e.g., SARS-CoV2 spike protein) or a fragment thereof (e.g., a fragment comprising an RBD) in the sample or subject, or in the control sample or subject, wherein a change, e.g., a statistically significant change, in the formation of the complex in the sample or subject relative to the control sample or subject is indicative of the presence of the coronavirus spike protein (e.g., SARS-CoV2 spike protein) or a fragment thereof (e.g., a fragment comprising an RBD) in the sample or subject. Complex formation can be detected by measuring or visualizing either the bound or unbound antibody molecule. Any suitable detection assays can be used, and conventional detection assays include, e.g., an enzyme-linked immunosorbent assays (ELISA), a radioimmunoassay (RIA) or tissue immunohistochemistry. The antibody molecule can be directly or indirectly labeled with a detectable substance to facilitate detection of the bound or unbound antibody. Suitable detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, and radioactive materials. Alternative to labeling the antibody molecule, a competition immunoassay utilizing a standard labeled with a detectable substance and an unlabeled antibody molecule can be used. In this assay, the sample, labeled standard, and antibody molecule are combined, and the amount of labeled standard bound to the unlabeled antibody molecule is determined. The amount of coronavirus (e.g., SARS-CoV-2), or coronavirus spike protein (e.g., SARS-CoV-2 spike protein) or a fragment thereof (e.g., a fragment comprising an RBD), in the sample is inversely proportional to the amount of labeled standard bound to the antibody molecule. Various samples can be used in accordance with the detection and diagnosis methods described herein. In an embodiment, the sample is a biological sample. The biological samples can include, e.g., body fluids, cells, cell lysates, cell extracts, proteins, or a mixture thereof. In an embodiment, the sample is obtained from a subject (e.g., a subject described herein). In an embodiment, the subject has, or is at risk of having, a coronavirus infection (e.g., a SARS-CoV2 infection). In an embodiment, the subject has, or is at risk of having a coronavirus-associated disorder (e.g., a SARS-CoV2-associated disorder). Exemplary samples include, but are not limited to, a swap sample (e.g., a sample from the nose or throat, e.g., anterior nares, mid-turbinate, nasopharyngeal, or oropharyngeal), a saliva sample, and a blood sample. The detection and diagnostic methods described herein can further include a second test for diagnosing a coronavirus infection (e.g., a SARS-CoV-2 infection), e.g., a PCR test or an antigen test. The antibody molecules described herein can be used to diagnose a disorder at can be treated or prevented by the antibody molecules described herein. The detection or diagnostic methods described herein can be used in combination with other methods described herein to treat or prevent a disorder described herein. Enumerated Embodiments 1. An antibody molecule capable of binding to a coronavirus spike protein (e.g., a SARS-CoV-2 spike protein), comprising: a heavy chain variable region (VH) comprising an HCDR1 of a VH described in Table 1, an HCDR2 of a VH described in Table 1, and an HCDR3 of a VH described in Table 1; and/or a light chain variable region (VL) comprising an LCDR1 of a VL described in Table 1, an LCDR2 of a VL described in Table 1, and an LCDR3 of a VL described in Table 1, optionally wherein the coronavirus spike protein (e.g., SARS-CoV spike protein) comprises one or more mutations (e.g., one or mutations described herein). 2. The antibody molecule of embodiment 1, wherein the HCDR1 comprises an HCDR1 described in Table 3, the HCDR2 comprises an HCDR2 described in Table 3, the HCDR3 comprises an HCDR3 described in Table 3, the LCDR1 comprises an LCDR1 described in Table 3, the LCDR2 comprises an LCDR2 described in Table 3, the LCDR3 comprises an LCDR3 described in Table 3. 3. The antibody molecule of embodiment 1 or 2, wherein the HCDR1, HCDR2, and HCDR3 are chosen from the same VH described in Table 1 or the same row in Table 3; and/or wherein the LCDR1, LCDR2, and LCDR3 are chosen from the same VL described in Table 1 or the same row in Table 3. 4. The antibody molecule of any of embodiments 1-3, wherein the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 are chosen from the VH and VL of the same row in Table 1 or the same row in Table 3. 5. The antibody molecule of any of embodiments 1-4, comprising a VH described in Table 1, or an amino acid sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical thereto, or differs by no more than 1, 2, 3, 4, 5, 10, 15, 20, or 25 amino acids therefrom. 6. The antibody molecule of any of embodiments 1-5, comprising a VH described in Table 1. 7. The antibody molecule of any of embodiments 1-6, comprising a VL described in Table 1, or an amino acid sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical thereto, or differs by no more than 1, 2, 3, 4, 5, 10, 15, 20, or 25 amino acids therefrom. 8. The antibody molecule of any of embodiments 1-7, comprising a VL described in Table 1. 9. The antibody molecule of any of embodiments 1-8, comprising: a VH described in Table 1, or an amino acid sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical thereto, or differs by no more than 1, 2, 3, 4, 5, 10, 15, 20, or 25 amino acids therefrom; and a VL described in Table 1 or an amino acid sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical thereto, or differs by no more than 1, 2, 3, 4, 5, 10, 15, 20, or 25 amino acids therefrom. 10. The antibody molecule of any of embodiments 1-9, comprising a VH described in Table 1 and a VL described in Table 1. 11. The antibody molecule of any of embodiments 1-10, wherein the VH and VL are chosen from the same row in Table 1. 12. The antibody molecule of any of embodiments 1-11, comprising a monoclonal antibody chosen from Table 1 or 3, e.g., mAb1.1, mAb1.2, mAb1.3, mAb1.4, mAb1.5, mAb1.6, mAb1.7, mAb1.8, mAb1.9, mAb1.10, mAb1.11, mAb1.12, mAb1.13, mAb1.14, mAb1.15, mAb1.16, mAb1.18, mAb1.19, mAb1.20, mAb1.21, mAb1.22, mAb1.23, mAb1.24, mAb1.25, mAb1.26, mAb1.27, mAb1.28, mAb1.29, mAb1.30, mAb1.31, mAb1.32, mAb1.33, mAb1.34, mAb1.35, mAb1.36, mAb1.37, mAb1.38, mAb1.39, mAb1.40, mAb1.41, mAb1.42, mAb1.43, mAb1.44, mAb1.45, mAb1.46, mAb1.47, mAb1.48, mAb1.49, mAb1.50, mAb1.51, mAb1.52, mAb1.53, mAb1.54, mAb1.55, mAb1.56, mAb1.57, mAb1.58, mAb1.59, mAb1.60, mAb1.61, mAb1.62, mAb1.63, mAb1.64, mAb1.65, mAb1.66, mAb1.67, mAb1.68, mAb1.69, mAb1.70, mAb1.71, mAb1.72, mAb1.73, mAb1.74, mAb1.75, mAb1.76, mAb1.77, mAb1.78, mAb1.79, mAb1.80, mAb1.81, mAb1.82, mAb1.83, mAb1.84, mAb1.85, mAb1.86, mAb1.87, mAb1.88, mAb1.89, mAb1.90, mAb1.91, mAb1.92, mAb1.93, mAb1.94, mAb1.95, mAb1.96, mAb1.97, mAb1.98, mAb1.99, mAb1.100, mAb1.101, mAb1.102, mAb1.103, mAb1.104, mAb1.105, mAb1.106, mAb1.107, mAb1.108, mAb1.109, mAb1.110, mAb1.111, mAb1.112, mAb1.113, mAb1.114, mAb1.115, mAb1.116, mAb1.117, mAb1.118, mAb1.119, mAb1.120, mAb1.121, mAb1.122, mAb1.123, mAb1.124, mAb1.125, mAb1.126, mAb1.127, mAb1.128, mAb1.129, mAb1.130, mAb1.131, mAb1.132, mAb1.133, mAb1.134, mAb1.135, mAb1.136, mAb1.137, mAb1.138, mAb1.139, mAb1.140, mAb1.141, or mAb1.142. 13. An antibody molecule capable of binding to a coronavirus spike protein (e.g., a SARS-CoV-2 spike protein), comprising: a heavy chain variable region (VH) comprising an HCDR1 of a VH described in Table 2, an HCDR2 of a VH described in Table 2, and an HCDR3 of a VH described in Table 2; and/or a light chain variable region (VL) comprising an LCDR1 of a VL described in Table 2, an LCDR2 of a VL described in Table 2, and an LCDR3 of a VL described in Table 2, optionally wherein the coronavirus spike protein (e.g., SARS-CoV spike protein) comprises one or more mutations (e.g., one or mutations described herein). 14. The antibody molecule of embodiment 13, wherein the HCDR1 comprises an HCDR1 described in Table 4, the HCDR2 comprises an HCDR2 described in Table 4, the HCDR3 comprises an HCDR3 described in Table 4, the LCDR1 comprises an LCDR1 described in Table 4, the LCDR2 comprises an LCDR2 described in Table 4, the LCDR3 comprises an LCDR3 described in Table 4. 15. The antibody molecule of embodiment 13, wherein the HCDR1, HCDR2, and HCDR3 are chosen from the same VH described in Table 2 or the same row in Table 4; and/or wherein the LCDR1, LCDR2, and LCDR3 are chosen from the same VL described in Table 2 or the same row in Table 4. 16. The antibody molecule of any of embodiments 13-15, wherein the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 are chosen from the VH and VL of the same row in Table 2 or the same row in Table 4. 17. The antibody molecule of any of embodiments 13-16, comprising a VH described in Table 2, or an amino acid sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical thereto, or differs by no more than 1, 2, 3, 4, 5, 10, 15, 20, or 25 amino acids therefrom. 18. The antibody molecule of any of embodiments 13-17, comprising a VH described in Table 2. 19. The antibody molecule of any of embodiments 13-18, comprising a VL described in Table 2, or an amino acid sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical thereto, or differs by no more than 1, 2, 3, 4, 5, 10, 15, 20, or 25 amino acids therefrom. 20. The antibody molecule of any of embodiments 13-19, comprising a VL described in Table 2. 21. The antibody molecule of any of embodiments 13-20, comprising: a VH described in Table 2, or an amino acid sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical thereto, or differs by no more than 1, 2, 3, 4, 5, 10, 15, 20, or 25 amino acids therefrom; and a VL described in Table 2 or an amino acid sequence that is at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical thereto, or differs by no more than 1, 2, 3, 4, 5, 10, 15, 20, or 25 amino acids therefrom. 22. The antibody molecule of any of embodiments 13-21, comprising a VH described in Table 2 and a VL described in Table 2. 23. The antibody molecule of any of embodiments 13-22, wherein the VH and VL are chosen from the same row in Table 2. 24. The antibody molecule of any of embodiments 13-23, comprising a monoclonal antibody chosen from Table 2 or 4, e.g., mAb2.1, mAb2.2, mAb2.3, mAb2.4, mAb2.5, mAb2.6, mAb2.7, mAb2.8, mAb2.9, mAb2.10, mAb2.11, mAb2.12, mAb2.13, mAb2.14, mAb2.15, mAb2.16, mAb2.17, mAb2.18, mAb2.19, mAb2.20, mAb2.21, mAb2.22, mAb2.23, mAb2.24, mAb2.25, mAb2.26, mAb2.27, mAb2.28, mAb2.29, mAb2.30, mAb2.31, mAb2.32, mAb2.33, mAb2.34, mAb2.35, mAb2.36, mAb2.37, mAb2.38, mAb2.39, mAb2.40, mAb2.41, mAb2.42, mAb2.43, mAb2.44, or mAb2.45. 25. The antibody molecule of any of the preceding embodiments, which comprises an antigen-binding fragment. 26. The antibody molecule of embodiment 25, wherein the antigen-binding fragment comprises a Fab, F(ab')2, Fv, scFv, or sc(Fv)2. 27. The antibody molecule of any of the preceding embodiments, which comprises a heavy chain constant region (e.g., one, two, or all of CH1, CH2, or CH3) chosen from the heavy chain constant regions of IgG1, IgG2, IgG3, or IgG4, e.g., a heavy chain constant region sequence described herein (e.g., comprising the amino acid sequence of SEQ ID NO: 135 or a fragment thereof). 28. The antibody molecule of any of the preceding embodiments, which comprises a light chain constant region (CL) chosen from the light chain constant regions of kappa or lambda, e.g., a light chain constant region described herein (e.g., comprising the amino acid sequence of SEQ ID NO: 134 or a fragment thereof). 29. The antibody molecule of any of the preceding embodiments, which comprises an Fc region, e.g., optionally wherein the Fc region comprises a mutation. 30. The antibody molecule of any of the preceding embodiments, wherein said antibody molecule is a humanized antibody molecule. 31. The antibody molecule of any of the preceding embodiments, wherein said antibody molecule is a monoclonal antibody molecule. 32. The antibody molecule of any of the preceding embodiments, wherein said antibody molecule is a synthetic or isolated antibody molecule. 33. The antibody molecule of any of the preceding embodiments, wherein said antibody molecule is a monospecific antibody molecule. 34. The antibody molecule of any of the preceding embodiments, wherein said antibody molecule is a multispecific antibody molecule, e.g., bispecific antibody molecule. 35. An antibody molecule that competes for binding to a coronavirus spike protein (e.g., SARS-CoV-2 spike protein) with an antibody molecule of any of embodiments 1-34. 36. An antibody molecule that binds to the same or overlapping epitope as the epitope recognized by an antibody molecule of any of embodiments 1-34. 37. A composition (e.g., pharmaceutical composition) comprising an antibody molecule of any of embodiments 1-34, and optionally a pharmaceutically acceptable carrier, excipient or stabilizer. 38. A nucleic acid encoding the VH, VL, or both, of an antibody molecule of any of embodiments 1-34. 39. A vector (e.g., expression vector) comprising the nucleic acid of embodiment 38. 40. A cell (e.g., host cell) comprising the nucleic acid of embodiment 38 or the vector of embodiment 39. 41. A method of producing an antibody molecule, comprising culturing the cell of embodiment 40 under conditions that allow expression of the antibody molecule. 42. A kit comprising an antibody molecule of any of embodiments 1-34, or the composition of embodiment 35, and instructions for use. 43. A method of inhibiting a coronavirus (e.g., a SARS-CoV-2), comprising contacting a coronavirus (e.g., a SARS-CoV-2) with an antibody molecule of any of embodiments 1-34, or a pharmaceutical composition of embodiment 35, optionally wherein the coronavirus (e.g., SARS-CoV- 2) is a coronavirus variant (e.g., SARS-CoV-2 variant), e.g., a SARS-CoV-2 variant described herein. 44. The method of embodiment 43, wherein the contacting step occurs in vitro, ex vivo, or in vivo. 45. A method of treating or preventing a coronavirus (e.g., a SARS-CoV-2) infection, comprising administering to a subject in need thereof an effective amount of an antibody molecule of any of embodiments 1-34, or the composition of embodiment 35, optionally further comprising administering to the subject a second therapeutic agent or modality (e.g., a second therapeutic agent or modality described herein), optionally wherein the coronavirus (e.g., SARS-CoV-2) is a coronavirus variant (e.g., SARS-CoV-2 variant), e.g., a SARS-CoV-2 variant described herein. 46. A method of treating or preventing COVID-19, or a symptom thereof, comprising administering to a subject in need thereof an effective amount of an antibody molecule of any of embodiments 1-34, or the composition of embodiment 35, optionally further comprising administering to the subject a second therapeutic agent or modality (e.g., a second therapeutic agent or modality described herein), e.g., prior to, concurrently with, or after administration of the antibody molecule, optionally wherein the COVID-19 is caused by is a SARS-CoV-2 variant, e.g., a SARS- CoV-2 variant described herein. 47. A method of treating or preventing a disorder associated with a coronavirus (e.g., a SARS-CoV-2), comprising administering to a subject in need thereof an effective amount of an antibody molecule of any of embodiments 1-34, or the composition of embodiment 35, optionally further comprising administering to the subject a second therapeutic agent or modality (e.g., a second therapeutic agent or modality described herein), e.g., prior to, concurrently with, or after administration of the antibody molecule, optionally wherein the coronavirus (e.g., SARS-CoV-2) is a coronavirus variant (e.g., SARS-CoV-2 variant), e.g., a SARS-CoV-2 variant described herein. 48. An antibody molecule of any of embodiments 1-34, or the composition of embodiment 35, for use in a method of treating or preventing a coronavirus (e.g., a SARS-CoV-2) infection in a subject, optionally wherein the method further comprises administering to the subject a second therapeutic agent or modality (e.g., a second therapeutic agent or modality described herein), e.g., prior to, concurrently with, or after administration of the antibody molecule, optionally wherein the coronavirus (e.g., SARS-CoV-2) is a coronavirus variant (e.g., SARS-CoV-2 variant), e.g., a SARS-CoV-2 variant described herein. 49. An antibody molecule of any of embodiments 1-34, or the composition of embodiment 35, for use in a method of treating or preventing COVID-19, or a symptom thereof, in a subject, optionally wherein the method further comprises administering to the subject a second therapeutic agent or modality, optionally wherein the method further comprises administering to the subject a second therapeutic agent or modality (e.g., a second therapeutic agent or modality described herein), e.g., prior to, concurrently with, or after administration of the antibody molecule, optionally wherein the COVID-19 is caused by a SARS-CoV-2 variant, e.g., a SARS-CoV-2 variant described herein. 50. An antibody molecule of any of embodiments 1-34, or the composition of embodiment 35, for use in a method of treating or preventing a disorder associated with a coronavirus (e.g., SARS-CoV-2) in a subject, optionally wherein the method further comprises administering to the subject a second therapeutic agent or modality, optionally wherein the method further comprises administering to the subject a second therapeutic agent or modality (e.g., a second therapeutic agent or modality described herein), e.g., prior to, concurrently with, or after administration of the antibody molecule, optionally wherein the coronavirus (e.g., SARS-CoV-2) is a coronavirus variant (e.g., SARS-CoV-2 variant), e.g., a SARS-CoV-2 variant described herein. 51. Use of an antibody molecule of any of embodiments 1-34, or the composition of embodiment 35, in the manufacture of a medicament for treating or preventing a coronavirus (SARS- CoV-2) infection in a subject, optionally wherein the medicament further comprises a second therapeutic agent or modality (e.g., a second therapeutic agent or modality described herein), e.g., used prior to, concurrently with, or after use of the antibody molecule, optionally wherein the coronavirus (e.g., SARS-CoV-2) is a coronavirus variant (e.g., SARS-CoV-2 variant), e.g., a SARS- CoV-2 variant described herein. 52. Use of an antibody molecule of any of embodiments 1-34, or the composition of embodiment 35, in the manufacture of a medicament for treating or preventing COVID-19 (e.g., caused by a SARS-CoV-2 variant), or a symptom thereof, in a subject, optionally wherein the medicament further comprises a second therapeutic agent or modality (e.g., a second therapeutic agent or modality described herein), e.g., used prior to, concurrently with, or after use of the antibody molecule, optionally wherein the COVID-19 is caused by a SARS-CoV-2 variant, e.g., a SARS-CoV- 2 variant described herein. 53. Use of an antibody molecule of any of embodiments 1-34, or the composition of embodiment 35, in the manufacture of a medicament for treating or preventing a disorder associated with a coronavirus (e.g., a SARS-CoV-2) in a subject, optionally wherein the medicament further comprises a second therapeutic agent or modality (e.g., a second therapeutic agent or modality described herein), optionally wherein the coronavirus (e.g., SARS-CoV-2) is a coronavirus variant (e.g., SARS-CoV-2 variant), e.g., used prior to, concurrently with, or after use of the antibody molecule, optionally wherein the coronavirus (e.g., SARS-CoV-2) is a coronavirus variant (e.g., SARS-CoV-2 variant), e.g., a SARS-CoV-2 variant described herein. 54. A method of detecting a coronavirus (e.g., a SARS-CoV-2), comprising (i) contacting a sample or a subject with an antibody molecule of any of embodiments 1-34 under conditions that allow interaction of the antibody molecule and the coronavirus (e.g., SARS-CoV-2) or a spike protein of the coronavirus (e.g., SARS-CoV-2) to occur, and (ii) detecting formation of a complex between the antibody molecule and the sample or subject, optionally wherein the coronavirus (e.g., SARS- CoV-2) is a coronavirus variant (e.g., SARS-CoV-2 variant), e.g., a SARS-CoV-2 variant described herein. 55. A plurality of antibody molecules comprising a first antibody molecule of any of embodiments 1-24 and a second antibody molecule (e.g., a second antibody molecule that is capable of binding to a coronavirus spike protein (e.g., a SARS-CoV-2 spike protein), e.g., provided (e.g., formulated separately and premixed together prior to administration), optionally wherein the coronavirus spike protein (e.g., SARS-CoV spike protein) comprises one or more mutations (e.g., one or mutations described herein). 56. The plurality of antibody molecules of embodiment 55, comprising: (a) a first antibody molecule of any of embodiments 1-12 and a second antibody molecule of any of embodiments 13-24; (b) a first antibody molecule of any of embodiments 1-12 and a second antibody molecule of any of embodiments 1-12; or (c) a first antibody molecule of any of embodiments 13-24 and a second antibody molecule of any of embodiments 13-24; or (d) a first antibody molecule of any of embodiments 1-24 and a second antibody molecule comprising sotrovimab (VIR-7831), VIR-7832, casirivimab, imdevimab, bamlanivimab (LY-CoV555), etesevimab (LY-CoV016), CT-P59, AZD8895, AZD1061, TY027, BRII-196, BRII- 198, MAD0004J08, JMB2002, LY-CovMab, C144-LS, C135-LS, ABBV-47D11, HFB30132A, ADM03820, DXP604, ZRC-3308, HLX70, COR-101, COVI-AMG, LY-CoV1404, LY3853113, DXP593, JS016, LY3832479, LY-CoV016, MW33, SCTA01, ADG20, TY027, AZD8895, AZD1061, CT-P59, or a combination thereof. 57. The plurality of antibody molecules of embodiment 55, wherein the second antibody molecule is not an antibody molecule of any of embodiments 1-24. 58. The plurality of antibody molecules of any of embodiments 55-57, wherein the first antibody molecule and/or the second antibody molecule comprises an antigen-binding fragment. 59. The plurality of antibody molecules of embodiment 58, wherein the antigen-binding fragment comprises a Fab, F(ab')2, Fv, scFv, or sc(Fv)2. 60. The plurality of antibody molecules of any of embodiments 55-59, wherein the first antibody molecule and/or the second antibody molecule comprises a heavy chain constant region (e.g., one, two, or all of CH1, CH2, or CH3) chosen from the heavy chain constant regions of IgG1, IgG2, IgG3, or IgG4, e.g., a heavy chain constant region described herein (e.g., comprising the amino acid sequence of SEQ ID NO: 135 or a fragment thereof). 61. The plurality of antibody molecules of any of embodiments 55-60, wherein the first antibody molecule and/or the second antibody molecule comprises a light chain constant region chosen from the light chain constant regions of kappa or lambda, e.g., a light chain constant region described herein (e.g., comprising the amino acid sequence of SEQ ID NO: 134 or a fragment thereof). 62. The plurality of antibody molecules of any of embodiments 55-61, wherein the first antibody molecule and/or the second antibody molecule comprises an Fc region, optionally wherein the Fc region comprises a mutation. 63. The plurality of antibody molecules of any of embodiments 55-62, wherein the first antibody molecule and/or the second antibody molecule is a humanized antibody molecule. 64. The plurality of antibody molecules of any of embodiments 55-63, wherein the first antibody molecule and/or the second antibody molecule is a monoclonal antibody molecule. 65. The plurality of antibody molecules of any of embodiments 55-64, wherein the first antibody molecule and/or the second antibody molecule is a synthetic or isolated antibody molecule. 66. The plurality of antibody molecules of any of embodiments 55-65, wherein the first antibody molecule and/or the second antibody molecule is a monospecific antibody molecule. 67. The plurality of antibody molecules of any of embodiments 55-66, wherein the first antibody molecule and/or the second antibody molecule is a multispecific antibody molecule, e.g., bispecific antibody molecule. 68. A composition (e.g., pharmaceutical composition) comprising a plurality of antibody molecules of any of embodiments 55-67, and optionally a pharmaceutically acceptable carrier, excipient or stabilizer, optionally wherein each of the plurality of antibody molecules are provided (e.g., formulated separately and premixed together prior to administration). 69. A kit comprising a plurality of antibody molecules of any of embodiments 55-67, or the composition of embodiment 68, and instructions for use. 70. A method of inhibiting a coronavirus (e.g., a SARS-CoV-2), comprising contacting a coronavirus (e.g., SARS-CoV-2) with a plurality of antibody molecules of any of embodiments 55-67, or a pharmaceutical composition of embodiment 68, optionally wherein the coronavirus (e.g., SARS- CoV-2) is a coronavirus variant (e.g., SARS-CoV-2 variant), e.g., a SARS-CoV-2 variant described herein. 71. The method of embodiment 70, wherein the contacting step occurs in vitro, ex vivo, or in vivo. 72. A method of treating or preventing a coronavirus (e.g., a SARS-CoV-2) infection, comprising administering to a subject in need thereof an effective amount of a plurality of antibody molecules of any of embodiments 55-67, or a pharmaceutical composition of embodiment 68, optionally wherein the first antibody molecule is administered prior to, concurrently with, or after administration of the second antibody molecule, optionally wherein the method further comprises administering to the subject an additional therapeutic agent or modality (e.g., a therapeutic agent or modality described herein), optionally wherein the coronavirus (e.g., SARS-CoV-2) is a coronavirus variant (e.g., SARS-CoV-2 variant), e.g., a SARS-CoV-2 variant described herein. 73. A method of treating or preventing COVID-19 (e.g., caused by a SARS-CoV-2 variant), or a symptom thereof, comprising administering to a subject in need thereof an effective amount of a plurality of antibody molecules of any of embodiments 55-67, or a pharmaceutical composition of embodiment 68, optionally wherein the first antibody molecule is administered prior to, concurrently with, or after administration of the second antibody molecule, optionally wherein the method further comprises administering to the subject an additional therapeutic agent or modality (e.g., a therapeutic agent or modality described herein), optionally wherein the COVID-19 is caused by a SARS-CoV-2 variant, e.g., a SARS-CoV-2 variant described herein. 74. A method of treating or preventing a disorder associated with coronavirus (e.g., a SARS-CoV-2), comprising administering to a subject in need thereof an effective amount of a plurality of antibody molecules of any of embodiments 55-67, or a pharmaceutical composition of embodiment 68, optionally wherein the first antibody molecule is administered prior to, concurrently with, or after administration of the second antibody molecule, optionally wherein the method further comprises administering to the subject an additional therapeutic agent or modality (e.g., a therapeutic agent or modality described herein), optionally wherein the coronavirus (e.g., SARS-CoV-2) is a coronavirus variant (e.g., SARS-CoV-2 variant), e.g., a SARS-CoV-2 variant described herein. 75. A plurality of antibody molecules of any of embodiments 55-67, or a pharmaceutical composition of embodiment 68, for use in a method of treating or preventing a coronavirus (e.g., a SARS-CoV-2) infection in a subject, optionally wherein the first antibody molecule is administered prior to, concurrently with, or after administration of the second antibody molecule, optionally wherein the method further comprises administering to the subject an additional therapeutic agent or modality, optionally wherein the coronavirus (e.g., SARS-CoV-2) is a coronavirus variant (e.g., SARS-CoV-2 variant), e.g., a SARS-CoV-2 variant described herein. 76. A plurality of antibody molecules of any of embodiments 55-67, or a pharmaceutical composition of embodiment 68, for use in a method of treating or preventing COVID-19, or a symptom thereof, in a subject, optionally wherein the first antibody molecule is administered prior to, concurrently with, or after administration of the second antibody molecule, optionally wherein the method further comprises administering to the subject an additional therapeutic agent or modality (e.g., a therapeutic agent or modality described herein), optionally wherein the COVID-19 is caused by a coronavirus variant (e.g., SARS-CoV-2 variant), e.g., a SARS-CoV-2 variant described herein. 77. A plurality of antibody molecules of any of embodiments 55-67, or a pharmaceutical composition of embodiment 68, for use in a method of treating or preventing a disorder associated with a coronavirus (e.g., a SARS-CoV-2) in a subject, optionally wherein the first antibody molecule is administered prior to, concurrently with, or after administration of the second antibody molecule, optionally wherein the method further comprises administering to the subject an additional therapeutic agent or modality (e.g., a therapeutic agent or modality described herein), optionally wherein the coronavirus (e.g., SARS-CoV-2) is a coronavirus variant (e.g., SARS-CoV-2 variant), e.g., a SARS- CoV-2 variant described herein. 78. Use of A plurality of antibody molecules of any of embodiments 55-67, or a pharmaceutical composition of embodiment 68, in the manufacture of a medicament for treating or preventing a coronavirus (e.g., a SARS-CoV-2) infection in a subject, optionally wherein the first antibody molecule is used prior to, concurrently with, or after use of the second antibody molecule, optionally wherein the medicament further comprises an additional therapeutic agent or modality (e.g., a therapeutic agent or modality described herein), optionally wherein the coronavirus (e.g., SARS-CoV-2) is a coronavirus variant (e.g., SARS-CoV-2 variant), e.g., a SARS-CoV-2 variant described herein. 79. Use of A plurality of antibody molecules of any of embodiments 55-67, or a pharmaceutical composition of embodiment 68, in the manufacture of a medicament for treating or preventing COVID-19, or a symptom thereof, in a subject, optionally wherein the medicament further comprises an additional therapeutic agent or modality (e.g., a therapeutic agent or modality described herein), optionally wherein the COVID-19 is caused by a SARS-CoV-2 variant, e.g., a SARS-CoV-2 variant described herein. 80. Use of A plurality of antibody molecules of any of embodiments 55-67, or a pharmaceutical composition of embodiment 68, in the manufacture of a medicament for treating or preventing a disorder associated with SARS-CoV-2 (e.g., a SARS-CoV-2 variant) in a subject, optionally wherein the first antibody molecule is used prior to, concurrently with, or after use of the second antibody molecule, optionally wherein the medicament further comprises an additional therapeutic agent or modality (e.g., a therapeutic agent or modality described herein), optionally wherein the coronavirus (e.g., SARS-CoV-2) is a coronavirus variant (e.g., SARS-CoV-2 variant), e.g., a SARS-CoV-2 variant described herein. 81. A formulation comprising an antibody molecule of any of embodiments 1-36 and one or more excipients. 82. The formulation of embodiment 81, wherein the one or more excipients comprise one, two, three, four, or all of a buffer, a salt, a surfactant, a carbohydrate, an amino acid, or an antioxidant. 83. The formulation of embodiment 81 or 82, wherein the buffer comprises acetate, citrate, histidine, succinate, phosphate, or Tris. 84. The formulation of any of embodiments 81-83, wherein the salt comprises sodium. 85. The formulation of any of embodiments 81-84, wherein the surfactant comprises polysorbate 80, polysorbate 20, or poloxamer 188. 86. The formulation of any of embodiments 81-85, wherein the carbohydrate comprises sucrose, mannitol, sorbitol, trehalose, or dextran 40. 87. The formulation of any of embodiments 81-86, wherein the amino acid comprises glycine or arginine. 88. The formulation of any of embodiments 81-87, wherein the antioxidant comprises ascorbic acid, methionine, or ethylenediaminetetraacetic acid (EDTA). 89. The formulation of any of embodiments 81-88, wherein the antibody molecule is present at a concentration of 1 mg/mL to 300 mg/mL, e.g., 2 mg/mL to 250 mg/mL, 5 mg/mL to 200 mg/mL, 10 mg/mL to 150 mg/mL, 20 mg/mL to 100 mg/mL, or 25 mg/mL to 50 mg/mL. 90. The formulation of any of embodiments 81-89, which has a pH of 5 to 8, e.g., 5.5 to 6.5, 6 to 7, or 6.5 to 7.5. 91. The formulation of any of embodiments 81-90, wherein the formulation is suitable for intravenous, subcutaneous, or intramuscular administration. 92. The formulation of any of embodiments 81-91, which is a liquid formulation, a lyophilized formulation, or a reconstituted formulation. 93. The formulation of any of embodiments 81-92, comprising 25 mg/mL to 35 mg/mL of the antibody molecule, 15 mM to 25 mM Na-Acetate or Na-Citrate, 6% to 10% (w/v) sucrose, and 0.03% to 0.05% (w/v) polysorbate 80, at a pH of 5 to 6. 94. The formulation of embodiment 93, comprising 30 mg/mL of an antibody molecule described herein, 20 mM Na-Acetate or Na-Citrate, 8% (w/v) sucrose, and 0.04 % (w/v) polysorbate 80, at a pH of 5.5. 95. A container (e.g., a vial) comprising an antibody molecule of any of embodiments 1- 36, the composition of embodiment 37, or the formulation of any of embodiments 81-94. 96. The container of embodiment 52, which is a 10R, single use, Type 1 glass vial, e.g., sealed with a 20 mm push-fit cap, e.g., suitable for storage at -20°C ± 5°C, e.g., for at least 3, 6, 9, 12, 15, 18, 21, or 24 months. EXAMPLES Example 1: Generation and Characterization of Anti-CoV-S Antibodies Generation of anti-CoV-S monoclonal antibodies A number of exemplary anti-CoV-S mAbs (referred to as mAb1.1-mAb1.16, mAb1.18- mAb1.142, and mAb2.1-mAb2.45 herein) were generated. Tables 1 and 2 show the VH and VL region sequences of exemplary monoclonal antibodies. Tables 3 and 4 show the HCDR and LCDR sequences of exemplary monoclonal antibodies. Antibody #1 and #2 were selected from the antibodies tested in Example 3. Functional analysis of anti-CoV-S monoclonal antibodies The exemplary anti-CoV-S mAbs were expressed in CHO-K1 cells and were analyzed for functional characteristics as described in Examples 2-7. Example 2: Anti-CoV-S Antibodies Bind Specifically to SARS-CoV-2 Spike Protein An ELISA method was used to assess the binding of exemplary anti-CoV-S antibodies and a SARS-CoV-2 S1 spike protein (antigen). Briefly, the antigen was coated on wells in a microplate and serially diluted antibody was added to the wells. The interaction was detected using a secondary antibody conjugated to an enzyme substrate. Representative binding profiles of exemplary anti-CoV-S antibodies are shown in FIGs.1A- 1B, and numerical results are summarized in Table 5. Binding curves were assessed relative to a reference standard of each antibody. The results indicate that both exemplary antibodies specifically bind to the RBD of the spike protein in vitro. Table 5 ELISA binding results for exemplary anti-CoV-S antibodies Example 3: Anti-CoV-S Antibodies Inhibit the Binding of SARS-Cov-2 RBD to ACE2 Receptors An ACE2 competitive cell-based binding assay was run to evaluate the ability of exemplary anti-CoV-S antibodies to inhibit the binding of the RBD of a SARS-CoV-2 spike protein to ACE2 receptors on the cell surface. Briefly, the antibody (at varying concentrations) would bind to biotinylated RBD of the spike protein to inhibit its binding with ACE2 expressed on cell surface. The results for mAb1.33, mAb1.44, mAb1.55, mAb1.77, mAb1.88, mAb1.99, mAb1.78, mAb1.47, mAb1.37, mAb1.48, mAb1.59, mab1.81, mAb1.92, mAb1.103, and mAb1.114 are shown in Table 6 and FIG.2A.
The results for mAb2.8, mAb2.9, mAb2.17, mAb2.18, mAb12.27, mAb2.35, mAb2.36, and mAb2.45 are shown in Table 7 and FIG.2B. Table 7 ACE2 inhibition results (IC ) These results indicate that exemplary anti-CoV-S antibodies effectively inhibit the SARS- CoV-2 virus from binding to the ACE2 receptor on the cell surface. Example 4: Anti-CoV-S Antibodies Inhibit the Binding of SARS-Cov-2 RBD to ACE2 Receptors An ACE2 competitive cell-based binding assay was run to evaluate the ability of exemplary anti-CoV-S antibodies to inhibit the binding of the RBD of a SARS-CoV-2 spike protein to ACE2 receptors on the cell surface. Briefly, the antibody (at varying concentrations) would bind to biotinylated RBD of the spike protein to inhibit its binding with ACE2 expressed on cell surface. The inhibition of a 1:1 combination of certain exemplary antibodies was also assessed in this assay, along with the individual antibodies. The results are shown in Table 8 and FIG.2C. Table 8 ACE2 inhibition results (IC ) These results indicate that exemplary anti-CoV-S effectively inhibit the SARS-CoV-2 virus from binding to the ACE2 receptor on the cell surface. In addition, results from the 1:1 combination studied in the ACE2 inhibition assay further support the rationale for combination of the two antibodies. Example 5: Anti-CoV-S Antibodies Neutralize Pseudovirus Infection Neutralization efficacy of exemplary anti-CoV-S antibodies was also assessed in a pseudovirus neutralization assay. Pseudovirus, expressing full sequence of 2019-nCov Spike Protein and luciferase reporter gene was used to infect the ACE2-CHOK1 engineered cell line. This cell line expresses ACE2 receptor, and was used to evaluate the ability of exemplary anti-CoV-S antibodies to neutralize the pseudo virus infection. The results obtained are summarized in Table 9. These results indicate that exemplary anti-CoV-S antibodies are effective in inhibiting pseudoviral particles from infecting cells bearing the ACE2 receptor. Example 6: Anti-CoV-S Antibodies Inhibit Live SARS-Cov-2 Viral Infection of Target Cells The Plaque Reduction Neutralization Test (PRNT) assay was performed to assess the in vitro efficacy of exemplary anti-CoV-S antibodies individually, and as a combination in inhibiting live SARS-CoV-2 viral infection of target cells (e.g., Vero cells). Two antibodies were tested in this assay. In addition, a 1:1 mixture of exemplary antibodies was also tested. The dose-dependent neutralization curves are shown in FIG.3 and the calculated PRNT 50 results are summarized in Table 10. Table 10 PRNT results These results indicate that the exemplary anti-CoV-S antibodies show very good neutralization of SARS-CoV-2 infection of target cells. Furthermore, the combination of two antibodies is equally, if not slightly more effective based on these assay results. These results further support the rationale for the cocktail treatment of COVID-19 with both exemplary antibodies. Example 7: Binding and Neutralization Activity of Anti-CoV-S Antibodies Against SARS-CoV- 2 Variants Both Antibody #1 and Antibody #2 were tested for binding to the mutated spike protein prevalent on SARS-CoV-2 variants of concern. Both exemplary antibodies show retention of binding against the B.1.1.7 variant (UK variant). Results from a direct binding ELISA assay are shown in FIG.4. To address the impact of emerging variants, the binding of Antibody #1 was assessed against the RBD of SARS-CoV-2 B.1.1.7 (UK variant) and SARS-CoV-2 B.1.617 (India variant). Additionally, the neutralization activity of Antibody #1 against the India variant was further assessed in a pseudovirus neutralization assay. A summary of the results is shown in Table 11 below. Table 11 Binding and Neutralization Assay Results for SARS CoV 2 variants The binding results obtained with the UK variant and India variant, demonstrated that Antibody #1 retains strong picomolar binding affinity against the RBD of both variants. In addition, pseudovirus neutralization results with the India variant showed that Antibody #1 is highly effective in inhibiting pseudoviral particles of this variant from infecting cells bearing the ACE2 receptor. Example 8: A Phase I, First-in-Human, Time Lagged, Randomized, Placebo Controlled, Double Blind, Single Ascending Dose Study of Anti-CoV-S Antibody Cocktail in Healthy Adult Volunteers Purpose and Rationale This study is designed to evaluate the safety, tolerability, and preliminary efficacy of administering exemplary anti-CoV-S antibody #1 and exemplary anti-CoV-S antibody #2 sequentially in a dose escalation scheme in healthy adult volunteers. The study is also designed to assess the pharmacokinetics (PK) parameters of exemplary anti- CoV-S antibody #1 and exemplary anti-CoV-S antibody #2. Objectives The primary objectives are to assess the safety and tolerability of Antibody #1 and Antibody #2 when administered individually or sequentially, by intravenous (IV) infusion in healthy adult volunteers. The secondary objectives are to assess the pharmacokinetics (PK) parameters for Antibody #1 and Antibody #2. The study includes up to 62 healthy volunteers across 5 groups and 4 treatment arms (including a placebo control arm) The study includes a dose escalation of each individual antibody from 0.5 mg / kg to 15 mg / kg. Additionally, a combination arm also assesses the dose escalation of an antibody cocktail (Antibody #1 and Antibody # 2 sequentially administered intravenously) from 5 mg / kg (i.e.2.5 mg /kg Antibody #1 + 2.5 mg / kg Antibody #2) up till 30 mg / kg (i.e.15 mg /kg Antibody #1 + 15 mg / kg Antibody #2). Trial Materials Antibody #1 and Antibody #2 Injection vials contain a solution composed of an antiviral human mAb (30 mg/mL) in an aqueous buffered vehicle. The Antibody #1 drug product is a sterile, preservative free, clear to slightly opalescent, colorless to slightly yellow solution, essentially free from visible particles, and is formulated in aqueous solution containing 20 mM Na-Acetate, 8% (w/v) sucrose and 0.04 % (w/v) polysorbate 80 at a pH of 5.5. The Antibody #2 drug product is a sterile, preservative free, clear to slightly opalescent, colorless to slightly yellow solution, essentially free from visible particles, and is formulated in aqueous solution containing 20 mM Na-Citrate, 8% (w/v) sucrose and 0.04 % (w/v) polysorbate 80 at a pH of 5.5. The clinical drug product will be supplied in a 10R, single use, Type 1 glass vial sealed with a 20 mm push-fit cap. The drug product is intended to be stored at -20°C ± 5°C (long term). INCORPORATION BY REFERENCE All publications, patents, and accession numbers mentioned herein are hereby incorporated by reference in their entirety as if each individual publication or patent was specifically and individually indicated to be incorporated by reference. EQUIVALENTS While specific embodiments of the subject invention have been discussed, the above specification is illustrative and not restrictive. Many variations of the invention will become apparent to those skilled in the art upon review of this specification and the claims below. The full scope of the invention should be determined by reference to the claims, along with their full scope of equivalents, and the specification, along with such variations.
Next Patent: REUSABLE DRINKING STRAW WASHING APPARATUS